{"markup":"\u003C!DOCTYPE html PUBLIC \u0022-\/\/W3C\/\/DTD HTML 4.0 Transitional\/\/EN\u0022 \u0022http:\/\/www.w3.org\/TR\/REC-html40\/loose.dtd\u0022\u003E\n\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022 content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022 dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022 foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022 og=\u0022http:\/\/ogp.me\/ns#\u0022 rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022 sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022 sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022 skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022 xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022 mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\ngoogletag.slots[\u0022mpu\u0022] = googletag.defineSlot(\u0022\/21798771943\/JITC-MPU\u0022, [[300, 250], [300, 600], [300, 300], [600, 500]], \u0022dfp-ad-mpu\u0022)\n  .addService(googletag.pubads());\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/www.highwirestage.com\/sites\/default\/files\/js\/js_1JirQ7tm_dyc9OUCKvnjR4PnELi_PnQFPwQyzJRjKVM.js\u0022\u003E\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/d1bxh8uas1mnw7.cloudfront.net\/assets\/embed.js\u0022\u003E\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/www.highwirestage.com\/sites\/default\/files\/js\/js_sOnGGqIrB3mbp3MD7iltJt0gFz_eMOOLNISLuhFXihM.js\u0022\u003E\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022panels_ajax_pane\u0022:{\u0022new-70fd4c70-563e-4b94-ae3b-2a97f3980c13\u0022:\u0022{\\u0022encrypted\\u0022:\\u0022{\\\\\\u0022encrypted\\\\\\u0022:\\\\\\u0022+3t3pWoeG1dct5XI9jvpfEa0mOKhJ3xRmLGFF\\\\\\\\\\\\\\\/mrdYdjBuFVktEiOLC7+1\\\\\\\\\\\\\\\/E6Jez6DqM1Ai52s6iab3nvmdkRX8MPnj\\\\\\\\\\\\\\\/6PpnIxwNIH4MotCiHZ05s9Eh9JbPmQqBfxQP+5UoLDJwxWHwwRQxxOHWYzMhgHdonLlVtNzgjv4dcKuhhMEjEIn4AHVgyETQ73xGLPEDhx+mJXT9YwAP\\\\\\\\\\\\\\\/oc+ELyEGlHcqj1F1uGHtiNKWoPYA6czLWfHncS9loUUs+4sJldy8ueEyh6to0yxGEZxLpP3yPAE+RlE+ogIl5uoEtKiSCNMHfM8S0vUye4bccTDKCMr6d0gXXShqxEV7TsVOfH8uQWo5kXhYgp9ZxqefQN7zsoA6lwojLr4bkOwrBQ9HqrnJqP2MANribphw0vHG4yS4sStD8vz5wP4BV6zYllP080QFrS5qZbQA3yIas+xo79JI7b2UgUnMas8mHt0w03iaNH8c1nBT9ixcK31puU8jD3p8eaS3cnKf7QDdx0nPbqWM2PKqigxsiOoTYrQEA7uNyp77MleLoWxPmv4Dtc1y0wxWFRQeX4JnTVXSD4UH5E9\\\\\\\\\\\\\\\/5nOtJGGOJl5Of4ceqZTmNvKypb6vkxpLgOLqK63KAA9RJbz23LZc7FRYuTTOhT0UvXBjNNFUoZbrVQ2BPbJXJBGD03oHIQAHG624\\\\\\\\\\\\\\\/QqSDGOWm42B4N5j9GGiiqXWQXEjRuAYhTyLsjyJtHhZsG8DGXUtfjVq7eNBl2r9GTXhrbiZEfn776XYvjoPuFyFZ029NBfR\\\\\\\\\\\\\\\/P6hoMA6pbgOjmYu5g63g391wiQOj0daIwxKAkFHu62aS7Ido\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\/NxDAjEMkvgYUn4CrAIObKro8aqHh8TpKPZxnymaWbY\\\\\\\\\\\\\\\/jlE70W4tdeujkal4dxcRbU186Qkb331EKwi0isbhXL5aPebj3Wsq1E+aYUdoyEdh3cYVgmk3sRwO7lg5HdA5z1oZatUFSyu19vLcxP3MhEBssCy5srXP9KcORU8KZM0MuZSUzUgcLqH1zyqwkZGN1NSN9+f7MG\\\\\\\\\\\\\\\/PsoySNQLSys\\\\\\\\\\\\\\\/5UzGz2QT0tyipKKh90WQsuZzAV9YOFdeJKRSpkJtmtP8qJjyzdyQi6cKGQRWpxQWkapw7ieo9BZFPRgVtazJRy6DYqyRyffu5l+b3gPdGQFbPWkNEwQ4VK989CGyfetdH9TWN1nCL8M8ETwk8Sq79npxzC7ypBh7AuDytUz\\\\\\\\\\\\\\\/oTSkjafrUqn096HdiH1oD+tRxB5\\\\\\\\\\\\\\\/dWRLt\\\\\\\\\\\\\\\/FGMufWIvujo7rAuEyXijr9x1sYsM5b2biAhYSbBwZqyoHgYMGNK2F9pEcDYd+KcWew5cOzfSgwgSgG5GatkAm83q6zQNZSokVEX6lQTU\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\/H\\\\\\\\\\\\\\\/16WrjM7NSQz8KNI7vGJ43By2q6JK9hpCrEasEaZk2xRv2EqQlvBCfYuo5cg7MpnViElwNsb4ziYNqz6T0hzMaFMTSH7RnwAsbpWr2vo5PvrWU3uMd75zn\\\\\\\\\\\\\\\/Wz0Y2eRzArckKtugS\\\\\\\\\\\\\\\/3v\\\\\\\\\\\\\\\/d0FTdEBNlRA2YfRzZa2DWHpqLYvsr1ntjlH4rRB4b2kYYiLsSIlaeG6Oqp7FuQ\\\\\\\\\\\\\\\/tozEWIVsASmfGYcYcdjVvTi6+xIWOxf3cOKHizd3Z9W5MWBIHsfe6EBC8F9pYSADbmhb8E2TkLr4GPS18IWjZjxtOt44NcwSmfILaHJrGXmNTc2zvDn4j8YhHFD1WZeKMLdgtNSkB9++DXG1Prr1KEc\\\\\\\\\\\\\\\/6VkReHUK5gwkkl7i05Jn1lZ7R7k+qJfj1C4oiDztjhg17cKb9hYFs+Cxcb\\\\\\\\\\\\\\\/Ukm2sBTV9dKSVGcojR+QBiDhfKp9evdQF0roCJhUkMqbgElPTOWmwvNWwMJWvcuAXXSkG9IkQDtI2SoI5hspm4M3b2mkOQxrgAtkIjeAR+YQpRutZLvVk3u6jbCPsRt8sWSD5\\\\\\\\\\\\\\\/1BXIUsPBY1ECcjwnECuca9g8IBTOSObT2\\\\\\\\\\\\\\\/E5Ayh0BGuvooxvcyL7rTejZSdvAdi2nX2F5v+XlpFzKQh\\\\\\\\\\\\\\\/zPDXNQR7FGv+jp\\\\\\\\\\\\\\\/D0mGKOCz+l+161ypDj75JMBqmK2ZgoK7q0i0KUcBwKdaqiQvxREKb5IBIrITYc\\\\\\\\\\\\\\\/h7Xxyqu4ZI2ns+fm5TNEBdHJHOSZITs7ld9opGGBqVJOG3V6hFFZlKnKxMqOa90+Xm77bvGaMJCvyIxeSy5LjqE9CEi+zMQE0LHB10IxVx3td5MMozO+31QKx2sYLNSfA7NfGBC3xbRrECAANrLDbJa3FVAa+7qJYi9kCWPeIO4mIeLVoXprUGEY7yMlWRo9h5FBYlZ7\\\\\\\\\\\\\\\/vQZKQb+tTFWREYBm2t72ahB30+DzVKTru+7b0G\\\\\\\\\\\\\\\/ZJvQA5KFDGQDGhZsXbLc7T2WyyVgyKudKsvgSV8OFVX741z6CuvaiNNYivs8EIm74rLMb5hSgT4KvHkRXmX2FxB45U1QvEeMgWJgwPFTSlL2DCse134+GbeNmV5KQyN8lZuu2X\\\\\\\\\\\\\\\/oWG0CPlzU8SjMSRl9lZ8tW6arwwzNON9HW0rXd2\\\\\\\\\\\\\\\/6dWoZPUQndiUp+xssX6DF3TKn468ZqVDqUSx+TtAzqddrkh7Bm57gewtjADHecdtNYc5hhRGmiiAoWuQpEfMSBWRutkKOn8Pt\\\\\\\\\\\\\\\/LX0TY6qLWCI5y0sXrSDu3LsET72ChI5k4=\\\\\\u0022,\\\\\\u0022iv\\\\\\u0022:\\\\\\u00220wxOQZqi+Gie8tLxrP2s1Q==\\\\\\u0022,\\\\\\u0022salt\\\\\\u0022:\\\\\\u00223fcf69c0544933648ca27e63b3137e55\\\\\\u0022}\\u0022,\\u0022hmac\\u0022:\\u0022098f37bb3a9abd2ee5b3687dbd9bd07f150e170de69b39b68e3f67e00940c8ff\\u0022}\u0022},\u0022highwire\u0022:{\u0022ac\u0022:{\u0022\\\/jitc\\\/9\\\/8\\\/e002597.atom\u0022:{\u0022access\u0022:{\u0022full\u0022:true,\u0022abstract\u0022:true},\u0022pisa_id\u0022:\u0022\u0022,\u0022apath\u0022:\u0022\\\/jitc\\\/9\\\/8\\\/e002597.atom\u0022,\u0022jcode\u0022:\u0022jitc\u0022}},\u0022markup\u0022:[{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022jitc;9\\\/8\\\/e002597\u0022},{\u0022requested\u0022:\u0022abstract\u0022,\u0022variant\u0022:\u0022abstract\u0022,\u0022view\u0022:\u0022abstract\u0022,\u0022pisa\u0022:\u0022jitc;9\\\/8\\\/e002597\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022jitc;9\\\/8\\\/e002597\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022jitc;9\\\/8\\\/e002597\u0022}],\u0022processed\u0022:[\u0022highwire_math\u0022]},\u0022MutationObserver\u0022:{\u0022js\u0022:\u0022\\\/sites\\\/all\\\/libraries\\\/mutationobserver\\\/MutationObserver.js\u0022},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u00220\u0022:1,\u0022sites\\\/default\\\/modules\\\/jnl_template_bmjj\\\/plugins\\\/highwire_markup_process\\\/js\\\/bmjj_author_affiliates.js\u0022:1,\u0022https:\\\/\\\/d1bxh8uas1mnw7.cloudfront.net\\\/assets\\\/embed.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/content_types\\\/js\\\/highwire_altmetrics.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/panels_ajax_pane\\\/panels_ajax_pane.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/www.highwirestage.com\/sites\/default\/files\/advagg_css\/css__ZqR9oFtEjI7t5h7UPJpE0tHpaVSMTAbm0a23YsPXKOs__uV3gzKhl1oWq7e-vguNsCBPtyeYJ-dxQaFmm4cFBmxE__3qvfz4I9k5oUIeimOjbmdyh6ZgM-xweyVc5gub1_nR4.css\u0022 media=\u0022all\u0022\u003E\u003Clink rel=\u0022stylesheet\u0022 type=\u0022text\/css\u0022 href=\u0022\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0022\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-jnl-template-bmjj-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022\u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup author-affiliates col-narrow-12 author-affiliates-corresp article\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 class=\u0022content-block-markup\u0022 xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 class=\u0022contributors\u0022\u003E\u003Col class=\u0022contributor-list\u0022 id=\u0022contrib-group-1\u0022\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-1\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0002-7694-0731\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0002-7694-0731\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003ELeisha A Emens\u003C\/span\u003E\u003Ca id=\u0022xref-aff-1-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-1\u0022\u003E1\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-2\u0022\u003E\u003Cspan class=\u0022name\u0022\u003ESylvia Adams\u003C\/span\u003E\u003Ca id=\u0022xref-aff-2-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-2\u0022\u003E2\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-3\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0002-0638-7969\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0002-0638-7969\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003EAshley Cimino-Mathews\u003C\/span\u003E\u003Ca id=\u0022xref-aff-3-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-3\u0022\u003E3\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-4\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EMary L Disis\u003C\/span\u003E\u003Ca id=\u0022xref-aff-4-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-4\u0022\u003E4\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-5\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0001-8914-2897\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0001-8914-2897\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003EMargaret E Gatti-Mays\u003C\/span\u003E\u003Ca id=\u0022xref-aff-5-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-5\u0022\u003E5\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-6\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EAlice Y Ho\u003C\/span\u003E\u003Ca id=\u0022xref-aff-6-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-6\u0022\u003E6\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-7\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EKevin Kalinsky\u003C\/span\u003E\u003Ca id=\u0022xref-aff-7-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-7\u0022\u003E7\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-8\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EHeather L McArthur\u003C\/span\u003E\u003Ca id=\u0022xref-aff-8-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-8\u0022\u003E8\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-9\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EElizabeth A Mittendorf\u003C\/span\u003E\u003Ca id=\u0022xref-aff-9-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-9\u0022\u003E9\u003C\/a\u003E\u003Cspan class=\u0022xref-sep\u0022\u003E,\u003C\/span\u003E\u003Ca id=\u0022xref-aff-10-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-10\u0022\u003E10\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-10\u0022\u003E\u003Cspan class=\u0022name\u0022\u003ERita Nanda\u003C\/span\u003E\u003Ca id=\u0022xref-aff-11-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-11\u0022\u003E11\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-11\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0001-9264-4628\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0001-9264-4628\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003EDavid B Page\u003C\/span\u003E\u003Ca id=\u0022xref-aff-12-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-12\u0022\u003E12\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-12\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0001-6710-4814\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0001-6710-4814\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003EHope S Rugo\u003C\/span\u003E\u003Ca id=\u0022xref-aff-13-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-13\u0022\u003E13\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-13\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EKrista M Rubin\u003C\/span\u003E\u003Ca id=\u0022xref-aff-14-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-14\u0022\u003E14\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-14\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EHatem Soliman\u003C\/span\u003E\u003Ca id=\u0022xref-aff-15-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-15\u0022\u003E15\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-15\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EPatricia A Spears\u003C\/span\u003E\u003Ca id=\u0022xref-aff-16-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-16\u0022\u003E16\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-16\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0002-5940-8671\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0002-5940-8671\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003ESara M Tolaney\u003C\/span\u003E\u003Ca id=\u0022xref-aff-17-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-17\u0022\u003E17\u003C\/a\u003E and \u003C\/li\u003E\u003Cli class=\u0022last\u0022 id=\u0022contrib-17\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EJennifer K Litton\u003C\/span\u003E\u003Ca id=\u0022xref-aff-18-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-18\u0022\u003E18\u003C\/a\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Col class=\u0022affiliation-list\u0022\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-1\u0022 name=\u0022aff-1\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E1\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EDepartment of Medicine,\n          UPMC Hillman Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EUniversity of\n          Pittsburgh\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EPittsburgh\u003C\/span\u003E,\n          \u003Cspan class=\u0022addr-line\u0022\u003EPennsylvania\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-2\u0022 name=\u0022aff-2\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E2\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EPerlmutter Cancer\n          Center\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003ENew York University Langone\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENew York\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENew\n          York\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-3\u0022 name=\u0022aff-3\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E3\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EDepartment of Pathology\n          and Oncology\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EJohns Hopkins University School of\n          Medicine\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EBaltimore\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMaryland\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-4\u0022 name=\u0022aff-4\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E4\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003ECancer Vaccine\n          Institute\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EUniversity of Washington\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ESeattle\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EWashington\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-5\u0022 name=\u0022aff-5\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E5\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EPelotonia Institute for\n          Immuno-Oncology, Division of Medical Oncology\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EThe Ohio State\n          University Comprehensive Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EColumbus\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EOhio\u003C\/span\u003E,\n          USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-6\u0022 name=\u0022aff-6\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E6\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EDepartment of Radiation\n          Oncology\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EMassachusetts General Hospital\u003C\/span\u003E,\n          \u003Cspan class=\u0022addr-line\u0022\u003EBoston\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMassachusetts\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-7\u0022 name=\u0022aff-7\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E7\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EWinship Cancer\n          Institute\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EEmory University\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EAtlanta\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EGeorgia\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-8\u0022 name=\u0022aff-8\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E8\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EDepartment of\n          Medicine\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EUT Southwestern\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EDallas\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ETexas\u003C\/span\u003E,\n          USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-9\u0022 name=\u0022aff-9\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E9\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EDivision of Breast\n          Surgery, Department of Surgery\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EBrigham and Women\u0027s\n          Hospital\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EBoston\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMassachusetts\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-10\u0022 name=\u0022aff-10\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E10\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EBreast Oncology\n          Program, Dana-Farber Cancer Institute\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EHarvard Medical\n          School\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EBoston\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMassachusetts\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-11\u0022 name=\u0022aff-11\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E11\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EDepartment of\n          Medicine, Section of Hematology\/Oncology\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EThe University of\n          Chicago Medicine Comprehensive Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EChicago\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EIllinois\u003C\/span\u003E,\n          USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-12\u0022 name=\u0022aff-12\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E12\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EEarle A Chiles Research Institute\u003C\/span\u003E,\n          \u003Cspan class=\u0022addr-line\u0022\u003EPortland\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EOregon\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-13\u0022 name=\u0022aff-13\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E13\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EHelen Diller Family\n          Comprehensive Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EUniversity of California San\n          Francisco\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ESan Francisco\u003C\/span\u003E,\n          \u003Cspan class=\u0022addr-line\u0022\u003ECalifornia\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-14\u0022 name=\u0022aff-14\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E14\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003ECenter for\n          Melanoma\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EMassachusetts General Hospital Cancer\n          Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EBoston\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMassachusetts\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-15\u0022 name=\u0022aff-15\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E15\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EDepartment of Breast\n          Oncology\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EH Lee Moffitt Cancer Center and Research\n          Institute\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ETampa\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EFlorida\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-16\u0022 name=\u0022aff-16\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E16\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EUniversity of North Carolina Lineberger\n          Comprehensive Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EChapel\n          Hill\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENorth Carolina\u003C\/span\u003E,\n          USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-17\u0022 name=\u0022aff-17\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E17\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EDepartment of Medical\n          Oncology\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EDana-Farber Cancer Institute\u003C\/span\u003E,\n          \u003Cspan class=\u0022addr-line\u0022\u003EBoston\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMassachusetts\u003C\/span\u003E, USA\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-18\u0022 name=\u0022aff-18\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\u003Csup\u003E18\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EDepartment of Breast\n          Medical Oncology, Division of Cancer Medicine\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EThe University\n          of Texas MD Anderson Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EHouston\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ETexas\u003C\/span\u003E,\n          USA\u003C\/address\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Col class=\u0022corresp-list\u0022\u003E\u003Cli class=\u0022corresp\u0022 id=\u0022corresp-1\u0022\u003E\u003Cspan class=\u0022corresp-label\u0022\u003ECorrespondence to\u003C\/span\u003E Dr Jennifer K Litton;\n            \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Ejlitton{at}mdanderson.org\u003C\/span\u003E\u003C\/span\u003E; Dr Leisha A Emens;\n            \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003Eemensla{at}upmc.edu\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup abstract-with-bc\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block\u0022 xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article abstract-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003EAbstract\u003C\/h2\u003E\u003Cp id=\u0022p-2\u0022\u003EBreast cancer has historically been a disease for which immunotherapy was largely\n          unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with\n          chemotherapy for the treatment of advanced\/metastatic triple-negative breast cancer (TNBC)\n          has demonstrated efficacy, including longer progression-free survival and increased\n          overall survival in subsets of patients. Based on clinical benefit in randomized trials,\n          ICIs in combination with chemotherapy for the treatment of some patients with\n          advanced\/metastatic TNBC have been approved by the United States (US) Food and Drug\n          Administration (FDA), expanding options for patients. Ongoing questions remain, however,\n          about the optimal chemotherapy backbone for immunotherapy, appropriate biomarker-based\n          selection of patients for treatment, the optimal strategy for immunotherapy treatment in\n          earlier stage disease, and potential use in histological subtypes other than TNBC. To\n          provide guidance to the oncology community on these and other important concerns, the\n          Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts\n          to develop a clinical practice guideline (CPG). The expert panel drew upon the published\n          literature as well as their clinical experience to develop recommendations for healthcare\n          professionals on these important aspects of immunotherapeutic treatment for breast cancer,\n          including diagnostic testing, treatment planning, immune-related adverse events (irAEs),\n          and patient quality of life (QOL) considerations. The evidence-based and consensus-based\n          recommendations in this CPG are intended to give guidance to cancer care providers\n          treating patients with breast cancer.\u003C\/p\u003E\u003Cdiv id=\u0022sec-1\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-3\u0022\u003E\u003Cstrong\u003EReaders\u0026acirc;\u0026#128;\u0026#153; note\u003C\/strong\u003E These guidelines have been updated to reflect emerging\n            evidence. Updates may occur for up to two years from the date of original publication.\n            This version is update 1 of the original article published on 13 August 2021\n            (\u003Cem\u003EJITC\u003C\/em\u003E 9(8):e002597). Previous updates can be found as data\n            supplements (there will be a link to the older version as PDF here). When citing\n            this paper please consider adding the update number and date of access for clarity.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Ebreast neoplasms\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eguidelines as topic\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eimmunotherapy\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eclinical trials as topic\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022license\u0022 id=\u0022license-1\u0022\u003E\u003Cspan class=\u0022ali-license-ref\u0022\u003E\u003Ca href=\u0022http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/\u0022 rel=\u0022license\u0022\u003Ehttp:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/\u003C\/a\u003E\u003C\/span\u003E\u003Cp id=\u0022p-1\u0022\u003EThis is an open access article distributed in accordance with the Creative\n            Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to\n            distribute, remix, adapt, build upon this work non-commercially, and license their\n            derivative works on different terms, provided the original work is properly cited,\n            appropriate credit is given, any changes made indicated, and the use is non-commercial.\n            See \u003Ca href=\u0022http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/\u0022 rel=\u0022license\u0022\u003Ehttp:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/\u003C\/a\u003E.\u003C\/p\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-dfp-pane oas-ads oas-ads-mid pull-right\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv id=\u0022dfp-ad-mpu-wrapper\u0022 class=\u0022dfp-tag-wrapper\u0022\u003E\n\n\u003Cdiv id=\u0022dfp-ad-mpu\u0022 class=\u0022dfp-tag-wrapper\u0022\u003E\n  \u003Cscript type=\u0022text\/javascript\u0022\u003E\n    googletag.cmd.push(function() {\n      googletag.display(\u0022dfp-ad-mpu\u0022);\n    });\n  \u003C\/script\u003E\u003C\/div\u003E\n\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-custom pane-1\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cp\u003E\u003Ca href=\u0022https:\/\/doi.org\/10.1136\/jitc-2021-002597\u0022 target=\u0022_new\u0022\u003Ehttps:\/\/doi.org\/10.1136\/jitc-2021-002597\u003C\/a\u003E\u003C\/p\u003E\n  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-altmetrics\u0022\u003E\n  \n        \u003Ch2 class=\u0022pane-title\u0022\u003EStatistics from Altmetric.com\u003C\/h2\u003E\n    \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv data-badge-details=\u0022right\u0022 data-badge-type=\u0022medium-donut\u0022 data-doi=\u002210.1136\/jitc-2021-002597\u0022 data-hide-no-mentions=\u0022true\u0022 class=\u0022altmetric-embed\u0022\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-custom pane-2 permissions-box\u0022\u003E\n  \n        \u003Ch2 class=\u0022pane-title\u0022\u003ERequest Permissions\u003C\/h2\u003E\n    \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cp\u003EIf you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center\u0026rsquo;s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.\u003C\/p\u003E\n  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-panels-ajax-pane-content permissions-box pane-highwire-permission-link\u0022 id=\u0022request-permissions\u0022\u003E\n  \n        \u003Ch2 class=\u0022pane-title\u0022\u003E\u003Cspan class=\u0022panels-ajax-pane-title\u0022 data-pid=\u0022new-70fd4c70-563e-4b94-ae3b-2a97f3980c13\u0022\u003E\u003C\/span\u003E\u003C\/h2\u003E\n    \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022panels-ajax-pane panels-ajax-pane-new-70fd4c70-563e-4b94-ae3b-2a97f3980c13\u0022 data-pid=\u0022new-70fd4c70-563e-4b94-ae3b-2a97f3980c13\u0022\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 class=\u0022content-block-markup\u0022 xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003E\u003Ca href=\u0022\/keyword\/breast-neoplasms\u0022 class=\u0022hw-term hw-article-keyword hw-article-keyword-breast-neoplasms\u0022 rel=\u0022nofollow\u0022\u003Ebreast neoplasms\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003E\u003Ca href=\u0022\/keyword\/guidelines-topic\u0022 class=\u0022hw-term hw-article-keyword hw-article-keyword-guidelines-as-topic\u0022 rel=\u0022nofollow\u0022\u003Eguidelines as topic\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003E\u003Ca href=\u0022\/keyword\/immunotherapy\u0022 class=\u0022hw-term hw-article-keyword hw-article-keyword-immunotherapy\u0022 rel=\u0022nofollow\u0022\u003Eimmunotherapy\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003E\u003Ca href=\u0022\/keyword\/clinical-trials-topic\u0022 class=\u0022hw-term hw-article-keyword hw-article-keyword-clinical-trials-as-topic\u0022 rel=\u0022nofollow\u0022\u003Eclinical trials as topic\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section intro\u0022 id=\u0022sec-2\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EIntroduction\u003C\/h2\u003E\u003Cp id=\u0022p-4\u0022\u003EBoth earlier detection and treatment based on identification of three major clinically\n        relevant subtypes of breast cancer (ie, hormone receptor (HR) positive, human epidermal\n        growth factor receptor 2 (HER2) positive and triple-negative) have improved outcomes for\n        patients with breast cancer.\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u0026acirc;\u0026#128;\u0026#147;5\u003C\/a\u003E\n        Although breast cancer mortality has decreased by 40% since 1989, prognosis remains\n        poor for patients who develop metastatic disease. For example, triple-negative breast cancer\n        (TNBC) is associated with earlier age of onset and is more aggressive than other subtypes\n        with a median survival of only 12\u0026acirc;\u0026#128;\u0026#147;18 months in the metastatic setting.\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E Historically, the therapeutic options for metastatic\n        TNBC have been limited to standard chemotherapy, a strategy that typically results in the\n        rapid emergence of chemotherapy-refractory disease.\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\n          8\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EIn recent years, immunotherapy has emerged as a novel option for many difficult-to-treat\n        cancers. In contrast to other solid tumors for which the role of immunotherapy is\n        well-established, breast cancer has long been considered to be an immunologically\n        \u0026acirc;\u0026#128;\u0026#152;cold\u0026acirc;\u0026#128;\u0026#153; tumor, with relatively lower levels of T cell infiltration and lower\n        mutational burdens compared to melanoma, non-small cell lung cancer, and other\n          malignancies.\u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E More recently, the role of the immune\n        system in both breast cancer progression and treatment response and resistance has come\n        under critical re-evaluation, opening the door toward immunotherapeutic treatment.\n        Retrospective analyses of tissue samples from clinical trials in breast cancer have revealed\n        associations between lymphocytic infiltration into tumors and survival outcomes.\u003Ca id=\u0022xref-ref-7-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7 8 10\u0026acirc;\u0026#128;\u0026#147;12\u003C\/a\u003E Furthermore, expression of\n        the immune checkpoint proteins programmed cell death protein 1 and its ligand (PD-1 and\n        PD-L1) within the tumor microenvironment\u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13 14\u003C\/a\u003E\n        supports a role for breast cancer immunoediting. This is the three-phase process by which\n        anti-cancer immune responses evolve to immune escape and disease progression.\u003Ca id=\u0022xref-ref-15-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15 16\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003EClinical trials evaluating immune checkpoint inhibitor (ICI) therapies for TNBC have\n        reported positive results. In 2019, the United States (US) Food and Drug Administration\n        (FDA) granted accelerated approval of the PD-L1-directed antibody, atezolizumab, in\n        combination with nanoparticle albumin-bound (nab) paclitaxel for advanced\/metastatic\n        PD-L1-positive (PD-L1+) TNBC,\u003Ca id=\u0022xref-ref-17-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E based on the results\n        of the phase III IMpassion130 trial.\u003Ca id=\u0022xref-ref-18-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E Furthermore,\n        in 2020, the FDA granted accelerated approval to the PD-1-directed antibody, pembrolizumab,\n        in combination with chemotherapy for advanced\/metastatic PD-L1+ TNBC,\u003Ca id=\u0022xref-ref-19-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E based on the results of the phase III KEYNOTE-355 trial. In 2021, the\n        accelerated approval for pembrolizumab was converted to full approval and the accelerated\n        approval for atezolizumab was voluntarily withdrawn. Ongoing clinical trials are\n        investigating immunotherapies in other breast cancer subtypes as well as in early-stage\n        disease, potentially expanding the population of patients with breast cancer who may benefit\n        from immunotherapy.\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003EApproval of anti-PD-(L)1 agents for the treatment of breast cancer is relatively recent\n        and, therefore, clinical experience with these new therapies is still somewhat limited.\n        Immunotherapy, while offering survival benefits to some patients, is markedly different from\n        conventional breast cancer therapies in several aspects including patient selection,\n        treatment-related adverse events (AEs) including immune-related AEs (irAEs), and response\n        patterns. To support the oncology community and provide evidence-based and consensus-based\n        recommendations on immunotherapy for breast cancer, the Society for Immunotherapy of Cancer\n        (SITC) convened a multidisciplinary panel of experts to develop a new clinical practice\n        guideline (CPG), covering topics including recommended therapies, emerging agents,\n        diagnostics and biomarkers, monitoring response to treatment, special patient populations,\n        toxicity management, and quality of life (QOL). The recommendations within this guideline\n        are not intended to supplant sound clinical judgment, but rather to provide clinicians with\n        the most current thinking on how experts integrate immunotherapy into the treatment of\n        patients with breast cancer.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-3\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EGuideline development methods\u003C\/h2\u003E\u003Cp id=\u0022p-8\u0022\u003EThe Institute of Medicine\u0026acirc;\u0026#128;\u0026#153;s (IOM) Standards for Developing Trustworthy Clinical\n        Practice Guidelines were used as a model to develop the recommendations in this manuscript.\n        IOM standards dictate that guideline development is led by a multidisciplinary expert panel\n        using a transparent process where both funding sources and conflicts of interest are readily\n        reported. This CPG is intended to provide guidance and is not a substitute for the\n        professional judgment of individual treating physicians.\u003C\/p\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EConflict of interest management\u003C\/h3\u003E\u003Cp id=\u0022p-9\u0022\u003EAs outlined by IOM standards, all financial relationships of expert panel members that\n          might result in actual, potential, or perceived conflicts of interest were individually\n          reported. Disclosures were made prior to the onset of manuscript development and updated\n          on an annual basis. In addition, panel members were asked to articulate any actual or\n          potential conflicts at all key decision points during guideline development, so that\n          participants would understand all possible influences, biases, and\/or the diversity of\n          perspectives on the panel. Although some degree of relationships with outside interests\n          are to be expected among experts, panel candidates with significant financial connections\n          that may compromise their ability to fairly weigh evidence (either actual or perceived)\n          were not eligible to participate in guideline development.\u003C\/p\u003E\u003Cp id=\u0022p-10\u0022\u003ERecognizing that guideline panel members are among the leading experts on the subject\n          matter under consideration and guideline recommendations should have the benefit of their\n          expertise, any identified potential conflicts of interests were managed as outlined in\n          SITC\u0026acirc;\u0026#128;\u0026#153;s disclosure and conflict of interest resolution policies. As noted in these\n          policies, panel members disclosing a real or perceived potential conflict of interest may\n          be permitted to participate in consideration and decision-making of a matter related to\n          that conflict, but only if deemed appropriate after discussion and agreement by the expert\n          panel.\u003C\/p\u003E\u003Cp id=\u0022p-11\u0022\u003EThe financial support for the development of this guideline was provided solely by SITC.\n          No commercial funding was received.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-5\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ERecommendation development\u003C\/h3\u003E\u003Cp id=\u0022p-12\u0022\u003EPanel recommendations are based on literature evidence, where possible, and clinical\n          experience, where appropriate.\u003Ca id=\u0022xref-ref-20-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003E20\u003C\/a\u003E Consensus for the\n          recommendations herein was generated by open communication and scientific debate in\n          small-group and whole-group settings, surveying and responses to clinical questionnaires,\n          as well as formal voting in consensus meetings.\u003C\/p\u003E\u003Cp id=\u0022p-13\u0022\u003EFor transparency, a draft of this CPG was made publicly available for comment during the\n          development process and prior to publication. All comments were evaluated and considered\n          for inclusion into the final manuscript according to the IOM standard.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-6\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EEvidence rating\u003C\/h3\u003E\u003Cp id=\u0022p-14\u0022\u003EThe evidence-based and consensus-based recommendations of the panel were refined\n          throughout the development process in order to obtain the highest possible agreement among\n          the experts, however, the minimum threshold was defined as 75% approval among the\n          voting members. Evidence supporting panel recommendations was graded according to the\n          Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence Working Group\n          \u0026acirc;\u0026#128;\u0026#152;The Oxford Levels of Evidence 2\u0026acirc;\u0026#128;\u0026#153; (2016 version). A summary of the OCEBM\n          grading scale may be found below (\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003Etable 1\u003C\/a\u003E). The\n          level of evidence (LE) for a given recommendation is expressed in parentheses following\n          the recommendation (eg, LE: 1). Recommendations without an associated LE were based on\n          expert consensus.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022##\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/25663\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\n\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/25663\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1\u003C\/span\u003E \u003Cp id=\u0022p-15\u0022 class=\u0022first-child\u0022\u003ESummary of \u0026acirc;\u0026#128;\u0026#152;The Oxford Levels of Evidence 2\u0026acirc;\u0026#128;\u0026#153;. (Adapted from Oxford\n              Center for Evidence-Based Medicine Levels of Evidence Working Group)\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-7\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EImmunotherapy with PD-(L)1 inhibitors for the treatment of advanced\/metastatic breast\n        cancer\u003C\/h2\u003E\u003Cp id=\u0022p-16\u0022\u003EAt the time of publication, two ICIs were FDA-approved specifically for the treatment of\n        advanced\/metastatic TNBC: atezolizumab and pembrolizumab. The indication for atezolizumab\n        was withdrawn in 2021. Both breast cancer-specific approvals were for ICIs given in\n        combination with cytotoxic chemotherapy, although the indicated backbone varies between\n        agents and is an ongoing area of investigation. Pembrolizumab is also approved in a\n        tissue-agnostic indication as monotherapy for tumors with high tumor mutational burden (TMB)\n        or microsatellite instability (MSI). Landmark studies leading to FDA approvals for ICIs are\n        summarized in \u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003Etable 2\u003C\/a\u003E, along with select\n        hypothesis-generating late-stage trials.\u003C\/p\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022##\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/25682\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\n\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/25682\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2\u003C\/span\u003E \u003Cp id=\u0022p-17\u0022 class=\u0022first-child\u0022\u003ETrials of ICIs for recurrent\/metastatic breast cancer and tissue-agnostic\n            indications\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EFDA-approved indications: advanced TNBC\u003C\/h3\u003E\u003Cp id=\u0022p-19\u0022\u003EThe first ICI to be approved by the FDA for the treatment of breast cancer was\n          atezolizumab, a fully humanized IgG1 isotype anti-PD-L1 monoclonal antibody (mAb).\u003Ca id=\u0022xref-ref-21-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003E21\u003C\/a\u003E Accelerated approval was granted in March 2019 for\n          atezolizumab in combination with nab-paclitaxel for treatment of adult patients with\n          PD-L1+ locally advanced or metastatic TNBC, as measured by the VENTANA PD-L1 (SP142)\n          immunohistochemical (IHC) assay and assessed on immune cells (ICs)\u003Ca id=\u0022xref-ref-17-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E; additional specifics of PD-L1 testing are described in detail in\n          the \u003Cstrong\u003EDiagnostics and biomarker testing in patients with advanced\/metastatic breast\n            cancer\u003C\/strong\u003E section. The indication for atezolizumab for TNBC was voluntarily\n          withdrawn in 2021. Although the approval did not specify line of therapy, data for the\n          clinical activity of atezolizumab beyond the first-line setting is limited. However, in\n          the phase Ib study of atezolizumab plus nab-paclitaxel for TNBC that led to the subsequent\n          large scale trials, tolerable safety and promising activity was observed among 32 patients\n          that received a median of three prior lines of therapy.\u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-20\u0022\u003EThe accelerated approval for atezolizumab was based on the first interim analysis of the\n          phase III IMpassion130 study, a multicenter, international, double-blind,\n          placebo-controlled randomized trial. Enrollment criteria included patients with\n          unresectable, locally advanced, or metastatic TNBC who had not received prior systemic\n          therapy (radiation therapy and previous chemotherapy was allowed if treatment with\n          curative intent was completed \u0026acirc;\u0026#137;\u0026yen;12 months before randomization). The study had four\n          pre-specified co-primary endpoints: progression-free survival (PFS) in both the\n          intent-to-treat (ITT) and PD-L1+ populations analyzed in parallel, and OS in both the ITT\n          and PD-L1+ populations analyzed hierarchically, first in the ITT group, and then if\n          significant in the PD-L1+ group. The trial randomized 902 patients in total, 451 in each\n          arm. In the ITT population, 404 patients (89.8%) in the atezolizumab group and 408\n          patients (90.7%) in the placebo group had metastatic disease at baseline.\u003Ca id=\u0022xref-ref-18-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E In the primary analysis, IMpassion130 met its PFS\n          endpoint in both the ITT and PD-L1+ populations (see \u003Ca id=\u0022xref-table-wrap-2-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003Etable\n            2\u003C\/a\u003E), although no benefit was observed in the PD-L1-negative group.\u003Ca id=\u0022xref-ref-23-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E For OS, a statistically significant benefit was not\n          seen in the ITT subgroup, so formal statistical testing could not be performed in the\n          PD-L1+ subgroup per the hierarchical statistical analysis plan. However, exploratory\n          analyses demonstrated a clinically meaningful improvement in OS with ICI compared with\n          placebo in the PD-L1+ subgroup of 9.5 and 7 months at the first and second interim OS\n          analyses, respectively.\u003Ca id=\u0022xref-ref-24-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003E24\u003C\/a\u003E In the final OS analysis,\n          there was a 7.5-month improvement in OS for the PD-L1+ subgroup, reflecting a HR of 0.67\n          (95% confidence interval [CI] 0.53 to 0.86).\u003Ca id=\u0022xref-ref-25-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-25\u0022\u003E25\u003C\/a\u003E Notably, the data for the PD-L1+ subgroup remained consistent in the first,\n          second and final OS analyses with a final HR of 0.67 and a final OS improvement of 7.5\n          months at a median follow-up of 18.8 months\u0026acirc;\u0026#128;\u0026#148;a clinically meaningful benefit. A\n          follow-up phase III randomized study, IMpassion131, which investigated the addition of\n          atezolizumab to paclitaxel (described in more detail in the \u003Cstrong\u003EEmerging data on PD-(L)1\n            inhibitors for recurrent\/metastatic breast cancer\u003C\/strong\u003E section) did not demonstrate\n          benefit, for reasons that remain unclear and require further investigation.\u003C\/p\u003E\u003Cp id=\u0022p-21\u0022\u003EKEYNOTE-355 was a randomized, double-blind, phase III study of the anti-PD-1 mAb\n          pembrolizumab combined with chemotherapy (physician\u0026acirc;\u0026#128;\u0026#153;s choice of paclitaxel,\n          nab-paclitaxel, or carboplatin plus gemcitabine) versus placebo and chemotherapy for\n          previously untreated, locally recurrent, inoperable, or metastatic TNBC. Eligibility\n          included patients who had recurrent disease \u0026acirc;\u0026#137;\u0026yen;6 months from completion of adjuvant\n          therapy. In the trial, PD-L1 status was determined by the PD-L1 IHC 22C3 pharmDx assay,\n          which assesses expression on both tumor cells (TCs) and ICs, resulting in a combined\n          positive score (CPS), which is the number of PD-L1 staining cells (TCs, lymphocytes,\n          macrophages) divided by the total number of viable TCs, multiplied by 100 (see the\n            \u003Cstrong\u003EDiagnostics and biomarker testing for patients with advanced\/metastatic breast\n            cancer\u003C\/strong\u003E section for additional details on PD-L1 testing). At a median follow-up of\n          17.5 months for the pembrolizumab arm (n=566) and 15.5 months for the chemotherapy arm\n          (n=281), significant PFS benefit was observed for patients with CPS\u0026acirc;\u0026#137;\u0026yen;10 (n=636)\n          tumors. In the CPS\u0026acirc;\u0026#137;\u0026yen;1 group (n=323), PFS also numerically increased with\n          pembrolizumab (see \u003Ca id=\u0022xref-table-wrap-2-3\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003Etable 2\u003C\/a\u003E), although this did not\n          reach the pre-specified threshold for statistical significance.\u003Ca id=\u0022xref-ref-26-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26\u003C\/a\u003E Benefit was observed regardless of whether patients received a\n          taxane or gemcitabine and carboplatin. Although this analysis was exploratory only and the\n          study was not powered to compare the regimens, the HRs in the CPS\u0026acirc;\u0026#137;\u0026yen;10 population for\n          nab-paclitaxel (n=99), paclitaxel (n=44), and gemcitabine and carboplatin (n=180) were\n          0.57 (95% CI 0.34 to 0.95), 0.33 (95% CI 0.14 to 0.76), and 0.77 (95%\n          CI 0.53 to 1.11).\u003Ca id=\u0022xref-ref-27-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-27\u0022\u003E27\u003C\/a\u003E Formal testing for PFS was not\n          performed in the ITT population. According to a press release in July 2021, KEYNOTE-355\n          met its primary survival endpoint with pembrolizumab demonstrating a statistically\n          significant and clinically meaningful improvement in OS for patients whose tumors\n          expressed PD-L1 with a combined positive score \u0026acirc;\u0026#137;\u0026yen;10 compared to chemotherapy alone.\n          Based on these data, the FDA granted accelerated approval to pembrolizumab in combination\n          with chemotherapy in November 2020 for the treatment of patients with locally recurrent,\n          unresectable, or metastatic TNBC whose tumors express PD-L1 with CPS\u0026acirc;\u0026#137;\u0026yen;10 as\n          determined by an FDA-approved test. Accelerated approval was converted to full (regular)\n          approval by the FDA in July 2021. Similar to atezolizumab, the approval does not specify\n          line of therapy nor chemotherapy backbone.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ETissue-agnostic FDA approvals for checkpoint inhibitors\u003C\/h3\u003E\u003Cp id=\u0022p-22\u0022\u003EPembrolizumab is approved for two \u0026acirc;\u0026#128;\u0026#152;tissue agnostic\u0026acirc;\u0026#128;\u0026#153; (ie, irrespective of\n          primary site of origin) indications, based on high level evidence that tumor neoantigens\n          elicit cytotoxic T cell responses.\u003Ca id=\u0022xref-ref-28-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-28\u0022\u003E28\u0026acirc;\u0026#128;\u0026#147;30\u003C\/a\u003E Somatic mutations give rise to mutant proteins that are\n          proteolytically processed and presented on major histocompatibility complex Class I (MHC\n          Class I) molecules. Therefore, TMB is generally considered a surrogate for neoantigen load\n          and a predictive biomarker for T cell reactivity.\u003Ca id=\u0022xref-ref-31-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-31\u0022\u003E31\n            32\u003C\/a\u003E One common driver for a highly mutagenic tumor phenotype is a deficiency in\n          one or more components of the mismatch repair (MMR) machinery. MMR deficient (dMMR) tumors\n          frequently display a molecular signature characterized by spontaneous loss or gain of\n          nucleotides in repetitive sequences, and instability in five or more loci is defined as\n          MSI-high (MSI-H).\u003Ca id=\u0022xref-ref-33-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-33\u0022\u003E33\u003C\/a\u003E Full FDA approval of\n          pembrolizumab for the treatment of MSI-H or dMMR tumors that have progressed on prior\n          therapy regardless of tissue of origin, was first issued in May 2017.\u003Ca id=\u0022xref-ref-34-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-34\u0022\u003E34\u003C\/a\u003E This approval was based on durable responses among 149 patients with\n          15 different tumor types in five single-arm multicohort multicenter trials:\n            KEYNOTE-016,\u003Ca id=\u0022xref-ref-35-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-35\u0022\u003E35\u003C\/a\u003E KEYNOTE-164,\u003Ca id=\u0022xref-ref-36-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-36\u0022\u003E36\u003C\/a\u003E KEYNOTE-012,\u003Ca id=\u0022xref-ref-37-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-37\u0022\u003E37\u003C\/a\u003E\n            KEYNOTE-028,\u003Ca id=\u0022xref-ref-38-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-38\u0022\u003E38\u003C\/a\u003E and KEYNOTE-158 (which included\n          five patients with histologically\/cytologically confirmed MSI-H\/dMMR advanced breast\n            cancer)\u003Ca id=\u0022xref-ref-39-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-39\u0022\u003E39\u003C\/a\u003E (see \u003Ca id=\u0022xref-table-wrap-2-4\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003Etable 2\u003C\/a\u003E). Pembrolizumab was also approved for non-MSI-H\/dMMR tumors with high\n          mutation burden (TMB-H) based on KEYNOTE-158 in June 2020. TMB-H was defined in this study\n          as \u0026acirc;\u0026#137;\u0026yen;10 mutations per megabase (mut\/Mb) as assayed by the FoundationOne CDx\n          companion diagnostic\u0026acirc;\u0026#128;\u0026#148;no patients with breast cancer were included in the analysis\n          that led to approval, however.\u003Ca id=\u0022xref-ref-40-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-40\u0022\u003E40\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-23\u0022\u003EIt is important to note that breast cancers are rarely MSI-H. Current data suggest that\n          roughly 1% of TNBC\u003Ca id=\u0022xref-ref-41-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-41\u0022\u003E41\u003C\/a\u003E and fewer than\n          2% of breast cancers overall are MSI-H.\u003Ca id=\u0022xref-ref-42-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-42\u0022\u003E42\u003C\/a\u003E In\n          addition, although mutation burdens vary across subtypes, with relatively higher mutation\n          frequencies observed in HER2+ tumors and TNBC,\u003Ca id=\u0022xref-ref-43-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-43\u0022\u003E43\u0026acirc;\u0026#128;\u0026#147;45\u003C\/a\u003E TMB-H is also infrequent in breast cancer. One analysis of 3,969\n          tumor samples across breast cancer subtypes estimated an overall rate of roughly 5%\n          TMB-H tumors, with slightly higher incidence in metastatic sites compared with the primary\n            lesions.\u003Ca id=\u0022xref-ref-46-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-46\u0022\u003E46\u003C\/a\u003E TMB-H has been associated with\n          improved outcomes in patients with breast cancer receiving immunotherapy, however, benefit\n          may be contingent on additional tumor properties, such as PD-L1 status.\u003Ca id=\u0022xref-ref-47-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-47\u0022\u003E47\u003C\/a\u003E In the phase II TAPUR trial, a basket study\n          evaluating commercially available targeted agents in patients with advanced cancers with\n          specific genomic alterations, 28 women with metastatic breast cancer and tumors with\n          mutation burdens ranging from 9 to 37 muts\/Mb received pembrolizumab. All patients had\n          received at least two prior lines of systemic treatment, with 26 (93%) having been\n          previously treated with three or more therapies. The overall response rate (ORR) was\n          21% (95% CI 8% to 41%), with a median PFS of 10.6 weeks\n          (95% CI 7.7 to 21.1) and a median OS of 31.6 weeks (95% CI 11.9 to not\n          estimable). No association was observed between increasing TMB and PFS or OS.\u003Ca id=\u0022xref-ref-48-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-48\u0022\u003E48\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-24\u0022\u003EData sets from phase II and III TNBC trials are currently being analyzed retrospectively\n          to determine the prognostic value of TMB for ICI therapy. In KEYNOTE-119,\u003Ca id=\u0022xref-ref-49-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-49\u0022\u003E49\u003C\/a\u003E high TMB was associated with increased clinical\n          benefit with immunotherapy. Similarly, in IMpassion130, increasing TMB was also associated\n          with improved PFS (highest TMB quartile HR 0.56 [95% CI 0.38 to 0.81]), but the\n          association was primarily driven by the PD-L1+ subgroup (HR 0.31 [95% CI 0.17 to\n          0.57] vs 0.84 [95% CI 0.48 to 1.47] for PD-L1-negative cases).\u003Ca id=\u0022xref-ref-47-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-47\u0022\u003E47\u003C\/a\u003E Key outcomes for KEYNOTE-119 and IMpassion130 are summarized in\n            \u003Ca id=\u0022xref-table-wrap-3-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003Etable 3\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T3\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022##\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/25679\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\n\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/25679\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 3\u003C\/span\u003E \u003Cp id=\u0022p-25\u0022 class=\u0022first-child\u0022\u003EAssociation with TMB and benefit with ICIs in KEYNOTE-119 and IMpassion130\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-10\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EEmerging data on PD-(L)1 inhibitors for advanced\/metastatic breast cancer\u003C\/h3\u003E\u003Cp id=\u0022p-27\u0022\u003ESeveral additional ICI-based approaches are currently under investigation for the\n          treatment of advanced\/metastatic breast cancer, including monotherapy regimens,\n          combinations with chemotherapy, and combinations with biologics. Results of emerging\n          approaches that have advanced through to later-phase trials are discussed below and\n          summarized in table 4. For further information on additional strategies limited to\n          early-phase trials, such as immunotherapy regimens that include targeted agents such as\n          poly ADP-ribose polymerase (PARP), radiation therapy, CDK4\/6 inhibitors, and AKT\n          inhibitors, see the \u003Cstrong\u003ENovel combination strategies and promising future\n            directions\u003C\/strong\u003E section.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-11\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAdvanced\/metastatic TNBC\u003C\/h3\u003E\u003Cp id=\u0022p-28\u0022\u003EThe optimal chemotherapy backbone for immunotherapy-containing regimens is unknown,\n          however current data suggest that paclitaxel is not indicated in combination with\n          atezolizumab for advanced\/metastatic TNBC. IMpassion131, a phase III placebo-controlled\n          study, compared the efficacy and safety of first-line atezolizumab combined with\n          paclitaxel versus placebo with paclitaxel.\u003Ca id=\u0022xref-ref-50-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-50\u0022\u003E50\u003C\/a\u003E In the\n          trial, adding atezolizumab to paclitaxel did not improve PFS or OS in either the PD-L1+ or\n          the ITT population.\u003Ca id=\u0022xref-ref-51-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-51\u0022\u003E51\u003C\/a\u003E On September 8, 2020, the FDA\n          issued an alert to oncology professionals stating that the combination of atezolizumab and\n          paclitaxel did not significantly reduce the risk of cancer progression and death compared\n          with placebo and paclitaxel in the PD-L1+ population, and healthcare providers were\n          directed \u003Cem\u003Enot\u003C\/em\u003E to replace nab-paclitaxel with paclitaxel in clinical\n            practice.\u003Ca id=\u0022xref-ref-52-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-52\u0022\u003E52\u003C\/a\u003E Additional trials evaluating\n          different chemotherapy backbones are ongoing, including the randomized,\n          placebo-controlled, phase III IMpassion132 study, which is evaluating atezolizumab with\n          capecitabine or gemcitabine\/carboplatin for inoperable locally advanced\/metastatic TNBC\n          recurring \u0026acirc;\u0026#137;\u0026curren;12 months after completing standard neoadjuvant and\/or adjuvant\n          anthracycline-based and taxane-based chemotherapy or definitive surgery, whichever\n          occurred last.\u003Ca id=\u0022xref-ref-53-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-53\u0022\u003E53\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-29\u0022\u003EPembrolizumab has been evaluated as monotherapy in multiple trials for TNBC. The\n          KEYNOTE-086 phase II study enrolled two cohorts of patients, one who had undergone prior\n          treatment with anthracycline and taxane in any disease setting with progression on or\n          after the most recent therapy, and another with no prior systemic therapy for metastatic\n          disease. Patients in the cohort treated with first-line pembrolizumab were required to\n          have PD-L1+ tumors defined as CPS\u0026acirc;\u0026#137;\u0026yen;1 by the 22C3 assay,\u003Ca id=\u0022xref-ref-54-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-54\u0022\u003E54 55\u003C\/a\u003E for whom an ORR of 21.4% was subsequently demonstrated\n          (95% CI 13.9% to 31.4%).\u003Ca id=\u0022xref-ref-56-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-56\u0022\u003E56\u003C\/a\u003E For\n          the 170 patients with previously treated advanced TNBC, ORR was 5.3% (95% CI\n          2.7% to 9.9%) in the total population and 5.7% (95% CI\n          2.4% to 12.2%) in the PD-L1+ populations. Median PFS was 2 months\n          (95% CI 1.9 to 2) and median OS was 9 months (95% CI 7.6 to 11.2) for all\n            patients.\u003Ca id=\u0022xref-ref-57-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-57\u0022\u003E57\u003C\/a\u003E In KEYNOTE-119, patients with\n          metastatic TNBC who had received one to two prior systemic therapies were randomized to\n          receive pembrolizumab (n=312) or physician\u0026acirc;\u0026#128;\u0026#153;s choice of capecitabine, eribulin\n          mesylate, gemcitabine, or vinorelbine (n=310). Patients were stratified by PD-L1 CPS. At a\n          median follow-up of 9.9 months for the pembrolizumab group and 10.9 months for the\n          chemotherapy group, single-agent pembrolizumab did not significantly improve OS compared\n          with single-agent chemotherapy in the ITT population nor the pre-specified subgroups. In\n          an exploratory analysis of patients with CPS\u0026acirc;\u0026#137;\u0026yen;20, median OS was 14.9 months with\n          pembrolizumab versus 12.5 months with chemotherapy (HR 0.58; 95% CI 0.38 to\n            0.88).\u003Ca id=\u0022xref-ref-58-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-58\u0022\u003E58\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-12\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAdvanced HER2+ breast cancer\u003C\/h3\u003E\u003Cp id=\u0022p-30\u0022\u003ESignals of clinical efficacy have been reported with the addition of ICIs to standard of\n          care therapies in HER2+ advanced breast cancer. Beyond immunotherapy, additional targeted\n          agents such as trastuzumab deruxtecan and tucatinib continue to offer more options to\n          patients with HER2+ disease.\u003Ca id=\u0022xref-ref-59-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-59\u0022\u003E59 60\u003C\/a\u003E In the phase\n          II KATE2 study, which randomized 133 patients to receive atezolizumab plus trastuzumab\n          emtansine (T-DM1) and 69 patients to receive placebo plus T-DM1, no statistically\n          significant difference in overall PFS was observed between the two arms. A trend toward\n          more favorable PFS and ORR were seen with the combination in patients with tumor\n          infiltrating lymphocyte (TIL) \u0026acirc;\u0026#137;\u0026yen;5% and\/or PD-L1+ tumors as defined by an IC\n          score \u003Cspan class=\u0022underline\u0022\u003E\u0026gt;\u003C\/span\u003E1 by the SP142 assay.\u003Ca id=\u0022xref-ref-61-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-61\u0022\u003E61\u003C\/a\u003E Updated data with a median follow-up of 19.5 months for the atezolizumab arm\n          and 18.2 months for the placebo arm revealed similar 1-year OS rates in both arms\n          (89.1% vs 89% for atezolizumab vs placebo; HR 0.74; 95% CI 0.42 to\n          1.30). In the PD-L1+ subgroup (n=57 in the atezolizumab arm and n=27 in the placebo arm),\n          the 1-year OS was numerically greater in the atezolizumab arm compared with placebo\n          (94.3% vs 87.9%; HR 0.55; 95% CI 0.22 to 1.38).\u003Ca id=\u0022xref-ref-61-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-61\u0022\u003E61\u003C\/a\u003E A definitive phase III trial is planned based on this\n          hypothesis-generating data.\u003C\/p\u003E\u003Cp id=\u0022p-31\u0022\u003EProviding further support for additional investigation of ICIs in HER2+ disease, the\n          phase Ib\/II PANACEA study explored pembrolizumab in combination with trastuzumab in\n          patients with HER2+, trastuzumab-resistant metastatic breast cancer. Of the 52 heavily\n          pre-treated patients enrolled in the phase II portion, 46 patients (77%) had PD-L1+\n          disease (CPS \u0026acirc;\u0026#137;\u0026yen;1%), and, of these, 7 (15%) achieved an objective\n          response and 4 (8%) maintained stable disease (SD) for more than 6 months.\u003Ca id=\u0022xref-ref-62-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-62\u0022\u003E62\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-13\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAdvanced ER+ breast cancer\u003C\/h3\u003E\u003Cp id=\u0022p-32\u0022\u003EKEYNOTE-028 was a phase Ib, open-label, multicohort study that investigated the safety\n          and antitumor activity of pembrolizumab in patients with PD-L1+ advanced solid tumors,\n          including 25 patients with estrogen receptor positive (ER+)\/HER2-negative (HER2\u0026acirc;\u0026#128;\u0026#147;)\n          advanced breast cancer, among whom three experienced partial response (PR), leading to an\n          ORR of 12% (95% CI 2.5% to 31.2%). The clinical benefit rate\n          (complete response (CR)+PR+SD (for \u0026acirc;\u0026#137;\u0026yen;24 weeks)) was 20% (95% CI\n          7% to 41%) and the median duration of response (DOR) was 12 months (range\n          7.4 to 15.9 months).\u003Ca id=\u0022xref-ref-38-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-38\u0022\u003E38\u003C\/a\u003E In the phase Ib JAVELIN\n          study, which evaluated the anti-PD-L1 avelumab in 72 women with HR+\/HER2\u0026acirc;\u0026#128;\u0026#147; disease\n          (with no requirements for PD-L1 expression), an ORR of 2.8% was observed.\u003Ca id=\u0022xref-ref-63-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-63\u0022\u003E63\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-33\u0022\u003EPembrolizumab has been evaluated in combination with eribulin mesylate for ER+ metastatic\n          breast cancer in a randomized phase II trial that enrolled 88 patients. At a median\n          follow-up of 10.5 months, no significant difference in median PFS and ORR was observed\n          with the addition of pembrolizumab to eribulin mesylate compared with eribulin mesylate\n          alone (PFS, 4.1 vs 4.2 months; HR 0.80; HR 95% CI 0.50 to 1.26; p =0.33; ORR\n          27% vs 34%, respectively; p =0.49). PD-L1 testing by the 22C3 assay was\n          performed for 65 patients, and 24 (36.9%) were found to have PD-L1+ tumors\n          (modified proportion score\u0026gt;1%). PD-L1 status was not associated with PFS,\n          although the group of patients with PD-L1+ tumors was small and thus had limited power to\n          assess benefit.\u003Ca id=\u0022xref-ref-64-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-64\u0022\u003E64\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-14\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPanel recommendations\u003C\/h3\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-1\u0022\u003E\u003Cli id=\u0022list-item-1\u0022\u003E\u003Cp id=\u0022p-34\u0022\u003EClinical trial enrollment remains a priority to further understand the benefit of\n              checkpoint inhibition in metastatic breast cancer.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-2\u0022\u003E\u003Cp id=\u0022p-35\u0022\u003EAll patients with unresectable locally advanced or metastatic TNBC should have tumor\n              tissue tested for PD-L1 by an FDA-approved assay for breast cancer.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-3\u0022\u003E\u003Cp id=\u0022p-36\u0022\u003EAll patients with locally advanced or metastatic breast cancer should undergo\n              comprehensive genomic profiling, including testing for TMB and MSI.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-4\u0022\u003E\u003Cp id=\u0022p-37\u0022\u003EWith the withdrawal of the indication for atezolizumab with nab-paclitaxel in\n              metastatic TNBC, one companion diagnostic is approved by the FDA for PD-L1 testing in\n              metastatic TNBC: the 22C3 assay with tumor and IC scoring by combined positive score.\n              Benefit is seen for adding pembrolizumab to chemotherapy in patients with tumors\n              expressing PD-L1 by CPS score \u0026acirc;\u0026#137;\u0026yen;10 (LE:2).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-5\u0022\u003E\u003Cp id=\u0022p-38\u0022\u003EFor patients with locally advanced\/metastatic TNBC and PD-L1+ tumors by CPS score\n              \u0026acirc;\u0026#137;\u0026yen;10 using the 22C3 assay, pembrolizumab plus nab-paclitaxel, paclitaxel, or\n              carboplatin and gemcitabine is recommended as one immunotherapy option for first-line\n              treatment (LE:2), based on clinically meaningful PFS improvement in KEYNOTE-355.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-6\u0022\u003E\u003Cp id=\u0022p-39\u0022\u003EFor patients with locally advanced\/metastatic TNBC, pembrolizumab should only be\n              added to chemotherapy (nab-paclitaxel, paclitaxel or carboplatin\/gemcitabine\n              combination) if tumors express PD-L1 with CPS\u0026acirc;\u0026#137;\u0026yen;10 by the 22C3 assay (until PD-L1\n              assays are harmonized) (LE: 2).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-7\u0022\u003E\u003Cp id=\u0022p-40\u0022\u003EFor patients with locally advanced\/metastatic TNBC and PD-L1+ tumors being treated\n              with atezolizumab, nab-paclitaxel is the only chemotherapy backbone that has\n              demonstrated activity in randomized clinical trials (LE: 2). The indication for\n              atezolizumab in this setting was voluntarily withdrawn in 2021.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-8\u0022\u003E\u003Cp id=\u0022p-41\u0022\u003EAll patients who are candidates for immunotherapy treatment for metastatic TNBC\n              should have tumor tissue tested for PD-L1 at least once, irrespective of line of\n              therapy or prior immunotherapy in the adjuvant or neoadjuvant setting.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-9\u0022\u003E\u003Cp id=\u0022p-42\u0022\u003EPatients deriving clinical benefit from atezolizumab-based treatment in the absence\n              of clinically significant toxicity or disease progression should continue on\n              atezolizumab plus nab-paclitaxel rather than change therapy.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-15\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EEmerging data on immunotherapy with PD-(L)1 Inhibitors for early-stage\/locally advanced\n        breast cancer\u003C\/h2\u003E\u003Cp id=\u0022p-43\u0022\u003EAt the time of guideline writing, one ICI, pembrolizumab, was approved by the FDA for the\n        treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as\n        neoadjuvant treatment and then continued as a single agent as adjuvant treatment after\n        surgery. The potential for permanent irAEs must be considered in the risk-benefit\n        calculation when discussing immunotherapy with a patient with early stage disease who is\n        treated with curative intent. Immunotherapy for early-stage breast cancer is an active and\n        rapidly evolving area of research. Several trials have been completed evaluating various ICI\n        and chemotherapy regimens in the neoadjuvant setting. Results of completed trials are\n        summarized in \u003Ca id=\u0022xref-table-wrap-4-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T4\u0022\u003Etable 4\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T4\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022##\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/25668\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\n\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/25668\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 4\u003C\/span\u003E \u003Cp id=\u0022p-44\u0022 class=\u0022first-child\u0022\u003ECompleted phase II\/III neoadjuvant immunotherapy trials for early-stage breast\n            cancer\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-16\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ENeoadjuvant setting\u003C\/h3\u003E\u003Cp id=\u0022p-47\u0022\u003EThe phase II I-SPY 2 trial indicated that the addition of pembrolizumab to standard\n          neoadjuvant chemotherapy improved estimated pCR rates in patients with high-risk stage\n          II\/III TNBC and Mammaprint-defined high-risk HR+\/HER2\u0026acirc;\u0026#128;\u0026#147; breast cancer. I-SPY 2 is a\n          platform trial with an adaptive design that evaluates multiple investigational agents\n          concurrently against a common control arm of weekly paclitaxel for 12 weeks followed by\n          doxorubicin plus cyclophosphamide given every 2\u0026acirc;\u0026#128;\u0026#147;3 weeks for 4 cycles.\n          \u0026acirc;\u0026#128;\u0026#152;Graduation\u0026acirc;\u0026#128;\u0026#153; for efficacy occurs if the predefined efficacy threshold of\n          85% probability of success in a subtype-specific, hypothetical 300 patient phase\n          III trial is met. The primary endpoint of the I-SPY 2 trial is pCR rate. The first\n          immunotherapy arm investigated the efficacy of 4 cycles of pembrolizumab added to\n          neoadjuvant paclitaxel followed by adjuvant chemotherapy.\u003Ca id=\u0022xref-ref-65-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-65\u0022\u003E65\u003C\/a\u003E In a recent report including 250 patients from I-SPY 2 randomized to standard\n          chemotherapy with or without pembrolizumab, the addition of pembrolizumab to paclitaxel\n          demonstrated improved estimated pCR rates across TNBC and ER+ subtypes compared with\n          standard chemotherapy. For the 69 patients receiving pembrolizumab (40 HR+\/HER2\u0026acirc;\u0026#128;\u0026#147;\n          and 29 TNBC), the final estimated pCR rates in the TNBC cohort were 60% versus\n          22% for pembrolizumab versus control. The estimated pCR rates were 30%\n          versus 13% in the HR+\/HER2\u0026acirc;\u0026#128;\u0026#147; cohort and 44% versus 17% among\n          all HER2\u0026acirc;\u0026#128;\u0026#147; patients.\u003Ca id=\u0022xref-ref-65-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-65\u0022\u003E65\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-48\u0022\u003EIn the I-SPY2 trial, pembrolizumab \u0026acirc;\u0026#128;\u0026#152;graduated\u0026acirc;\u0026#128;\u0026#153; for both HR+\/HER2\u0026acirc;\u0026#128;\u0026#147;\n          and TNBC after 69 patients had been randomized to receive the investigational therapy and\n          201 were randomized to the control group. Pembrolizumab was the first of 10 agents to\n          graduate for HR+\/HER2\u0026acirc;\u0026#128;\u0026#147; disease. A second arm investigated 8 cycles of\n          pembrolizumab, half of which were given without chemotherapy.\u003Ca id=\u0022xref-ref-66-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-66\u0022\u003E66\u003C\/a\u003E In this arm, patients received paclitaxel plus pembrolizumab for 4\n          cycles followed by 4 cycles of pembrolizumab alone, without adjuvant chemotherapy. Of the\n          73 patients who were randomized to this arm, three progressed while receiving\n          pembrolizumab alone. Treatment with pembrolizumab alone was no longer allowed due to the\n          potential concern for progression for those randomized to pembrolizumab alone, and\n          investigators were given the option to administer adjuvant chemotherapy with pembrolizumab\n          or proceed with definitive surgery following the 12 weeks of paclitaxel plus\n          pembrolizumab. The estimated pCR rates for the HR+\/HER2\u0026acirc;\u0026#128;\u0026#147; and TNBC signatures were\n          the same for the pembrolizumab versus control arms, at 15% (95% CI\n          10% to 29%) versus 15% (95% CI 9% to 20%) and\n          27% (95% CI 9% to 45%) versus 27% (95% CI\n          19% to 50%), respectively.\u003Ca id=\u0022xref-ref-66-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-66\u0022\u003E66\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-49\u0022\u003ESix different pembrolizumab plus chemotherapy regimens were evaluated as neoadjuvant\n          therapy for high-risk, early-stage TNBC in the phase Ib trial KEYNOTE-173. All cohorts\n          received a single run-in dose of pembrolizumab for cycle one, followed by 8 cycles of\n          pembrolizumab in combination with a taxane (nab-paclitaxel for five of six cohorts and\n          paclitaxel for the remaining cohort) with or without carboplatin at varying dosing levels\n          for 12 weeks. For an additional 12 weeks before surgery, all patients received doxorubicin\n          and cyclophosphamide. The overall pCR rate for all cohorts was 60% (90% CI\n          30% to 85%), with ORR ranging from 70% to 100% in the\n          different chemotherapy dosing regimens. At a median follow-up of 19.6 months, the 12-month\n          EFS rate was 100% and 88% for patients who did and did not achieve pCR,\n          respectively. Four cohorts (three groups who received pembrolizumab with nab-paclitaxel\n          and carboplatin as well as the group receiving paclitaxel plus carboplatin) had a 12-month\n          EFS rate of 100%.\u003Ca id=\u0022xref-ref-67-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-67\u0022\u003E67\u003C\/a\u003E In exploratory analyses,\n          significant associations with pCR rates were observed for pre-treatment PD-L1 CPS\n          (p=0.0127), and both pre-treatment and on-treatment stromal TILs (p=0.0059 and 0.0085,\n            respectively).\u003Ca id=\u0022xref-ref-68-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-68\u0022\u003E68\u003C\/a\u003E The results of KEYNOTE-173\n          informed the chemotherapy backbone selection for the subsequent phase III KEYNOTE-522\n          trial.\u003C\/p\u003E\u003Cp id=\u0022p-50\u0022\u003EIn July 2021, the FDA granted regular approval to pembrolizumab for the treatment of\n          patients with high-risk TNBC in combination with chemotherapy as neoadjuvant treatment and\n          then continued as a single agent as adjuvant treatment after surgery. Approval was based\n          on KEYNOTE-522, a randomized phase III trial, which assigned patients with previously\n          untreated stage II or stage III TNBC in a 2:1 ratio to receive neoadjuvant therapy with 4\n          cycles of pembrolizumab (200 mg) every 3 weeks plus paclitaxel and carboplatin (n=784\n          patients) or placebo every 3 weeks plus paclitaxel and carboplatin (n=390 patients). Both\n          groups received an additional 4 cycles of pembrolizumab or placebo, and both groups\n          received doxorubicin+cyclophosphamide or epirubicin+cyclophosphamide before surgery. After\n          definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks\n          for up to 9 cycles. At the first interim analysis of the initial 602 randomized patients,\n          the pCR rate was 64.8% (95% CI 59.9% to 69.5%) in the group\n          receiving pembrolizumab and 51.2% (95% CI 44.1% to 58.3%) in\n          the group receiving placebo (p\u0026lt;0.001). In the trial, improved pCR rates with\n          pembrolizumab were generally consistent across subgroups, regardless of tumor size or\n          PD-L1 status. The increase in pCR rate with the addition of pembrolizumab was numerically\n          greater for patients with node positive disease (20.6% increase; 95% CI\n          8.9% to 31.9%) than for those without lymph node involvement (6.3%\n          increase; 95% CI \u0026acirc;\u0026#128;\u0026#147;5.3% to 18.2%).\u003Ca id=\u0022xref-ref-69-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-69\u0022\u003E69 70\u003C\/a\u003E Recently released data from the third pre-planned interim\n          analysis including the entire ITT population (n=1174) showed pCR rates of 63%\n          (95% CI 59.5 to 66.4) and 55.6% (95% CI 50.6 to 60.6) in the\n          pembrolizumab and placebo arms, respectively, for a stratified delta of 7.5%\n          (95% CI 1.6 to 13.4). At a median follow-up of 26.1 months with roughly 53%\n          of required events, the EFS HR was 0.65 (95% CI 0.48 to 0.88).\u003Ca id=\u0022xref-ref-71-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-71\u0022\u003E71\u003C\/a\u003E The fourth pre-planned interim analysis was presented during an\n          online ESMO Virtual Plenary session on July 15, 2021.\u003Ca id=\u0022xref-ref-72-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-72\u0022\u003E72\u003C\/a\u003E With a median follow-up of 39.1 months, the addition of pembrolizumab to\n          chemotherapy resulted in a statistically significant and clinically meaningful improvement\n          in EFS, with a HR of 0.63 (95% CI 0.48 to 0.82; p=0.00031). No new safety signals\n          emerged. Most immune-mediated AEs were low-grade, occurred in the neoadjuvant phase, and\n          were manageable with treatment interruption, steroid administration, and\/or hormone\n          replacement. Treatment-related AEs of grade \u0026acirc;\u0026#137;\u0026yen;3 occurred in 77.1% of the\n          patients who received pembrolizumab compared with 73.3% of the patients in the\n          placebo group, leading to discontinuation of any trial drug in 27.7% and\n          14.1% in each arm, respectively. The most common irAEs reported among patients\n          receiving pembrolizumab (incidence \u0026acirc;\u0026#137;\u0026yen;10 patients) were infusion reactions\n          (18%), hypothyroidism (15.1%), severe skin reactions (5.7%),\n          hyperthyroidism (5.2%), adrenal insufficiency (2.4%), pneumonitis\n          (2.2%), thyroiditis (2.0%), hypophysitis (1.9%), colitis\n          (1.7%), and hepatitis (1.4%).\u003Ca id=\u0022xref-ref-72-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-72\u0022\u003E72\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-51\u0022\u003EAlso in I-SPY2, the combination of the anti-PD-L1 mAb durvalumab, the PARP inhibitor\n          olaparib, and paclitaxel followed by doxorubicin+cyclophosphamide as neoadjuvant therapy\n          demonstrated improved pCR rates compared with paclitaxel followed by\n          doxorubicin\/cyclophosphamide alone in patients with high-risk HER2\u0026acirc;\u0026#128;\u0026#147; stage II or III\n          breast cancer. Based on results from a total of 73 patients, including 21 with TNBC and 52\n          with HR+ tumors, the durvalumab plus olaparib plus paclitaxel arm graduated 13 months\n          after enrollment had started with \u003Cspan class=\u0022underline\u0022\u003E\u0026gt;\u003C\/span\u003E0.85% predictive\n          probability of success. Among the 72 patients who completed surgery and were evaluable for\n          pCR, the final predicted probabilities of success in a future phase III study were\n          81% for all HER2\u0026acirc;\u0026#128;\u0026#147; cancers (estimated pCR rate 37%), 80% for\n          TNBC (estimated pCR rate 47%) and 74.5% for HR+\/HER2\u0026acirc;\u0026#128;\u0026#147; patients\n          (estimated pCR rate 28%).\u003Ca id=\u0022xref-ref-73-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-73\u0022\u003E73\u003C\/a\u003E For further\n          discussion of PARP inhibition in combination with immunotherapy see the \u003Cstrong\u003ENovel\n            combination strategies and promising future directions\u003C\/strong\u003E section.\u003C\/p\u003E\u003Cp id=\u0022p-52\u0022\u003EDurvalumab was also evaluated in the GeparNuevo trial, which randomized 174 patients with\n          operable TNBC to receive durvalumab or placebo in addition to standard neoadjuvant\n          nab-paclitaxel. The overall pCR rate in the durvalumab arm was 53.4% (95% CI\n          42.5% to 61.4%) compared with 44.2% (95% CI 33.5% to\n          55.3%) in the control arm. Notably, however, benefit with durvalumab was largely\n          observed in the subset of 117 patients that received durvalumab during a run-in window 2\n          weeks prior to the initiation of chemotherapy, with pCR rates in this cohort of 61%\n          versus 41.4% (odds ratio [OR]=2.22; 95% CI 1.06 to 4.64; p=0.035;\n          interaction p=0.048). Although characteristics at baseline were generally balanced between\n          treatment arms, patients in the group receiving durvalumab during the window phase were\n          more likely to have stage IIA tumors and nodal involvement before beginning therapy. Due\n          to the Independent Data Monitoring Committee\u0026acirc;\u0026#128;\u0026#153;s concern about the delay in starting\n          chemotherapy, the study was amended to eliminate the window-phase after those 117 patients\n          were enrolled. Significantly higher pCR rates were observed among patients with higher\n          levels of stromal TILs in both arms in the complete cohort of patients (p\u0026lt;0.01).\n          Among the patients who received durvalumab in the window phase, changes in the numbers of\n          intratumoral TILs between baseline and after the window phase significantly predicted\n          achieving pCR (n=41) in both univariate (OR 5.15; 95% CI 1.10 to 24.05; p=0.037)\n          and multivariate regression analyses (OR 9.36; 95% CI 1.26 to 69.65; p=0.029). A\n          trend toward increased response rates in PD-L1+ tumors was observed in both arms, with a\n          significant association between pCR rates and PD-L1+ TCs for the durvalumab group\n          (p=0.045) and between pCR rates and PD-L1+ ICs in the placebo group (p=0.040), as measured\n          by the VENTANA PD-L1 (SP263) assay.\u003Ca id=\u0022xref-ref-74-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-74\u0022\u003E74\u003C\/a\u003E The findings\n          of the window cohort in GeparNuevo are provocative and raise the question of how best to\n          sequence immunotherapy and chemotherapy.\u003C\/p\u003E\u003Cp id=\u0022p-53\u0022\u003EThe NeoTRIPaPDL1 Michelangelo trial was a randomized phase III trial that enrolled 280\n          patients with previously untreated TNBC and investigated neoadjuvant chemotherapy with\n          carboplatin and nab-paclitaxel for 8 cycles with or without atezolizumab, followed by\n          surgery and adjuvant anthracycline-based treatment.\u003Ca id=\u0022xref-ref-75-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-75\u0022\u003E75\n            76\u003C\/a\u003E The primary endpoint was 5-year EFS and secondary endpoints were pCR and\n          safety. The secondary endpoint of pCR rate for the atezolizumab arm was not significantly\n          higher than the control arm, regardless of PD-L1 status (overall study population:\n          43.5% vs 40.8%; PD-L1+ disease: 51.9% vs 48.0%; PD-L1-negative\n          disease: 32.2% vs 32.3%). Follow-up is ongoing for the primary EFS\n          endpoint.\u003C\/p\u003E\u003Cp id=\u0022p-54\u0022\u003EIMpassion031, a double-blind phase III study, randomized 333 patients with previously\n          untreated stage II\u0026acirc;\u0026#128;\u0026#147;III TNBC 1:1 to receive nab-paclitaxel followed by dose-dense\n          doxorubicin and cyclophosphamide plus atezolizumab (n=165) or placebo (n=168) followed by\n          surgery. Patients were unblinded after surgery and adjuvant atezolizumab was continued at\n          a fixed dose of 1,200 mg IV every 3 weeks for 11 doses, for a total of approximately 12\n          months of therapy. At a median follow-up of 20.6 months in the atezolizumab plus\n          chemotherapy group and 19.8 months in the placebo plus chemotherapy group, pCR was\n          observed in 95 patients (58%; 95% CI 50% to 65%) in the\n          immunotherapy arm and 69 patients (41%; 95% CI 34% to 49%) in\n          the placebo plus chemotherapy group (rate difference 17%; 95% CI 6%\n          to 27%; one-sided p=0.0044 [significance boundary 0.0184]). For patients with\n          PD-L1+ tumors, the pCR rate was 69% in the atezolizumab arm (53 out of 77 patients;\n          95% CI 57% to 79%) compared with 49% (37 of 75 patients;\n          95% CI 38% to 61%) in the placebo arm, for a rate difference of\n          20% (95% CI, 4% to 35%; one-sided p=0.021 [significance\n          boundary 0.0184]). Grade 3\u0026acirc;\u0026#128;\u0026#147;4 AEs were balanced between the arms, and\n          treatment-related serious AEs occurred in 37 (23%) and 26 (16%) patients,\n          respectively, for the atezolizumab and placebo groups.\u003Ca id=\u0022xref-ref-77-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-77\u0022\u003E77\u003C\/a\u003E Data from the ongoing GeparDouze trial will further evaluate the addition of\n          immunotherapy to an anthracycline, taxane, and platinum backbone.\u003Ca id=\u0022xref-ref-78-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-78\u0022\u003E78\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-55\u0022\u003EAdditional ongoing studies include KEYNOTE-756, a global, randomized, double-blind, phase\n          III study, which is investigating pembrolizumab plus chemotherapy as neoadjuvant treatment\n          followed by pembrolizumab plus endocrine therapy as adjuvant treatment for patients with\n          high-risk, early-stage ER+\/HER2\u0026acirc;\u0026#136;\u0026#146; breast cancer.\u003Ca id=\u0022xref-ref-79-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-79\u0022\u003E79\u003C\/a\u003E Also, the ongoing CheckMate 7FL trial is evaluating the benefits of adding\n          nivolumab to standard neoadjuvant chemotherapy and to adjuvant endocrine therapy for\n          patients with newly diagnosed high-risk, HR+\/HER2\u0026acirc;\u0026#136;\u0026#146; primary breast cancer.\u003Ca id=\u0022xref-ref-80-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-80\u0022\u003E80\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-17\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAdjuvant setting\u003C\/h3\u003E\u003Cp id=\u0022p-56\u0022\u003ELimited data are available on the efficacy of immunotherapy for adjuvant treatment of\n          early-stage breast cancer. Although the experimental arm of KEYNOTE-522 included adjuvant\n          pembrolizumab in addition to neoadjuvant chemotherapy and pembrolizumab, it is unclear\n          whether or not the DFS benefit was derived from the neoadjuvant or adjuvant portions, or\n          both. Several ongoing studies are specifically evaluating checkpoint inhibitors either as\n          monotherapy or in combination with chemotherapy as adjuvant treatment.\u003C\/p\u003E\u003Cp id=\u0022p-57\u0022\u003EThe ongoing ALEXANDRA\/IMpassion030 study is an international, phase III, open-label trial\n          randomizing a total of 2,300 patients with stage I-II TNBC 1:1 to receive standard\n          adjuvant chemotherapy with or without atezolizumab.\u003Ca id=\u0022xref-ref-76-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-76\u0022\u003E76\u003C\/a\u003E The primary endpoint is invasive disease-free survival (iDFS) and secondary\n          endpoints include iDFS by PD-L1 status and lymph node status, OS, safety, and QOL.\n          Patients will be stratified by type of surgery, nodal status, and PD-L1 status.\u003C\/p\u003E\u003Cp id=\u0022p-58\u0022\u003ESWOG S1418 is a randomized phase III trial evaluating pembrolizumab in the adjuvant\n          setting for patients with residual TNBC measuring at least 1 cm in the breast and\/or lymph\n          node involvement after neoadjuvant chemotherapy and definitive surgery.\u003Ca id=\u0022xref-ref-81-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-81\u0022\u003E81\u003C\/a\u003E A total of 1,000 patients are being enrolled and\n          randomized 1:1 to pembrolizumab or observation. The primary endpoint is iDFS, and\n          secondary endpoints are OS, distant relapse-free survival, and safety.\u003C\/p\u003E\u003Cp id=\u0022p-59\u0022\u003EAvelumab is being evaluated as adjuvant therapy in A-Brave, a trial of 335 patients with\n          high-risk TNBC. The protocol-defined patient population will include two strata of\n          patients: those who have completed curative intent surgery of the primary tumor followed\n          by adjuvant chemotherapy with at least 3 cycles of anthracycline and taxane-based therapy\n          (stratum A), and those who have who have completed neoadjuvant chemotherapy with residual\n          disease after curative intent surgery of the primary tumor (stratum B). The primary\n          endpoint is DFS, and secondary endpoints are OS and safety.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-18\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EFuture directions\u003C\/h3\u003E\u003Cp id=\u0022p-60\u0022\u003ESeveral important questions remain regarding the optimal integration of immunotherapy\n          into treatment for early-stage breast cancer, including the unknown benefits of checkpoint\n          inhibitors in the metastatic setting if patients have previously been treated with these\n          agents for early-stage disease. It will also be key to establish whether pCR corresponds\n          to EFS or OS benefit with ICIs administered in the neoadjuvant setting. Future trials will\n          be needed to address if there is a role for de-escalating the chemotherapy backbone, the\n          role for continuing immunotherapy in patients that do or do not achieve pCR, the optimal\n          duration of immunotherapy, the optimal sequencing of chemotherapy and immunotherapy, and\n          the clinicopathologic features and\/or biomarkers that predict who will benefit from the\n          addition of immunotherapy to neoadjuvant chemotherapy as well as who is at increased risk\n          for irAEs.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-19\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPanel recommendations\u003C\/h3\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-2\u0022\u003E\u003Cli id=\u0022list-item-10\u0022\u003E\u003Cp id=\u0022p-61\u0022\u003EFor all patients with stage II and III TNBC, clinical trial enrollment should be\n              considered if available.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-11\u0022\u003E\u003Cp id=\u0022p-62\u0022\u003EFor patients with stage II and III TNBC, improved pCR rates with either neoadjuvant\n              pembrolizumab or atezolizumab have been observed, regardless of PD-L1 status (LE:\n              2).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-12\u0022\u003E\u003Cp id=\u0022p-63\u0022\u003EFor patients with high-risk early-stage TNBC, pembrolizumab in combination with\n              chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant\n              treatment after surgery is a standard of care based on statistically significant and\n              clinically meaningful improvement in EFS in KEYNOTE-522. Overall survival (OS) data is\n              still maturing (LE: 2).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-13\u0022\u003E\u003Cp id=\u0022p-64\u0022\u003EFor patients with stage II and III TNBC and no available trial, the addition of\n              atezolizumab to standard neoadjuvant chemotherapy may be considered, although not\n              FDA-approved at the time of publication and the IMpassion031 trial was not powered to\n              assess EFS (LE: 2).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-14\u0022\u003E\u003Cp id=\u0022p-65\u0022\u003EBased on accumulated data to date, immunotherapy regimens for stage II and III TNBC\n              should at least include an anthracycline and a taxane with or without carboplatin (LE:\n              2).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-15\u0022\u003E\u003Cp id=\u0022p-66\u0022\u003EFor patients with stage II and III TNBC in KEYNOTE-522, patients continued\n              immunotherapy from the neoadjuvant setting into the adjuvant setting. The potential\n              benefits of adjuvant immunotherapy must be weighed against the potential for\n              toxicities with treatment.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-20\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EDiagnostics and biomarker testing in patients with advanced\/metastatic breast\n        cancer\u003C\/h2\u003E\u003Cp id=\u0022p-67\u0022\u003EBreast cancer is a heterogeneous disease with multiple histologic and molecular subtypes.\n        Generally, breast cancer is classified into three clinically relevant categories: luminal,\n        characterized by expression of ER and\/or progesterone receptor (PR); HER2+; and TNBC. Gene\n        expression profiling reveals further distinctions within the IHC-based classifications:\n        luminal A (ER+\/HER2-\/Ki67-low) and luminal B (ER+\/HER2+ or ER+\/HER2\u0026acirc;\u0026#128;\u0026#147;\/Ki67-high),\n        HER2+, claudin-low, and basal-like.\u003Ca id=\u0022xref-ref-82-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-82\u0022\u003E82\u0026acirc;\u0026#128;\u0026#147;84\u003C\/a\u003E TNBC is also heterogeneous and may be classified into six molecular\n          subtypes,\u003Ca id=\u0022xref-ref-85-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-85\u0022\u003E85\u003C\/a\u003E but these classifications are not\n        currently indicated to guide treatment decisions. Luminal disease indicates eligibility for\n        endocrine therapy, and HER2+ tumors are treated with anti-HER2 antibodies including\n        trastuzumab and pertuzumab, antibody-drug conjugates such as trastuzumab deruxtecan,\n        trastuzumab emtansine, or tyrosine kinase inhibitors including neratinib and tucatinib,\n        among other agents.\u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4 60 86 87\u003C\/a\u003E Guidelines\n        from the College of American Pathologists (CAP) provide more detailed recommendations for\n        scoring HR and HER2 status by IHC, and confirming HER2 IHC equivocal cases by other methods\n        including fluorescence in situ hybridization (FISH).\u003Ca id=\u0022xref-ref-88-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-88\u0022\u003E88\n          89\u003C\/a\u003E Historically, the TNBC subtype lacked targeted therapy options aside from PARP\n        inhibition for \u003Cem\u003EBRCA\u003C\/em\u003E-mutated cancers.\u003Ca id=\u0022xref-ref-90-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-90\u0022\u003E90\u003C\/a\u003E However, patients with TNBC are now eligible for anti-PD-(L)1 immunotherapy as\n        well as treatment with the Trop-2 directed antibody-drug conjugate sacituzumab\n          govitecan.\u003Ca id=\u0022xref-ref-91-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-91\u0022\u003E91\u003C\/a\u003E At the time of guideline preparation,\n        aside from the pan-tumor anti-PD-(L)1 approvals for TMB-H or MSI-H cancers, TNBC is the only\n        breast cancer subtype for which immunotherapy is approved.\u003C\/p\u003E\u003Cdiv id=\u0022sec-21\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EBiomarkers at first relapse\u003C\/h3\u003E\u003Cp id=\u0022p-68\u0022\u003EGenomic instability frequently leads to phenotypic alterations in recurrent tumors\n          compared with the primary site,\u003Ca id=\u0022xref-ref-92-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-92\u0022\u003E92 93\u003C\/a\u003E and\n          therefore repeat biopsy of a metastatic lesion is strongly recommended. Treatment may\n          select for modified marker expression in recurrent tumors and genetic alterations that may\n          also contribute to a metastatic tumor\u0026acirc;\u0026#128;\u0026#153;s ability to spread. Changes in ER\/PR and\n          HER2 expression in metastases have been reported at rates ranging from 30% to\n          40% for ER\/PR and 10% to 15% for HER2.\u003Ca id=\u0022xref-ref-94-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-94\u0022\u003E94 95\u003C\/a\u003E Changes in ER, PR, and HER2 status have also been observed\n          after neoadjuvant chemotherapy,\u003Ca id=\u0022xref-ref-96-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-96\u0022\u003E96\u003C\/a\u003E with implications\n          for therapy selection in recurrent disease. Similarly, metastases frequently harbor\n          distinct genomic alterations compared with primary tumors, leading to the emergence of new\n          actionable mutations in as many as 24% of patients, including acquired homologous\n          repair deficiency, \u003Cem\u003EPI3K\u003C\/em\u003E mutations, and TMB-H status.\u003Ca id=\u0022xref-ref-92-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-92\u0022\u003E92 93 97 98\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-69\u0022\u003ENotably, PD-L1 expression may be discordant in metastatic versus primary lesions, with\n          higher PD-L1 positivity observed in early-stage lesions relative to metastatic sites.\u003Ca id=\u0022xref-ref-99-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-99\u0022\u003E99\u003C\/a\u003E In general, metastatic tumors contain fewer ICs and\n          decreased markers of immune activation relative to primary breast tumors.\u003Ca id=\u0022xref-ref-13-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13 99 100\u003C\/a\u003E In addition, the degree of immune\n          infiltration and PD-L1 labeling varies between metastatic sites, with certain metastatic\n          niches, such as lung, displaying greater IC and PD-L1 positivity than other\n          immunologically colder niches, such as liver.\u003Ca id=\u0022xref-ref-101-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-101\u0022\u003E101\u003C\/a\u003E\n          Although the liver has classically been referred to as a \u0026acirc;\u0026#128;\u0026#152;graveyard\u0026acirc;\u0026#128;\u0026#153; for\n          effector T cells and a \u0026acirc;\u0026#128;\u0026#152;school\u0026acirc;\u0026#128;\u0026#153; for regulatory T cells, a more nuanced\n          understanding of the roles of several cell types, including monocytes and parenchymal\n          cells, in creating a generally immunosuppressive hepatic microenvironment is beginning to\n            emerge.\u003Ca id=\u0022xref-ref-102-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-102\u0022\u003E102 103\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-70\u0022\u003EImportantly, however, PD-L1 IHC as a companion diagnostic for use of atezolizumab or\n          pembrolizumab in TNBC can be performed on either the archival primary tumor tissue or on a\n          metastatic tumor sample.\u003Ca id=\u0022xref-ref-18-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18 104\u003C\/a\u003E In\n          IMpassion130, any PD-L1+ result, whether in the primary or a metastatic lesion, was\n          associated with clinical benefit. However, the likelihood of a positive PD-L1 result is\n          higher in the primary tumor relative to metastases, and in an inflamed metastatic tumor\n          relative to a non-inflamed tumor.\u003Ca id=\u0022xref-ref-105-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-105\u0022\u003E105\u003C\/a\u003E Thus, it is\n          recommended to pursue biopsy of metastatic lesions, if clinically accessible, for\n          re-assessment of ER\/PR\/HER2 and additional biomarker analysis including next-generation\n          sequencing (NGS) and PD-L1, if appropriate.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-22\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ENext-generation sequencing\u003C\/h3\u003E\u003Cp id=\u0022p-71\u0022\u003EGenomic sequencing may identify patients who are eligible to receive pembrolizumab based\n          on tumor MSI-H\/TMB-H status (for details on the recommended indications see the\n            \u003Cstrong\u003ETissue-agnostic approvals for checkpoint inhibitors\u003C\/strong\u003E section). Many\n          commercially available NGS assays also offer PD-L1 testing, although none are currently\n          approved as companion diagnostics for immunotherapy in breast cancer. The FoundationOne\n          CDx assay is FDA-approved as a companion diagnostic to identify TMB-H tumors, for which\n          pembrolizumab monotherapy is indicated as an FDA-approved option.\u003Ca id=\u0022xref-ref-40-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-40\u0022\u003E40\u003C\/a\u003E Roughly 5% of breast cancers overall are TMB-H,\u003Ca id=\u0022xref-ref-46-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-46\u0022\u003E46\u003C\/a\u003E and the rate of hypermutation varies across\n          subtypes, with higher frequencies observed in HER2+ tumors and TNBC.\u003Ca id=\u0022xref-ref-106-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-106\u0022\u003E106 107\u003C\/a\u003E Tumor hypermutation may be prognostic for outcomes after\n          treatment with anti-PD-(L)1 therapies, as a pan-tumor meta-analysis (including breast\n          cancers) found comparable areas under the curve for PD-L1 expression and TMB-H in\n          predicting response.\u003Ca id=\u0022xref-ref-108-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-108\u0022\u003E108\u003C\/a\u003E Increased TMB was also\n          shown to be associated with PFS benefit in IMpassion130, but the association was primarily\n          driven by the PD-L1+ subgroup.\u003Ca id=\u0022xref-ref-47-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-47\u0022\u003E47\u003C\/a\u003E Beyond TMB\n          assessment, NGS is also useful to identify other actionable gene mutations, such\n            \u003Cem\u003EPI3K\u003C\/em\u003E alterations, for which alpelisib in combination with\n            fulvestrant\u003Ca id=\u0022xref-ref-109-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-109\u0022\u003E109\u003C\/a\u003E is a treatment option in\n          ER+\/HER2\u0026acirc;\u0026#128;\u0026#147; disease. Amplification of the \u003Cem\u003ECD274\u003C\/em\u003E locus, which encodes\n          PD-L1, may also be detected by NGS, although the significance is unclear in breast\n          cancer.\u003C\/p\u003E\u003Cp id=\u0022p-72\u0022\u003EAlthough the FDA approval for use of pembrolizumab in MSI-H tumors does not specify a\n          companion diagnostic, the FoundationOne CDx and other assays include an assessment of MSI.\n          However, the overall prevalence of MSI in breast cancer is low.\u003Ca id=\u0022xref-ref-43-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-43\u0022\u003E43\u0026acirc;\u0026#128;\u0026#147;45\u003C\/a\u003E Although the incidence has yet to be\n          comprehensively elucidated across subtypes, MSI-H has been reported as occurring in less\n          than 2% of all breast cancers,\u003Ca id=\u0022xref-ref-42-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-42\u0022\u003E42\u003C\/a\u003E with\n          reported rates as low as 0.9% for TNBC.\u003Ca id=\u0022xref-ref-41-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-41\u0022\u003E41\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-73\u0022\u003EIn addition to somatic NGS, germ-line genetic testing in the metastatic setting may also\n          guide eligibility for PARP inhibitor therapy among \u003Cem\u003EBRCA1\u003C\/em\u003E and\n            \u003Cem\u003EBRCA2\u003C\/em\u003E mutation carriers.\u003Ca id=\u0022xref-ref-110-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-110\u0022\u003E110\n            111\u003C\/a\u003E Defective DNA repair due to mutations in \u003Cem\u003EBRCA1\u003C\/em\u003E and\n            \u003Cem\u003EBRCA2\u003C\/em\u003E leads to genomic instability and elevated TMB.\u003Ca id=\u0022xref-ref-112-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-112\u0022\u003E112 113\u003C\/a\u003E However, \u003Cem\u003EBRCA1\u003C\/em\u003E and\n            \u003Cem\u003EBRCA2\u003C\/em\u003E play non-overlapping roles in maintaining genomic integrity,\u003Ca id=\u0022xref-ref-114-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-114\u0022\u003E114\u003C\/a\u003E which may underlie the distinctive\n          immunophenotypes that have been associated with mutations in either gene. For example,\n          increased PD-L1 expression and a higher abundance of TILs were reported in\n            \u003Cem\u003EBRCA1\u003C\/em\u003E-mutant but not \u003Cem\u003EBRCA2\u003C\/em\u003E-mutant tumors.\u003Ca id=\u0022xref-ref-113-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-113\u0022\u003E113\u003C\/a\u003E Currently, it is unknown whether germ-line\n            \u003Cem\u003EBRCA1\u003C\/em\u003E or \u003Cem\u003EBRCA2\u003C\/em\u003E mutations confer additional sensitivity\n          to immunotherapy, or whether an optimal sequencing strategy for immunotherapy with PARP\n          inhibitors exists. Additionally, other mutations in DNA damage response genes may cause\n          tumors to become deficient in homologous recombination repair, a phenotype known as\n          \u0026acirc;\u0026#128;\u0026#152;BRCA-ness,\u0026acirc;\u0026#128;\u0026#153; that may also be used to predict benefit with PARP inhibition\n          and platinum-based chemotherapy.\u003Ca id=\u0022xref-ref-115-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-115\u0022\u003E115 116\u003C\/a\u003E\n          Notably, in the IMpassion130 trial, germ-line deleterious \u003Cem\u003EBRCA1\/2\u003C\/em\u003E\n          mutations did not predict benefit to atezolizumab plus nab-paclitaxel independently of\n          PD-L1 positivity.\u003Ca id=\u0022xref-ref-23-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E However, combination therapy\n          with anti-PD-1 and PARPi is an active area of investigation (for more details on emerging\n          therapies see the \u003Cstrong\u003ENovel combination strategies and promising future\n            directions\u003C\/strong\u003E section).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-23\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPD-L1 expression\u003C\/h3\u003E\u003Cp id=\u0022p-74\u0022\u003EPD-L1 expression in the tumor microenvironment can represent an immunologic brake on\n          antitumor immune responses, as evidenced by PD-L1 expression by ICs, or an immune evasion\n          strategy by the cancer, as evidenced by constitutive or adaptive PD-L1 expression by\n            TCs.\u003Ca id=\u0022xref-ref-117-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-117\u0022\u003E117\u003C\/a\u003E PD-L1 is an important, but imperfect,\n          predictive biomarker for response to PD-(L)1 checkpoint inhibition across tumor\n            types,\u003Ca id=\u0022xref-ref-118-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-118\u0022\u003E118\u003C\/a\u003E including TNBC.\u003Ca id=\u0022xref-ref-18-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18 26\u003C\/a\u003E The role of PD-L1 as a prognostic biomarker in breast\n          carcinoma has conflicting results in the literature.\u003Ca id=\u0022xref-ref-119-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-119\u0022\u003E119\u003C\/a\u003E Meta-analyses suggest that PD-L1 expression on ICs is a favorable prognostic\n            feature,\u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14 120\u003C\/a\u003E but additional prospective\n          and standardized assessments are warranted. Additionally, PD-L1 \u0026acirc;\u0026#128;\u0026#152;positivity\u0026acirc;\u0026#128;\u0026#153;\n          rates in breast cancer vary widely in the literature, reflective of heterogeneous sample\n          sizes and subtype composition, testing methods, and interpretation criteria. Generally,\n          PD-L1 expression is most common in TNBC and HER2+ breast cancer subtypes,\u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10 11 13 117\u003C\/a\u003E as well as in tumors with\n          high TILs.\u003Ca id=\u0022xref-ref-10-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10 11 13 105 117\u003C\/a\u003E In\n          TNBC, PD-L1 expression is mostly observed on ICs, and PD-L1 positivity is more common in\n          ICs in primary tumors than in recurrent or metastatic samples.\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12 105 121\u003C\/a\u003E PD-L1 positivity is uncommon in ER+ breast cancer\n          and in non-inflamed tumors.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-24\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPD-L1 IHC assays and interpretation\u003C\/h3\u003E\u003Cp id=\u0022p-75\u0022\u003EAs of the current writing, four anti-PD-L1 antibody clones are commonly used to evaluate\n          tumor samples via IHC: SP142, SP263, 22C3 and 28\u0026acirc;\u0026#128;\u0026#147;8. Although the individual PD-L1\n          antibody clones SP142, SP263, 22C3 and 28\u0026acirc;\u0026#128;\u0026#147;8 are equally sensitive for PD-L1,\u003Ca id=\u0022xref-ref-122-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-122\u0022\u003E122\u003C\/a\u003E the associated commercially available\n            \u003Cem\u003Eassays\u003C\/em\u003E (ie, testing platforms, components, and methods) have different\n          sensitivities for PD-L1.\u003Ca id=\u0022xref-ref-123-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-123\u0022\u003E123\u0026acirc;\u0026#128;\u0026#147;126\u003C\/a\u003E Characteristics of the four available antibodies and companion\n          assays are summarized in \u003Ca id=\u0022xref-table-wrap-5-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T5\u0022\u003Etable 5\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T5\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022##\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/25648\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\n\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/25648\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 5\u003C\/span\u003E \u003Cp id=\u0022p-76\u0022 class=\u0022first-child\u0022\u003ESummary of anti-PD-L1 antibodies and companion assays\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-78\u0022\u003EThree PD-L1 assays have been designated as \u0026acirc;\u0026#128;\u0026#152;companion diagnostics\u0026acirc;\u0026#128;\u0026#153; by the\n          FDA, one of which is indicated for breast cancer: the VENTANA PD-L1 (SP142) assay and the\n          PD-L1 IHC 22C3 pharmDx assay. The companion diagnostic indication for TNBC for the VENTANA\n          PD-L1 (SP142) assay was withdrawn in 2021. The PD-L1 IHC 28\u0026acirc;\u0026#128;\u0026#147;8 pharmDx assay\u003Ca id=\u0022xref-ref-127-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-127\u0022\u003E127\u003C\/a\u003E is not approved for breast cancer. Both the PD-L1\n          IHC 22C3 pharmDx assay and the PD-L1 IHC 28\u0026acirc;\u0026#128;\u0026#147;8 pharmDx assay are run on the Dako\n          platform. The use of these assays is coupled to the FDA-approved use of specific\n          anti-PD-(L)1 checkpoint inhibitors in respective clinical scenarios.\u003Ca id=\u0022xref-ref-117-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-117\u0022\u003E117 118 127\u0026acirc;\u0026#128;\u0026#147;129\u003C\/a\u003E In the US, the FDA-approval\n          for use of ICIs in this setting requires determination of PD-L1 status with a companion\n          diagnostic that is FDA-approved for use in breast cancer\u003Ca id=\u0022xref-ref-104-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-104\u0022\u003E104\u003C\/a\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-79\u0022\u003EThe scoring criteria to determine PD-L1 status in TNBC with the SP142 assay is the\n          \u0026acirc;\u0026#128;\u0026#152;IC score\u0026acirc;\u0026#128;\u0026#153;,\u003Ca id=\u0022xref-ref-130-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-130\u0022\u003E130\u003C\/a\u003E which is different\n          from the TC score, tumor proportion score, and CPS utilized to assess PD-L1 status with\n          the 22C3 and 28\u0026acirc;\u0026#128;\u0026#147;8 assays.\u003Ca id=\u0022xref-ref-118-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-118\u0022\u003E118\u003C\/a\u003E The IC score\n          is the percentage tumor area occupied by PD-L1+ ICs, including lymphocytes, plasma cells,\n          neutrophils, and macrophages. TNBC is considered \u0026acirc;\u0026#128;\u0026#152;PD-L1 positive\u0026acirc;\u0026#128;\u0026#153; and the\n          patient eligible to receive atezolizumab per the formerly FDA-approved indication if the\n          tumor shows PD-L1+ ICs occupying \u0026acirc;\u0026#137;\u0026yen;1% of the tumor area. The indication for\n          atezolizumab for TNBC was withdrawn in 2021. By contrast, the scoring criteria to\n          determine PD-L1 status in TNBC with the 22C3 assay is the CPS scoring system, which is the\n          total number of PD-L1+ cells (including TCs, lymphocytes, and macrophages) divided by the\n          total number of viable TCs, multiplied by 100. TNBC is considered \u0026acirc;\u0026#128;\u0026#152;PD-L1\n          positive\u0026acirc;\u0026#128;\u0026#153; and the patient eligible to receive pembrolizumab per the FDA-approved\n          indication if the tumor has CPS\u0026acirc;\u0026#137;\u0026yen;10.\u003C\/p\u003E\u003Cp id=\u0022p-80\u0022\u003EOf note, the label indications for both pembrolizumab and atezolizumab do not explicitly\n          specify which companion diagnostic should be used to assay tumor samples for PD-L1; each\n          merely states that expression should be \u0026acirc;\u0026#128;\u0026#152;determined by an FDA-approved\n          test\u0026acirc;\u0026#128;\u0026#153;. However, the approvals do differ in eligibility criteria\u0026acirc;\u0026#128;\u0026#148;atezolizumab\n          is indicated for patients whose tumors express PD-L1 as defined by IC \u0026acirc;\u0026#137;\u0026yen;1, whereas\n          pembrolizumab is indicated for patients whose tumors express PD-L1 as defined by\n          CPS\u0026acirc;\u0026#137;\u0026yen;10. Therefore, it is important to use the appropriate assay to measure PD-L1\n          expression when considering treatment with pembrolizumab (ie, 22C3) or atezolizumab (ie,\n          SP142). This is particularly important as clinical concordance is suboptimal, as\n          demonstrated by a retrospective assay comparison in IMpassion130.\u003Ca id=\u0022xref-ref-131-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-131\u0022\u003E131 132\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-81\u0022\u003EThere is substantial debate regarding inter-observer variability and reproducibility of\n          PD-L1 scoring in ICs with the SP142 assay, particularly at the 1% threshold for\n            positivity.\u003Ca id=\u0022xref-ref-133-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-133\u0022\u003E133 134\u003C\/a\u003E The use of pictoral\n          interpretation guides, digital image analysis software, and standardized training may\n          mitigate some of the variability, but additional studies are warranted.\u003Ca id=\u0022xref-ref-135-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-135\u0022\u003E135\u003C\/a\u003E PD-L1 IHC assays and interpretation are also\n          limited by the lack of standardized control of varying expression levels for validation.\n          Implementation of standard control slides for assay validation and laboratory proficiency\n          testing have been proposed to standardize PD-L1 assessment across sites.\u003Ca id=\u0022xref-ref-136-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-136\u0022\u003E136\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-82\u0022\u003EThe SP142 assay is also less sensitive than the other antibodies with their associated\n          assays (ie, SP263, 22C3, and 28\u0026acirc;\u0026#128;\u0026#147;8 assays), which is reportedly attributable to\n          assay conditions intended to optimize IC labeling.\u003Ca id=\u0022xref-ref-137-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-137\u0022\u003E137\u003C\/a\u003E These assays are not directly interchangeable, and when using a\n          \u0026gt;1% threshold for positivity, the latter assays will classify more TNBC as\n          PD-L1+ than the SP142 assay. Post-hoc analysis of the IMpassion130 clinical trial suggests\n          that these additional patients identified as PD-L1+ by the other assays do not demonstrate\n          the same benefit from atezolizumab as the group of patients identified as PD-L1+ by the\n          SP142 assay.\u003Ca id=\u0022xref-ref-131-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-131\u0022\u003E131\u003C\/a\u003E To fully validate the use of the\n          SP263, 22C3, or 28\u0026acirc;\u0026#128;\u0026#147;8 assays to identify the same patient population as demonstrated\n          benefit from atezolizumab in the IMpassion130 clinical trial, the scoring threshold to\n          determine positivity must be adjusted to achieve equal positive predictive value as the\n          SP142 assay.\u003C\/p\u003E\u003Cp id=\u0022p-83\u0022\u003EOf note, multiple clinical trials assessing the use of other PD-(L)1 ICIs in breast\n          cancer are ongoing\u003Ca id=\u0022xref-ref-26-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26\n            38 63 74 138\u0026acirc;\u0026#128;\u0026#147;142\u003C\/a\u003E (for more details of the studies, see the \u003Cstrong\u003EEmerging\n            data on PD-(L)1 inhibitors sections in the Advanced breast cancer\u003C\/strong\u003E and\n            \u003Cstrong\u003EEarly-stage breast cancer\u003C\/strong\u003E sections). The potential approvals of these\n          agents could be coupled with different PD-L1 IHC companion diagnostics, or perhaps not\n          require PD-L1 assessment for eligibility at all. Current data support the importance of\n          PD-L1 expression for patient selection in metastatic disease but not necessarily in early\n          breast cancer.\u003Ca id=\u0022xref-ref-26-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26 70 77 143\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-25\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPD-L1 specimen considerations\u003C\/h3\u003E\u003Cp id=\u0022p-84\u0022\u003EPatterns of immune infiltration and PD-L1 expression can vary between a primary and\n          metastatic tumor, as well as between different metastatic sites, as discussed above.\n          Assessment of PD-L1 status can be particularly challenging in a tissue sample of\n          metastatic carcinoma involving a lymph node, because PD-L1 expression should be assessed\n          only in the tumor-infiltrating ICs located within the tumor area and not the normal\n          resident ICs of the lymph node. If possible, a non-lymph node tumor section is preferable\n          for PD-L1 assessment. Additionally, as of this guideline preparation, neither the SP142\n          assay nor the 22C3 assay is validated for use in decalcified specimens or fine needle\n          aspirated tissue smears or cell blocks,\u003Ca id=\u0022xref-ref-130-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-130\u0022\u003E130\u003C\/a\u003E and\n          these specimens should not be used for PD-L1 testing in this setting. Data from\n          IMpassion130 supports using atezolizumab and nab-paclitaxel for patients with metastatic\n          TNBC with any tissue sample, whether metastatic or primary, that is determined to be\n          PD-L1+ by the SP142 assay. As discussed above, metastatic tumors to the liver are less\n          likely to be inflamed and thus less likely to be PD-L1+, with median IC score as low as\n          0.5% for liver compared with 3% in lymph nodes and 1% in primary\n          breast sites.\u003Ca id=\u0022xref-ref-101-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-101\u0022\u003E101\u003C\/a\u003E If multiple biopsy sites are\n          available, testing for PD-L1 in liver samples should be avoided. However, if no other\n          sites are clinically feasible, despite small numbers, PD-L1+ results from liver biopsies\n          have predicted response to immune checkpoint inhibition.\u003Ca id=\u0022xref-ref-144-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-144\u0022\u003E144\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-26\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPredictive value of PD-L1 expression for response to treatment with anti-PD-(L)1\n          therapy\u003C\/h3\u003E\u003Cp id=\u0022p-85\u0022\u003EConflicting reports have emerged on the predictive power of PD-L1 expression and response\n          to therapy depending on the treatment setting. In the advanced setting, the treatment\n          effect of immune checkpoint inhibition increased with higher levels of PD-L1 expression in\n          the phase III KEYNOTE-355 study evaluating the addition of pembrolizumab to chemotherapy\n          for previously untreated, locally recurrent, inoperable, or metastatic TNBC.\u003Ca id=\u0022xref-ref-26-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26\u003C\/a\u003E Similarly, in IMpassion130, pre-specified biomarker\n          analysis found that PD-L1 expression on ICs occupying \u0026acirc;\u0026#137;\u0026yen;1% of the tumor area\n          defined a threshold that was strongly predictive of efficacy for atezolizumab plus\n          nab-paclitaxel in the advanced setting.\u003Ca id=\u0022xref-ref-23-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E\n          Conversely, in trials to date for early-stage disease, response rates have generally been\n          consistent across PD-L1+ and PD-L1-negative tumors. In IMpassion031, improved pCR rates\n          were seen with the addition of atezolizumab to neoadjuvant chemotherapy in the entire ITT\n          population and no differences were seen associated with PD-L1 status.\u003Ca id=\u0022xref-ref-77-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-77\u0022\u003E77\u003C\/a\u003E Additionally, in KEYNOTE-522, which evaluated the addition of\n          pembrolizumab to neoadjuvant chemotherapy, the benefits with ICI treatment were generally\n          consistent across subgroups regardless of PD-L1 expression.\u003Ca id=\u0022xref-ref-139-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-139\u0022\u003E139\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-27\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EOther biomarkers\u003C\/h3\u003E\u003Cp id=\u0022p-86\u0022\u003EIn breast cancer, TILs are assessed within the confines of the carcinoma and are defined\n          as the percentage stromal area occupied by mononuclear inflammatory cells (ie, stromal\n          TILs [sTILs]).\u003Ca id=\u0022xref-ref-145-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-145\u0022\u003E145\u003C\/a\u003E Assessment of TILs is included\n          as a prognostic biomarker in the 2019 WHO classification of Breast Tumors.\u003Ca id=\u0022xref-ref-146-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-146\u0022\u003E146 147\u003C\/a\u003E Although consensus guidelines have been\n            published\u003Ca id=\u0022xref-ref-145-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-145\u0022\u003E145\u003C\/a\u003E that have supported retrospective\n          analyses and the incorporation of TIL evaluation as integral and integrated biomarkers in\n          several trials (see \u003Ca href=\u0022http:\/\/www.TILsinBreastCancer.org\u0022\u003Ewww.TILsinBreastCancer.org\u003C\/a\u003E), TIL scores are not indicated for routine\n          clinical practice. Concerns about inter-observer variability in TIL assessment have also\n          been raised,\u003Ca id=\u0022xref-ref-148-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-148\u0022\u003E148\u003C\/a\u003E but machine-learning-based\n          approaches for scoring may improve reproducibility in the future. sTILs have demonstrated\n          predictive prognostic power in TNBC and HER2+ breast cancer, with higher levels of\n          infiltration being linked to improved outcomes.\u003Ca id=\u0022xref-ref-12-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12 145 149\u0026acirc;\u0026#128;\u0026#147;151\u003C\/a\u003E In a 2009 study that\n          investigated the relationship between lymphocytic infiltration at diagnosis in\n          node-positive samples with clinical outcomes from the BIG 01-98 adjuvant phase III trial,\n          a 10% increase in sTILs was associated with 15% reduced risk of relapse\n          (p=0.025) and 17% reduced risk of death in TNBC. For HER2+ tumors treated with\n          anthracycline-only chemotherapy, a significant interaction was observed between increasing\n          sTILs and both DFS and OS (DFS p=0.042; OS p=0.018).\u003Ca id=\u0022xref-ref-151-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-151\u0022\u003E151\u003C\/a\u003E For ER+\/HER2\u0026acirc;\u0026#136;\u0026#146; breast cancer, the prognostic value is less clear. One\n          pooled analysis of 3,771 patients receiving neoadjuvant therapy demonstrated that although\n          increases in sTILs were associated with response to chemotherapy in all molecular\n          subtypes, TILs were only correlated with longer OS in TNBC\u0026acirc;\u0026#128;\u0026#148;no association with\n          survival was shown in HER2+ breast cancer, and increased TILs was linked to shorter OS in\n          luminal-HER2\u0026acirc;\u0026#128;\u0026#147; disease.\u003Ca id=\u0022xref-ref-152-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-152\u0022\u003E152\u003C\/a\u003E Additionally, a\n          case\u0026acirc;\u0026#128;\u0026#147;cohort series of 987 patients with early ER+\/HER2\u0026acirc;\u0026#128;\u0026#147; breast cancer found\n          that high TILs was associated with better distant DFS, but only in the group of patients\n          treated with adjuvant therapy.\u003Ca id=\u0022xref-ref-151-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-151\u0022\u003E151 153\u003C\/a\u003E In\n          contrast to the data in early breast cancer, exploratory analyses of IMpassion130 showed\n          that sTILs were associated with PD-L1+ status but did not independently predict PFS nor OS\n          in advanced TNBC.\u003Ca id=\u0022xref-ref-23-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-87\u0022\u003EThe functional characteristics and spatial distribution of TILs within the tumor\n          microenvironment may be important in the generation of effective antitumor immune\n          responses. While multiplex, high-resolution TIL profiling technologies are, at the time of\n          writing, purely investigational, an increased understanding of the prognostic value of\n          individual infiltrating T-cell subsets may inform the development of future biomarkers or\n          rationally designed immunotherapeutic approaches. Substantial heterogeneity may exist in\n          the spatial distribution of TILs between regions of samples taken from the same\n            tumor,\u003Ca id=\u0022xref-ref-154-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-154\u0022\u003E154\u003C\/a\u003E although the average lymphocyte score\n          from a single biopsy has been shown to reasonably represent the tumor as a whole.\u003Ca id=\u0022xref-ref-155-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-155\u0022\u003E155\u003C\/a\u003E In TNBC, enrichment of CD8\u003Csup\u003E+\u003C\/sup\u003E TILs with a\n          characteristic tissue-resident memory gene expression signature was significantly\n          associated with improved patient survival in early-stage disease, having greater\n          prognostic power than CD8 expression alone.\u003Ca id=\u0022xref-ref-156-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-156\u0022\u003E156\u003C\/a\u003E In\n          ER+ breast cancer, TIL spatial heterogeneity was more highly prognostic for late\n          recurrence 5 years after endocrine therapy than any other tumor immune score\n            measures.\u003Ca id=\u0022xref-ref-157-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-157\u0022\u003E157\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-88\u0022\u003EOther biomarkers may also predict response to immune checkpoint blockade. The genomic\n          amplification of \u003Cem\u003ECD274\u003C\/em\u003E, the gene that encodes PD-L1, is frequently\n          observed in Hodgkin lymphoma and sometimes detected in solid tumors including breast\n            cancers.\u003Ca id=\u0022xref-ref-158-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-158\u0022\u003E158 159\u003C\/a\u003E Amplifications of\n            \u003Cem\u003ECD274\u003C\/em\u003E may have important prognostic value for response to ICI therapy.\n          One analysis of 118,187 tumor samples (including a subset of 2,039 samples with clinical\n          annotation) found an overall prevalence of \u003Cem\u003ECD274\u003C\/em\u003E amplification of\n          0.7% overall, and just 0.02% in breast cancers. Importantly, the ORR for\n          ICI-treated patients with solid tumors with \u003Cem\u003ECD274\u003C\/em\u003E amplification was\n          66.7%, with median PFS of 15.2 months.\u003Ca id=\u0022xref-ref-159-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-159\u0022\u003E159\u003C\/a\u003E\n          In TNBC specifically, increased copy number for the chromosomal region that encodes PD-L1,\n          PD-L2, and JAK2\u0026acirc;\u0026#128;\u0026#148;sometimes called the PDJ locus, 9p24\u0026acirc;\u0026#128;\u0026#148;is more frequently\n          detected in TNBC compared with in ER+ and HER2+ subtypes and in other solid tumors.\u003Ca id=\u0022xref-ref-160-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-160\u0022\u003E160\u003C\/a\u003E Exposure to neoadjuvant chemotherapy may select\n          for 9p24 amplifications in TNBC,\u003Ca id=\u0022xref-ref-161-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-161\u0022\u003E161\u003C\/a\u003E and\n          amplifications at the locus correlate with increased protein expression of PD-L1 by IHC\n          and mRNA in situ hybridization.\u003Ca id=\u0022xref-ref-158-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-158\u0022\u003E158\u003C\/a\u003E Amplification\n          of 9p24 was associated with worse OS in studies of patients not receiving\n            immunotherapy,\u003Ca id=\u0022xref-ref-160-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-160\u0022\u003E160 161\u003C\/a\u003E and studies are\n          ongoing to determine prognostic value of this biomarker in the context of immune\n          checkpoint inhibition. Exploratory analysis of 126 patients with metastatic breast cancer\n          who were enrolled in the SAFIR-IMMUNO study (a randomized trial comparing durvalumab to\n          maintenance chemotherapy) found that 20% of all tumors and 35% of TNBCs had\n          copy gain (3 or 4 copies) or amplification (\u0026gt;4 copies) of \u003Cem\u003ECD274\u003C\/em\u003E.\n          Notably, only patients with amplifications in \u003Cem\u003ECD247\u003C\/em\u003E had improved OS with\n          durvalumab (HR 0.18; 95% CI 0.05 to 0.71).\u003Ca id=\u0022xref-ref-162-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-162\u0022\u003E162\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-89\u0022\u003EThe identification of additional biomarkers for patient selection and response prediction\n          for immunotherapy is an ongoing area of research. Promising areas include mRNA-based\n          signatures, such as an interferon gene expression profile that has been shown to predict\n          response to PD-1 blockade in a variety of tumor types, including breast cancer,\u003Ca id=\u0022xref-ref-163-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-163\u0022\u003E163\u003C\/a\u003E and liquid biopsy-based biomarkers that quantify\n          circulating TCs, nucleic acids, and proteins.\u003Ca id=\u0022xref-ref-164-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-164\u0022\u003E164\u003C\/a\u003E\n          Future prospective trials will be needed to validate any novel immunotherapy biomarkers\n          and ensure generalizability across breast cancer subtypes and patient populations.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-28\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPanel recommendations\u003C\/h3\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-3\u0022\u003E\u003Cli id=\u0022list-item-16\u0022\u003E\u003Cp id=\u0022p-90\u0022\u003EFor patients with TNBC being considered for treatment with pembrolizumab in\n              combination with chemotherapy, tumor tissue should be tested for PD-L1 by the PD-L1\n              22C3 pharmDx assay and scored by the CPS system, until PD-L1 assays are harmonized\n              (LE: 2). A TNBC is PD-L1+ by 22C3, and the patient eligible for pembrolizumab, with a\n              CPS \u0026acirc;\u0026#137;\u0026yen;10.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-17\u0022\u003E\u003Cp id=\u0022p-91\u0022\u003EPD-L1 testing is not recommended for patients with early-stage breast cancer at this\n              time (LE: 2).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-18\u0022\u003E\u003Cp id=\u0022p-92\u0022\u003EAlthough PD-L1 testing of primary lesions may not correlate with expression in\n              metastatic disease, benefit was observed in IMpassion130 with any PD-L1+ result\n              regardless of whether primary or metastatic tumor. PD-L1 testing should be performed\n              on the metastatic tumor, if available, but testing on primary tumor is acceptable (LE:\n              2).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-19\u0022\u003E\u003Cp id=\u0022p-93\u0022\u003EWhen considering metastatic sites to test for PD-L1, it is preferable to prioritize\n              extrahepatic sites or the primary tumor, if available.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-20\u0022\u003E\u003Cp id=\u0022p-94\u0022\u003EPD-L1 testing should not be performed on fine needle aspirated cell-block specimens\n              or decalcified bone.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-21\u0022\u003E\u003Cp id=\u0022p-95\u0022\u003EStromal TIL assessment in primary lesions is prognostic in early TNBC and HER2+\n              breast cancer (LE: 1), but has not been validated to direct clinical decision-making\n              for chemotherapy or immunotherapy.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-22\u0022\u003E\u003Cp id=\u0022p-96\u0022\u003EBiomarker assessment, including repeat receptor profiles (ER\/PR\/HER2) and PD-L1\n              status as well as NGS should be considered at first relapse (LE: 3).\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-29\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EEvaluation and management of treatment response\u003C\/h2\u003E\u003Cdiv id=\u0022sec-30\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EImaging\u003C\/h3\u003E\u003Cp id=\u0022p-97\u0022\u003EAs with cytotoxic therapy, recommended evaluation of tumor response to immunotherapy\n          should be performed with a CT scan or MRI. The WHO criteria\u003Ca id=\u0022xref-ref-165-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-165\u0022\u003E165\u003C\/a\u003E and the Response Evaluation Criteria In Solid Tumors (RECIST)\n            guidelines\u003Ca id=\u0022xref-ref-166-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-166\u0022\u003E166\u003C\/a\u003E define standard measurement\n          methods for converting radiology image observations into quantitative and statistically\n          tractable frameworks for measuring changes in tumor size associated with therapy. However,\n          the unique patterns of responses observed with immunotherapy have led to the development\n          of several modified criteria for reporting responses in solid tumors (described below).\n          According to some analyses, conventional response criteria may underestimate ORR for\n          immunotherapy-treated patients by as much as 15%.\u003Ca id=\u0022xref-ref-167-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-167\u0022\u003E167\u003C\/a\u003E Additionally, due to the inability to differentiate metabolically active\n          cancer cells from activated ICs and inflammation, standard positron emission tomography\n          (PET) imaging may present challenges in assessing tumor response for patients with breast\n          cancer on immunotherapy.\u003Ca id=\u0022xref-ref-168-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-168\u0022\u003E168\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-98\u0022\u003EThe mechanism of action of ICIs can cause unusual response patterns on imaging when\n          compared with traditional responses to cytotoxic chemotherapy. While many patients still\n          may have an initial reduction in tumor burden, other patients may experience\n          non-traditional responses like initial tumor growth followed by tumor reduction (termed\n          pseudoprogression), a period of rapid tumor growth (termed hyperprogression), or a period\n          of prolonged stability followed by an eventual decrease in tumor growth.\u003Ca id=\u0022xref-ref-169-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-169\u0022\u003E169\u003C\/a\u003E Although pseudoprogression, an apparent increase\n          in tumor burden or appearance of new lesions on therapy, has been described in up to\n          roughly 10% of patients with melanoma treated with checkpoint inhibitors,\u003Ca id=\u0022xref-ref-170-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-170\u0022\u003E170\u003C\/a\u003E the phenomenon seems to be tumor-dependent with\n          much lower rates of pseudoprogression (\u0026lt;5%) noted in breast cancer\n            studies.\u003Ca id=\u0022xref-ref-63-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-63\u0022\u003E63 144\u003C\/a\u003E Potential mechanisms behind\n          the appearance of enlarged lesions in solid tumors on imaging include infiltration of\n          activated T cells, an inflammatory response due to cytokine release, or may simply reflect\n          the time needed for the immune system to mount an appropriate response for tumor\n            control.\u003Ca id=\u0022xref-ref-169-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-169\u0022\u003E169\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-99\u0022\u003EBecause the traditional RECIST system does not consistently capture clinical benefit with\n          immunotherapy, several systems, including immune-related response criteria (irRC),\u003Ca id=\u0022xref-ref-171-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-171\u0022\u003E171\u003C\/a\u003E the immune-related RECIST (irRECIST),\u003Ca id=\u0022xref-ref-172-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-172\u0022\u003E172\u003C\/a\u003E immune-modified RECIST,\u003Ca id=\u0022xref-ref-173-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-173\u0022\u003E173\u003C\/a\u003E and immunotherapy RECIST (iRECIST)\u003Ca id=\u0022xref-ref-174-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-174\u0022\u003E174\u003C\/a\u003E were developed (\u003Ca id=\u0022xref-table-wrap-6-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T6\u0022\u003Etable 6\u003C\/a\u003E). Evaluation\n          of tumor burden in two dimensions is mandated by irRC, which requires more effort than the\n          one-dimensional evaluation of RECIST.\u003Ca id=\u0022xref-ref-175-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-175\u0022\u003E175\u003C\/a\u003E The\n          irRECIST criteria combine the features of irRC and RECIST and requires only\n          one-dimensional measurement\u003Ca id=\u0022xref-ref-172-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-172\u0022\u003E172\u003C\/a\u003E; however, irRECIST\n          has not been consistently applied across studies and therefore may not permit cross-study\n          comparisons of efficacy. In contrast to irRECIST, measurements of the new lesion(s) are\n          not incorporated into the tumor burden with iRECIST. Additionally, iRECIST was developed\n          by consensus.\u003C\/p\u003E\u003Cdiv id=\u0022T6\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022##\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/25652\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\n\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/25652\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 6\u003C\/span\u003E \u003Cp id=\u0022p-100\u0022 class=\u0022first-child\u0022\u003EComparison of immune-related response criteria (Adapted from Kataoka \u0026amp; Hirano,\n                \u003Cem\u003EAnn Transl Med, 2018)\u003C\/em\u003E\u003Ca id=\u0022xref-ref-288-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-288\u0022\u003E288\u003C\/a\u003E)\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-103\u0022\u003EA retrospective analysis of 14 published trials found that responses assessed by iRECIST\n          compared with RECIST v1.1 led to a roughly 1 month longer median DOR in the analysis\n            population,\u003Ca id=\u0022xref-ref-176-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-176\u0022\u003E176\u003C\/a\u003E a modest but potentially\n          meaningful difference. Ongoing efforts are attempting to develop a standardized, universal\n          scoring system for pathologic response to PD-(L)1 blockade (immune-related pathologic\n          response criteria) that encompasses features characteristic of immunotherapy for diverse\n          tumor types,\u003Ca id=\u0022xref-ref-177-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-177\u0022\u003E177 178\u003C\/a\u003E but this pan-tumor\n          criteria has not yet been validated in prospective studies. Additionally, an immunotherapy\n          response assessment for neuro-oncology, iRANO,\u003Ca id=\u0022xref-ref-179-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-179\u0022\u003E179\u003C\/a\u003E\n          has been developed, which may have future implications for the management of brain\n          metastases, though these criteria have not been extensively validated in patients with\n          breast cancer. Notably the randomized phase III studies completed to date in locally\n          advanced\/metastatic TNBC (KEYNOTE-119, KEYNOTE-355, and IMpassion130) adopted RECIST v1.1\n          for determination of disease status. Currently it is recommended that if one of the immune\n          response criteria is used, the standard RECIST measurements should also be used to help\n          with validity and cross trial comparisons.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-31\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ETreatment beyond progression\u003C\/h3\u003E\u003Cp id=\u0022p-104\u0022\u003EFor several decades, the overarching dogma for managing recurrent or refractory disease\n          was that therapy should be changed at progression, based on the assumption that resistance\n          is stable. With a growing body of evidence for the existence of unstable mechanisms of\n          drug resistance,\u003Ca id=\u0022xref-ref-180-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-180\u0022\u003E180\u003C\/a\u003E however, chemotherapy\n          rechallenge has become an established paradigm across several disease settings. In breast\n          cancer, retreatment with the same chemotherapy regimen that was used as adjuvant therapy\n          has demonstrated clinical benefit,\u003Ca id=\u0022xref-ref-181-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-181\u0022\u003E181 182\u003C\/a\u003E\n          provided there is a sufficient disease-free interval. In the HER2+ setting, treatment with\n          trastuzumab beyond progression has been shown to increase clinical benefit rate for\n          patients receiving capecitabine\u003Ca id=\u0022xref-ref-183-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-183\u0022\u003E183\u003C\/a\u003E and increases\n          OS in patients with brain metastases.\u003Ca id=\u0022xref-ref-184-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-184\u0022\u003E184\u003C\/a\u003E Whether\n          treatment beyond progression offers similar benefits for patients receiving immunotherapy\n          remains an ongoing area of investigation.\u003C\/p\u003E\u003Cp id=\u0022p-105\u0022\u003EBased on current iRECIST guidelines, as well as the Trial Reporting in Immuno-Oncology\n          guidelines published in 2018 by the American Society of Clinical Oncology (ASCO) and\n            SITC,\u003Ca id=\u0022xref-ref-185-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-185\u0022\u003E185\u003C\/a\u003E clinical assessment and patient\n          functional status are important when determining if a patient should continue on a given\n          immunotherapy in the setting of progressive disease. Both guidelines specify that for\n          patients to receive treatment beyond progression, the patient should have stable or\n          improved clinical condition, have no severe laboratory abnormalities, and be tolerating\n          the treatment well with limited\/mild side effects. Most importantly, there should be no\n          clinical progression and no additional progression noted on subsequent confirmation\n          imaging scans.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-32\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EManagement of isolated sites of progression on immunotherapy\u003C\/h3\u003E\u003Cp id=\u0022p-106\u0022\u003EThe appearance of new lesions while on treatment in the metastatic setting, including\n          immunotherapy, is not necessarily a reason to discontinue therapy. As mentioned above,\n          pseudoprogression may result in the appearance of new lesions which then later decrease in\n          size on subsequent reimaging. There may also be true progression with the appearance of a\n          new solitary lesion (ie, oligoprogression). This can occur due to tumor heterogeneity\n          and\/or the development of new resistance mechanisms to therapy. In these cases, there may\n          be an isolated site of disease progression in patients who otherwise have a good response\n          to treatment. There is no standard management for these isolated lesions in the setting of\n          otherwise responsive disease.\u003Ca id=\u0022xref-ref-174-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-174\u0022\u003E174\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-107\u0022\u003EOnce a new lesion(s) is confirmed, is it reasonable to consider local treatment(s) to the\n          isolated site(s) of progression, as long as the patient has good performance status and is\n          otherwise responding to or stable on the current treatment. Localized treatment may\n          involve local ablative therapies like brachytherapy or stereotactic body radiation therapy\n          (SBRT) and\/or surgical therapies like a metastasectomy, as is currently done in many other\n          metastatic tumor types. Although studies are limited in the breast cancer disease setting,\n          improved outcomes after surgical resection of isolated sites of progression have been\n          reported for gastrointestinal, adrenal, and large single brain metastases for patients\n          with melanoma being treated with immunotherapy.\u003Ca id=\u0022xref-ref-186-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-186\u0022\u003E186\u0026acirc;\u0026#128;\u0026#147;188\u003C\/a\u003E In breast cancer, a systematic review of outcomes after local\n          ablative therapies for the management of hepatic metastases reported CR rates of roughly\n          90% after hepatic resection, stereotactic radiofrequency ablation, SBRT, and\n            brachytherapy.\u003Ca id=\u0022xref-ref-189-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-189\u0022\u003E189\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-108\u0022\u003EIn cases where surgery is not an option, radiation therapy may synergize with\n          immunotherapy through the induction of immunogenic cell death.\u003Ca id=\u0022xref-ref-190-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-190\u0022\u003E190\u003C\/a\u003E Until recently, the evidence for efficacy was limited to case\n          reports and preclinical models. A small, signal-seeking phase II trial establishing the\n          safety and early activity of pembrolizumab with radiation in heavily pre-treated,\n          metastatic TNBC regardless of PD-L1 status demonstrated tolerabilty and a signal of\n          activity with the combination.\u003Ca id=\u0022xref-ref-191-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-191\u0022\u003E191\u003C\/a\u003E At this time,\n          the benefit of local treatment for an isolated progressive tumor is still being\n          determined. However, given that radiation is a commonly accessible local treatment that is\n          already well-integrated into cancer treatment, many physicians will opt for local therapy\n          in order to continue on a treatment regimen that is controlling other sites of\n          disease.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-33\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EDuration of immunotherapy\u003C\/h3\u003E\u003Cp id=\u0022p-109\u0022\u003EThe decision to discontinue therapy is a challenging and ongoing topic of debate in the\n          immuno-oncology field. Although the ultimate endpoint for any cancer treatment is overall\n          survival, ongoing and durable responses have been seen with immunotherapy, raising the\n          difficult question of when it is appropriate to stop therapy. Of those patients who have\n          durable responses to immunotherapy, it is not known how long treatment should continue.\n          Experience from melanoma suggests that durable remissions may be maintained in as many as\n          85% of patients who stop receiving anti-PD-1 therapy after achieving CR.\u003Ca id=\u0022xref-ref-186-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-186\u0022\u003E186 192\u003C\/a\u003E At this time, there are also accounts of\n          patients with breast cancer who have come off immunotherapy due to toxicity but continue\n          to have durable responses years after treatment was stopped.\u003Ca id=\u0022xref-ref-193-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-193\u0022\u003E193\u003C\/a\u003E Most initial trials of ICIs for breast cancer had a set period of\n          treatment, but at this time as these agents matriculate into routine oncology practice,\n          the ideal duration of therapy is unknown.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-34\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPost-immunotherapy treatment choice\u003C\/h3\u003E\u003Cp id=\u0022p-110\u0022\u003ELimited data are available on which to base a decision on optimal treatment after\n          immunotherapy. In the IMpassion130 trial, subsequent anticancer therapy was administered\n          to 242 patients (53.7%) in the atezolizumab plus nab-paclitaxel group and to 272\n          patients (60.3%) in the placebo plus nab-paclitaxel group, with most patients\n          receiving chemotherapy during follow-up and less than 4% receiving further\n            immunotherapy.\u003Ca id=\u0022xref-ref-18-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E Standard chemotherapy agents\n          have immunomodulatory effects,\u003Ca id=\u0022xref-ref-194-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-194\u0022\u003E194\u003C\/a\u003E however, the\n          effects of cytotoxic agents are pleiotropic and potential interactions with\n          immunotherapies are difficult to predict from pharmacokinetics and preclinical models\n          alone. While optimal sequencing is unknown at this time, understanding effects of various\n          treatments on the tumor microenvironment may help to guide future studies on optimal\n          sequencing of therapies.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-35\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPanel recommendations\u003C\/h3\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-4\u0022\u003E\u003Cli id=\u0022list-item-23\u0022\u003E\u003Cp id=\u0022p-111\u0022\u003EThe application of formal response criteria (ie, RECIST) are not currently\n              recommended off-study. If one of the immune response criteria is used, the standard\n              RECIST measurements should also be used to help with validity and cross-trial\n              comparisons.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-24\u0022\u003E\u003Cp id=\u0022p-112\u0022\u003EWhen pseudoprogression is suspected and treatment beyond progression is being\n              considered, the patient should have stable or improved clinical condition, no severe\n              laboratory abnormalities, and be tolerating the treatment well with limited\/mild side\n              effects. Treatment beyond progression should be discontinued in cases where clinical\n              progression occurs or if additional progression is confirmed on subsequent imaging\n              scans.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-25\u0022\u003E\u003Cp id=\u0022p-113\u0022\u003EFor management of isolated site(s) of progression for a patient receiving\n              immunotherapy, it is reasonable to consider local therapy for the isolated site(s) of\n              progression as long as the patient has good performance status and is otherwise\n              responding to the current treatment. However, there are no data that local treatment\n              will improve clinical outcomes.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-36\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EToxicity considerations: patient selection and management\u003C\/h2\u003E\u003Cdiv id=\u0022sec-37\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EBaseline factors for consideration\u003C\/h3\u003E\u003Cp id=\u0022p-114\u0022\u003EThe decision to proceed with immunotherapy depends on the likelihood that the tumor will\n          respond to treatment and the patient\u0026acirc;\u0026#128;\u0026#153;s projected ability to tolerate therapy. For\n          patients with early-stage disease, the potential for benefit with immunotherapy must also\n          be weighed against the risk of irAEs. Patients with autoimmune disorders, chronic viral\n          infections, AIDS, ongoing clinically significant immunosuppressant use, organ dysfunction,\n          pregnancy, older age, and impaired functional status are generally considered to be\n          challenging populations to treat with checkpoint inhibitors. As more patients receive\n          checkpoint inhibitors in real-world settings, however, emerging data are painting a\n          clearer picture of the risk\/benefit tradeoffs in some groups of patients, and it is\n          becoming clear that some of these \u0026acirc;\u0026#128;\u0026#152;challenging populations\u0026acirc;\u0026#128;\u0026#153; may safely\n          receive treatment.\u003C\/p\u003E\u003Cp id=\u0022p-115\u0022\u003EPatients living with HIV infection have historically been excluded from clinical trials\n          of checkpoint inhibitors due to concerns about potential risk for viral reactivation or\n          increased toxicity on therapy. Before the advent of highly active antiretroviral therapy\n          (HAART), it was believed that the incidence of breast cancer may be lower in patients with\n          AIDS than in the general population.\u003Ca id=\u0022xref-ref-195-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-195\u0022\u003E195\u003C\/a\u003E However,\n          subsequent analyses have revealed that patients living with HIV are at increased risk of\n          mortality for all non-AIDS-related cancers, including breast cancer.\u003Ca id=\u0022xref-ref-196-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-196\u0022\u003E196\u0026acirc;\u0026#128;\u0026#147;198\u003C\/a\u003E Although experience with immunotherapy,\n          specifically in patients with breast cancer and HIV, is limited, a systematic review of\n          ICI treatment in 72 patients with advanced-stage cancers who were also being treated with\n          HAART for HIV infection found no new safety signals, comparable response rates to\n          non-HIV-infected individuals, and maintenance of viral suppression as well as\n            CD4\u003Csup\u003E+\u003C\/sup\u003E T cell counts.\u003Ca id=\u0022xref-ref-199-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-199\u0022\u003E199\u003C\/a\u003E Prospective\n          trials have also demonstrated safety and efficacy for ICI therapy for patients living with\n          HIV and a variety of solid tumors.\u003Ca id=\u0022xref-ref-200-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-200\u0022\u003E200 201\u003C\/a\u003E\n          Although further studies are needed in the breast cancer setting, none of the data to date\n          indicate that HIV infection is an absolute contraindication to ICI therapy, provided the\n          patient is compliant with appropriate antiretroviral therapy.\u003C\/p\u003E\u003Cp id=\u0022p-116\u0022\u003ESome studies have suggested that patients with pre-existing autoimmune disorders may be\n          safely treated with anti-PD-(L)1 therapies. In one study, 52 patients with melanoma and\n          pre-existing autoimmune disorders were treated with either pembrolizumab or nivolumab.\n          Twenty patients (38%) had flares of their autoimmune disease requiring\n          immunosuppression, but toxicities were generally mild, manageable, and did not necessitate\n          discontinuation of therapy.\u003Ca id=\u0022xref-ref-202-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-202\u0022\u003E202\u003C\/a\u003E The decision to\n          proceed with immunotherapy in a patient with pre-existing autoimmune conditions should\n          include assessing the risk of severe morbidity and\/or mortality from the underlying\n          disorder versus risk of relapse or death from the cancer diagnosis. Similarly, if\n          considering using immunotherapy to treat patients with breast cancer receiving\n          immunosuppressive therapy for an underlying autoimmune disorder, it is critical to\n          consider the underlying reason for the immunosuppression as well as the clinical benefit\n          expected from the immunosuppressive agent.\u003C\/p\u003E\u003Cp id=\u0022p-117\u0022\u003EAnalyses of outcomes among older patients receiving checkpoint inhibitors in clinical\n            trials\u003Ca id=\u0022xref-ref-203-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-203\u0022\u003E203\u003C\/a\u003E and real-world settings\u003Ca id=\u0022xref-ref-204-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-204\u0022\u003E204\u003C\/a\u003E suggest that the toxicity profiles and response\n          rates for immunotherapy in the elderly do not differ markedly from those in the general\n          population. Those results must be interpreted with a note of caution, however, as the\n          older patients that were included were all relatively fit (ie, good baseline performance\n          status). Geriatric assessments for elderly individuals may be useful to evaluate the\n          potential safety of more intense therapeutic regimens including immunotherapy.\u003Ca id=\u0022xref-ref-205-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-205\u0022\u003E205\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-118\u0022\u003EBaseline corticosteroid use has been associated with worse survival outcomes in patients\n          with lung cancer treated with anti-PD-(L)1 agents.\u003Ca id=\u0022xref-ref-206-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-206\u0022\u003E206 207\u003C\/a\u003E The interpretation of these findings is complicated however, because\n          patients receiving corticosteroids for palliative indications may also have significant\n          comorbidities at baseline. One study that analyzed outcomes stratified by reason for\n          corticosteroid administration found that median PFS and OS were significantly shorter\n          among patients who received \u0026acirc;\u0026#137;\u0026yen;10 mg prednisone for palliative indications associated\n          with their underlying malignancy compared with those who received \u0026acirc;\u0026#137;\u0026yen;10 mg prednisone\n          for non-cancer related reasons and compared with patients receiving 0 to \u0026lt;10 mg of\n            prednisone.\u003Ca id=\u0022xref-ref-208-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-208\u0022\u003E208\u003C\/a\u003E The role of glucocorticoids in\n          breast cancer is complex and further complicated due to natural variability in endogenous\n          hormone levels throughout a woman\u0026acirc;\u0026#128;\u0026#153;s menstrual cycle.\u003Ca id=\u0022xref-ref-209-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-209\u0022\u003E209\u003C\/a\u003E Glucocorticoid receptor signaling has been linked to the emergence\n          of chemoresistance in breast cancer.\u003Ca id=\u0022xref-ref-210-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-210\u0022\u003E210\u003C\/a\u003E Although\n          scant data are available on the impact of steroid administration on immunotherapy efficacy\n          in the treatment of breast cancer, a meta-analysis including 16 studies of patients with\n          lung cancer demonstrated no adverse effects on survival outcomes when corticosteroids were\n          used for the management of irAEs.\u003Ca id=\u0022xref-ref-211-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-211\u0022\u003E211\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-119\u0022\u003EThe incidence of breast cancer in solid organ transplant recipients is similar to that in\n          the general population, and given the overall frequency of transplant patients with\n          excellent outcomes, it is likely that providers will encounter patients with breast cancer\n          and a history of solid organ transplantation.\u003Ca id=\u0022xref-ref-212-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-212\u0022\u003E212\u003C\/a\u003E\n          There is limited data on the outcomes of transplant patients with checkpoint inhibitor\n          therapy, but existing data suggests a significant risk of graft rejection.\u003Ca id=\u0022xref-ref-213-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-213\u0022\u003E213\u003C\/a\u003E For this reason, routine ICI treatment of patients\n          with breast cancer and a prior organ transplant outside of a study or at a specialized\n          center is discouraged.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-38\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EMonitoring patients on treatment (toxicities, time frame)\u003C\/h3\u003E\u003Cp id=\u0022p-120\u0022\u003EThe goal of appropriate monitoring during immunotherapy treatment is to promptly detect\n          immune-related toxicities and intervene before these toxicities cause significant\n          morbidity or mortality. An important principle is to properly educate patients and staff\n          about the symptoms that require prompt reporting to avoid life-threatening complications\n          (described in more detail in the \u003Cstrong\u003EPatient education and QOL\u003C\/strong\u003E section). The most\n          frequently reported irAEs in breast cancer ICI trials are rash and pruritus (up to\n          18%), thyroid disorders (up to 12%), and liver function abnormalities (up to\n            10%).\u003Ca id=\u0022xref-ref-214-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-214\u0022\u003E214\u003C\/a\u003E Incidences of irAEs reported in\n          trials of ICI monotherapy or combination regimens for TNBC are summarized in \u003Ca id=\u0022xref-table-wrap-7-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T7\u0022\u003Etable 7\u003C\/a\u003E. Particular attention should be paid to new or\n          worsening fatigue, headaches, rash, respiratory symptoms, changes in bowel function,\n          visual changes\/eye pain, or musculoskeletal symptoms. Careful monitoring of laboratory\n          studies is also required, including electrolytes, creatinine, glucose, liver function, and\n          thyroid hormone levels.\u003C\/p\u003E\u003Cdiv id=\u0022T7\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022##\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/25653\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\n\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/25653\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 7\u003C\/span\u003E \u003Cp id=\u0022p-121\u0022 class=\u0022first-child\u0022\u003EReported incidence of irAEs in published ICI clinical trials for metastatic TNBC\n              (adapted from D\u0026acirc;\u0026#128;\u0026#153;Abreo and Adams, \u003Cem\u003ENat Rev Clin Oncol, 2019\u003C\/em\u003E\u003Ca id=\u0022xref-ref-214-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-214\u0022\u003E214\u003C\/a\u003E)\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-123\u0022\u003EBaseline history\/physical exam should include assessment of autoimmune, infectious,\n          neurologic, bowel, musculoskeletal, or endocrine pre-existing conditions. Pulse oximetry\n          assessment and monitoring is recommended. An electrocardiogram (EKG) should be considered\n          to provide a pre-treatment baseline for comparison with future EKGs obtained due to\n          cardiac-related symptoms. Baseline troponin levels should also be obtained to provide\n          useful information for evaluating potential future cardiotoxicity, and subsequently\n          measured as clinically indicated.\u003C\/p\u003E\u003Cp id=\u0022p-124\u0022\u003EMost immunotherapy agents include monitoring recommendations as part of their prescribing\n          information; for example, the package insert for pembrolizumab recommends monitoring for\n          changes in hepatic and thyroid function.\u003Ca id=\u0022xref-ref-19-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E However,\n          accumulated experience with ICIs in real-world settings has led to the emergence of some\n          general principles on the type and frequency of monitoring needed. Routine monitoring of\n          patients is generally more frequent during the initial 4 cycles of treatment, with\n          clinical assessments and laboratory testing complete blood count (CBC), comprehensive\n          metabolic panel (CMP), hemoglobin A1c (HgbA1c), thyroid stimulating hormone (TSH), free T4\n          (FT4), and morning serum cortisol recommended at baseline and every 4 weeks.\u003Ca id=\u0022xref-ref-215-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-215\u0022\u003E215\u003C\/a\u003E After the first four cycles then testing intervals\n          can be increased to every 6\u0026acirc;\u0026#128;\u0026#147;12 weeks, or as indicated. Additionally, morning serum\n          cortisol should be measured prior to surgery in patients receiving pembrolizumab in the\n          neoadjuvant setting. Combination immunotherapy regimens may require closer monitoring as\n          immune-related toxicity rates tend to be higher compared with monotherapy.\u003Ca id=\u0022xref-ref-215-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-215\u0022\u003E215 216\u003C\/a\u003E Other tests such as amylase, lipase,\n          C-reactive protein, creatine phosphokinase (CPK), erythrocyte sedimentation rate (ESR),\n          brain MRI, CT scans of the thorax\/abdomen, pulmonary function tests, troponin and EKGs\n          should be performed as indicated. Most patients with metastatic breast cancer receive some\n          of these imaging tests routinely for assessment of treatment response, so additional scans\n          in asymptomatic patients are generally not required.\u003C\/p\u003E\u003Cp id=\u0022p-125\u0022\u003EAny organ system in the body can be affected by irAEs, and the most commonly reported\n          toxicities across all cancer types are dermatologic, gastrointestinal, endocrine,\n          respiratory, and hepatic.\u003Ca id=\u0022xref-ref-215-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-215\u0022\u003E215\u0026acirc;\u0026#128;\u0026#147;218\u003C\/a\u003E For breast cancer, the top three most commonly reported irAEs in\n          published trials are hypothyroidism, rash or pruritus, and hepatitis (see \u003Ca id=\u0022xref-table-wrap-7-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T7\u0022\u003Etable 7\u003C\/a\u003E). Although the timing of onset and organ\n          systems affected by irAEs may vary, dermatologic toxicities are among the most frequently\n          reported. In one pooled analysis of patients receiving immunotherapy for metastatic\n          melanoma, skin toxicities tended to occur earlier (median 5 week onset), whereas\n          endocrinopathies and renal toxicities tended to occur later (median 10\u0026acirc;\u0026#128;\u0026#147;15 weeks).\n          The median time to onset for most other immune-related events was about 8 weeks.\u003Ca id=\u0022xref-ref-219-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-219\u0022\u003E219\u003C\/a\u003E For TNBC, the timing to onset for irAEs was\n          similar to that seen in other tumor types.\u003Ca id=\u0022xref-ref-214-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-214\u0022\u003E214\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-39\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EManagement of irAEs\u003C\/h3\u003E\u003Cp id=\u0022p-126\u0022\u003EICIs are associated with distinct toxicity profiles compared with conventional breast\n          cancer treatments. Oftentimes, the same mechanisms that give rise to antitumor effects\n          also underlie the AEs seen with immunotherapy\u0026acirc;\u0026#128;\u0026#148;namely, uninhibited immune activity.\n          For ICI therapy, the overall incidence of irAEs across published trials has been estimated\n          to be up to 75% for anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) monotherapy\n          (ipilimumab) and up to 30% for anti-PD-(L)1 agents.\u003Ca id=\u0022xref-ref-215-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-215\u0022\u003E215\u003C\/a\u003E Detailed guidelines on the recognition and management of irAEs have been\n          published elsewhere, including by SITC\u003Ca id=\u0022xref-ref-215-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-215\u0022\u003E215 217\n            220\u003C\/a\u003E and care typically includes withholding immunotherapy, administering\n          corticosteroids, and, in some instances, administering second-line immune-modulatory\n          agents such as tumor necrosis factor (TNF) inhibitors. In general, immunotherapy may be\n          continued in the setting of grade 1\u0026acirc;\u0026#128;\u0026#147;2 immune toxicity that can be managed with\n          topical or systemic low-dose steroids, whereas grade \u0026acirc;\u0026#137;\u0026yen;3 toxicity, or symptomatic\n          grade 2 toxicity necessitates at least temporary discontinuation of therapy and referral\n          to or consultation with appropriate specialists.\u003C\/p\u003E\u003Cp id=\u0022p-127\u0022\u003EWith more data becoming available on the use of immunotherapy in clinical trial and\n          real-world settings, patterns of irAEs that were not evident during individual studies are\n          emerging, such as high rates of thyroiditis. A meta-analysis including 38 randomized\n          clinical trials evaluating the usage of ICIs for treatment of advanced solid tumors\n          including a total of 7,551 patients found an overall incidence of hypothyroidism of\n          6.6% (95% CI 5.5% to 7.8%).\u003Ca id=\u0022xref-ref-221-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-221\u0022\u003E221\u003C\/a\u003E The incidence of hypothyroidism in real-world settings may be higher than in\n          clinical trials, as one retrospective analysis of electronic health records for 1,146\n          individuals treated with ICIs at a single center between 2012 and 2018 identified thyroid\n          irAEs in 19% of patients.\u003Ca id=\u0022xref-ref-222-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-222\u0022\u003E222\u003C\/a\u003E Another\n          analysis of 29,294,336 records spanning 5 years from the FDA AEs reporting system found\n          that the four most common endocrine-related AEs with ICIs were hypothyroidism, primary\n          adrenal insufficiency, hypophysitis (secondary adrenal insufficiency), and\n            hyperthyroidism.\u003Ca id=\u0022xref-ref-223-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-223\u0022\u003E223\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-40\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPatterns of irAEs in patients with breast cancer\u003C\/h3\u003E\u003Cp id=\u0022p-128\u0022\u003EIn the IMpassion130 trial, a total of 259 patients (57.3%) in the atezolizumab\n          plus nab-paclitaxel group and 183 (41.8%) in the placebo plus nab-paclitaxel group\n          had AEs of special interest that were suggestive of potential immune-related causes.\u003Ca id=\u0022xref-ref-18-6\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E In IMpassion130, the leading cause for atezolizumab\n          discontinuation was peripheral neuropathy. Serious AEs were reported in 105 of 453\n          patients in the atezolizumab group (23%) compared with 81 of 437 patients in the\n          placebo group (19%), and one death due to an AE of special interest was reported in\n          the primary analysis in each arm of the study\u0026acirc;\u0026#128;\u0026#148;in both cases, hepatitis. On\n          secondary analysis, the AEs of special interest that differed substantially between the\n          atezolizumab group and the placebo group were any-grade rash, hypothyroidism,\n          hyperthyroidism, pneumonitis, and adrenal insufficiency.\u003Ca id=\u0022xref-ref-24-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003E24\u003C\/a\u003E In KEYNOTE-355, irAEs occurred in 26% of patients in the pembrolizumab\n          plus chemotherapy arm, with 5% of patients experiencing irAEs of grade \u0026acirc;\u0026#137;\u0026yen;3.\n          The only irAE of grade \u0026acirc;\u0026#137;\u0026yen;3 that occurred in 10 or more patients was skin toxicity\n          (n=10; 2%). In the immunotherapy group, hypothyroidism and hyperthyroidism occurred\n          in 87 (15%) and 15 (5%) patients, respectively. Hypothyroidism and\n          hyperthyroidism occurred in 9 (3%) and 3 (1%) patients in the control\n            group.\u003Ca id=\u0022xref-ref-26-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26\u003C\/a\u003E Management of immune toxicities in other\n          organ systems follows similar recommendations to existing expert panel guidelines.\u003Ca id=\u0022xref-ref-215-6\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-215\u0022\u003E215 217 220\u003C\/a\u003E Referral to appropriate\n          specialists for persistent autoimmunity is recommended.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-41\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ELate irAEs in immunotherapy-experienced patients\u003C\/h3\u003E\u003Cp id=\u0022p-129\u0022\u003EUnlike the AEs associated with chemotherapies or targeted drugs, irAEs may arise months\n          or even years after cessation of immunotherapy. Definitive data on the incidence rates and\n          severity of delayed onset AEs are challenging to obtain, in part because the reporting\n          mandates and follow-up periods for clinical trials have been limited.\u003Ca id=\u0022xref-ref-224-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-224\u0022\u003E224\u003C\/a\u003E One retrospective analysis of data safety reporting from 194\n          published immunotherapy clinical trials across disease settings spanning 10 years\n          identified 23 qualifying cases of irAEs arising more than 90 days after the reporting\n            window.\u003Ca id=\u0022xref-ref-225-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-225\u0022\u003E225\u003C\/a\u003E Data are even sparser on delayed\n          onset-irAEs in patients with breast cancer receiving immunotherapies due to the relatively\n          recent introduction of these treatments into clinical use. It is important to emphasize\n          that immune effects can occur within a week to more than 1 year after initiation of\n          therapy (including after cessation of therapy, and even after exposure to a single dose),\n          so monitoring over a period of 12\u0026acirc;\u0026#128;\u0026#147;24 months for symptoms of immune toxicities\n          following therapy initiation is recommended. Further study on this topic is needed.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-42\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ERechallenging with ICI after irAE: when is retreatment appropriate?\u003C\/h3\u003E\u003Cp id=\u0022p-130\u0022\u003EThe decision to rechallenge patients with immunotherapy following an irAE depends on the\n          perceived benefit versus risk for the patient. The risk-benefit calculation for a patient\n          with a symptomatic irAE should be based on the severity of the event, time to recovery to\n          grade 1 or lower toxicity, the ability to taper off steroids without recurrence of\n          toxicity, and if immunotherapy is clearly providing clinical benefit. Most expert\n          guidelines, including from SITC,\u003Ca id=\u0022xref-ref-220-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-220\u0022\u003E220\u003C\/a\u003E recommend\n          permanent cessation of immunotherapy agents for most grade 3\u0026acirc;\u0026#128;\u0026#147;4 toxicities and\n          potential rechallenge for grade 2 AEs that resolve to grade 0\u0026acirc;\u0026#128;\u0026#147;1 promptly with\n          supportive therapy.\u003Ca id=\u0022xref-ref-215-7\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-215\u0022\u003E215 217 226\u003C\/a\u003E Some\n          exceptions to this rule are continuation of therapy for stable endocrinopathies and\n          rechallenge in cases of grade 3 colitis, as only roughly 30% of patients develop\n          recurrent colitis after retreatment with anti-PD-1 ICI.\u003Ca id=\u0022xref-ref-227-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-227\u0022\u003E227\u003C\/a\u003E Conversely, treatment is permanently stopped for grade 2 cardiac and\n          neurologic complications. Currently, there are no data to suggest that patients with prior\n          PD-(L)1 treatment are less likely to respond to rechallenge. Although the onset of irAEs\n          on therapy has been linked with improved OS and PFS for some tumor types,\u003Ca id=\u0022xref-ref-228-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-228\u0022\u003E228\u003C\/a\u003E special consideration is warranted about the value\n          of continuing therapy for patients with breast cancer as the overall clinical benefits\n          with ICI (particularly for PFS) are more modest when compared with other immune-responsive\n          tumor types.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-43\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EOther general concerns for patients with breast cancer treated with\n          immunotherapy\u003C\/h3\u003E\u003Cp id=\u0022p-131\u0022\u003ECurative locoregional therapy including definitive surgery and adjuvant radiation therapy\n          have been used sequentially or concurrently with anti-PD-(L)1 immunotherapy in the\n            I-SPY2,\u003Ca id=\u0022xref-ref-65-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-65\u0022\u003E65\u003C\/a\u003E KEYNOTE-522,\u003Ca id=\u0022xref-ref-70-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-70\u0022\u003E70\u003C\/a\u003E and IMpassion031\u003Ca id=\u0022xref-ref-77-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-77\u0022\u003E77\u003C\/a\u003E studies.\n          Of note, for immunotherapy in the adjuvant setting, monitoring for irAEs may be\n          challenging if patients transfer to another healthcare provider. For example, if a patient\n          receives adjuvant therapy at a tertiary care center, but then transfers care to a local\n          oncologist, it is essential there is exchange of information among providers regarding the\n          risk of toxicity and need for ongoing vigilance for irAEs. In published trials, there has\n          not been an increased incidence of perioperative complications with immunotherapy.\u003Ca id=\u0022xref-ref-65-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-65\u0022\u003E65 68 229\u003C\/a\u003E While rare with PD-(L)1 agents,\n          adrenal insufficiency is associated with ICIs, and therefore obtaining a preoperative\n          cortisol level is recommended for patients who have received neoadjuvant checkpoint\n          inhibitors.\u003C\/p\u003E\u003Cp id=\u0022p-132\u0022\u003EPneumonitis is associated with receipt of prior thoracic or chest wall\/breast radiation,\n          and checkpoint inhibitor therapy may increase risk for pulmonary toxicities.\u003Ca id=\u0022xref-ref-230-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-230\u0022\u003E230 231\u003C\/a\u003E Patients with breast cancer undergoing\n          post-mastectomy or regional nodal irradiation are exposed to some level of radiation dose\n          to the lungs, but the rates of pneumonitis did not appear significantly higher in the\n          patients receiving adjuvant pembrolizumab concurrent with adjuvant radiation in\n            KEYNOTE-522.\u003Ca id=\u0022xref-ref-70-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-70\u0022\u003E70\u003C\/a\u003E Additional data are required to\n          better understand how different radiation techniques (eg, protons, intensity modulated\n          radiation therapy, volumetric arc therapy, and dose and fractionation regimen) may affect\n          the risk of pneumonitis over time when radiation is delivered concurrently or in close\n          proximity with ICIs. No data exist regarding the specific impact of adjuvant immunotherapy\n          on breast reconstruction outcomes or cosmesis, including in patients who received\n          radiation. Radiation techniques may be relevant in terms of potential impact on the risk\n          of developing lymphopenia, particularly when radiation therapy is given with immunotherapy\n          to large target volumes.\u003C\/p\u003E\u003Cp id=\u0022p-133\u0022\u003EFinally, patients with cancer are at increased risk for severe complications with\n          influenza infection.\u003Ca id=\u0022xref-ref-232-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-232\u0022\u003E232 233\u003C\/a\u003E Several\n          retrospective analyses have demonstrated that inactivated influenza vaccines are safe and\n          effective in patients being treated with ICIs.\u003Ca id=\u0022xref-ref-234-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-234\u0022\u003E234\n            235\u003C\/a\u003E Vaccination with clinically indicated vaccines (eg, seasonal influenza,\n          COVID-19) should be encouraged. Currently, data are lacking on the safety of\n          live-attenuated vaccines in the context of checkpoint blockade specifically, but current\n          recommendations for patients with cancer undergoing immunosuppressive therapy state that\n          live-attenuated vaccines should be administered \u0026acirc;\u0026#137;\u0026yen;4 weeks prior to onset or\n          \u0026acirc;\u0026#137;\u0026yen;3 months after immune restoration.\u003Ca id=\u0022xref-ref-236-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-236\u0022\u003E236\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-44\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPanel recommendations\u003C\/h3\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-5\u0022\u003E\u003Cli id=\u0022list-item-26\u0022\u003E\u003Cp id=\u0022p-134\u0022\u003EIn patients with pre-existing comorbidities, active autoimmune disease requiring\n              systemic immunosuppression (\u0026gt;10 mg prednisone equivalent or biologics), or\n              those who have experienced toxicities with prior therapies, the benefits of\n              immunotherapy must be weighed against the potential for severe AEs.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-27\u0022\u003E\u003Cp id=\u0022p-135\u0022\u003EPatients should be monitored for symptoms of immune toxicities during immunotherapy\n              and for at least 12 months after discontinuation of treatment. Importantly, irAEs may\n              occur after immunotherapy has been discontinued and other therapy initiated (LE:\n              1).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-28\u0022\u003E\u003Cp id=\u0022p-136\u0022\u003EFor patients with early stage TNBC who receive pembrolizumab, serum cortisol should\n              be tested at baseline, prior to surgery, and as clinically indicated.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-29\u0022\u003E\u003Cp id=\u0022p-137\u0022\u003EFor patients with breast cancer who experience irAEs during immunotherapy treatment,\n              management should generally follow the most updated guidelines (eg, SITC, ASCO,\n              National Comprehensive Cancer Network (NCCN)) as this field is rapidly evolving.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-30\u0022\u003E\u003Cp id=\u0022p-138\u0022\u003EFor patients with breast cancer who develop thyroid disorders or adrenal\n              insufficiency while on treatment, immunotherapy can generally be continued (LE:\n              2).\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-45\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EPatient education and QOL\u003C\/h2\u003E\u003Cdiv id=\u0022sec-46\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPatient and caregiver education\u003C\/h3\u003E\u003Cp id=\u0022p-139\u0022\u003EICIs represent a new treatment option for metastatic TNBC. As more patients with breast\n          cancer receive ICI therapy, it is crucial for all members of a care team to be\n          knowledgeable about the unique toxicity profile associated with immunotherapy compared\n          with conventional oncology agents and to take into account a holistic view of QOL during\n          and after treatment.\u003C\/p\u003E\u003Cp id=\u0022p-140\u0022\u003EThe potential for toxicity underscores the importance of open communication among the\n          patient, family, and treating oncology team.\u003Ca id=\u0022xref-ref-237-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-237\u0022\u003E237\u003C\/a\u003E\n          Patient education is critical, including how immunotherapy eliminates cancer, how it is\n          administered, and the potential for irAEs.\u003Ca id=\u0022xref-ref-215-8\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-215\u0022\u003E215\n            218\u003C\/a\u003E Patients need to understand that, due to the different way immunotherapy\n          eliminates cancer, many toxicities that the patient may experience are different than what\n          is experienced with chemotherapy or hormonal therapy (for detailed descriptions of irAEs,\n          see the \u003Cstrong\u003EPatient selection and toxicity management\u003C\/strong\u003E section). This is\n          particularly important when talking to patients with metastatic breast cancer who have\n          experience with chemotherapy or endocrine therapy and may expect dose reduction in the\n          event of toxicity, as opposed to withholding ICI. It may be useful to use metaphors to\n          communicate with patients, such as describing how ICIs essentially take off the\n          \u0026acirc;\u0026#128;\u0026#152;brakes\u0026acirc;\u0026#128;\u0026#153; of the immune system and thereby enable an antitumor immune\n          response. Patients may have to make difficult decisions about their treatment. Caregivers\n          also provide support to patients during cancer treatment, so it is important to include\n          caregivers and other family members when providing education to patients about\n          immunotherapy.\u003C\/p\u003E\u003Cp id=\u0022p-141\u0022\u003ECurrently, PD-(L)1 inhibition is only FDA-approved for metastatic TNBC; however, there\n          are many clinical trials testing immunotherapies in early-stage breast cancer.\u003Ca id=\u0022xref-ref-65-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-65\u0022\u003E65 74\u003C\/a\u003E Patients with metastatic breast cancer report\n          interest in ongoing side effects and how therapy will interfere with daily living\n            long-term.\u003Ca id=\u0022xref-ref-238-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-238\u0022\u003E238 239\u003C\/a\u003E In this setting, it is\n          reassuring that patient-reported outcomes (PRO) demonstrated no impact on health-related\n          quality of life (HRQOL) and day-to-day functioning when atezolizumab was added to\n          nab-paclitaxel compared with the group receiving chemotherapy only in IMpassion130.\u003Ca id=\u0022xref-ref-240-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-240\u0022\u003E240\u003C\/a\u003E In patients with early-stage breast cancer, the\n          decision to pursue adjuvant and\/or neoadjuvant therapy may be difficult and must include a\n          discussion about the possibility of acute irAEs and the potential for long-term (and\n          perhaps unknown) immune-related toxicities after treatment has ended. In particular,\n          referral of patients with endocrinopathies (particularly adrenal insufficiency) to\n          endocrinology for follow-up is recommended. Patients with adrenal insufficiency must be\n          educated on the importance of regular-dosing and stress-dosing of steroids to avoid\n          life-threatening adrenal crises,\u003Ca id=\u0022xref-ref-241-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-241\u0022\u003E241\u003C\/a\u003E and may want\n          to consider obtaining a Medic-Alert bracelet. Medical records\/summary of care documents\n          should be updated to reflect the diagnosis.\u003C\/p\u003E\u003Cp id=\u0022p-142\u0022\u003EFor patients with early-stage breast cancer in particular, it is important to discuss\n          impact on fertility. Although robust data on whether immunotherapy directly has adverse\n          effects on conception and gestation are currently lacking\u003Ca id=\u0022xref-ref-242-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-242\u0022\u003E242\u003C\/a\u003E (with the exception of two isolated case reports of pregnancies successfully\n          carried to term during treatment with ICIs for melanoma\u003Ca id=\u0022xref-ref-243-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-243\u0022\u003E243 244\u003C\/a\u003E), immune-related endocrinopathies may have long-term\n          consequences on fertility. If available, an oncofertility consultation prior to initiation\n          of immunotherapy may assist patients in making decisions regarding their future ability to\n          have children.\u003Ca id=\u0022xref-ref-245-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-245\u0022\u003E245\u003C\/a\u003E Also, immunotherapy may affect\n          pituitary function, which can result in an inability to lactate or galactorrhea.\n          Autoimmune hypophysitis in healthy women is rare, but occurs more frequently in women who\n          are or were pregnant.\u003Ca id=\u0022xref-ref-246-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-246\u0022\u003E246\u003C\/a\u003E It is not known if prior\n          immunotherapy affects this risk in women of childbearing age who go on to conceive after\n          therapy is completed.\u003C\/p\u003E\u003Cp id=\u0022p-143\u0022\u003ENCCN guidelines recommend that patients use effective birth control during and for at\n          least 5 months following completion of immunotherapy treatments, and many clinical trials\n          mandate the use of contraception for up to 6 months after the final dose on study.\n          However, the data supporting these recommendations are limited.\u003Ca id=\u0022xref-ref-242-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-242\u0022\u003E242\u003C\/a\u003E Checkpoint inhibitor therapy is considered category D in\n            pregnancy.\u003Ca id=\u0022xref-ref-247-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-247\u0022\u003E247\u003C\/a\u003E Additionally, if a woman requires\n          treatment with steroid-sparing immunosuppressive agents such as mycophenolate while on ICI\n          therapy, risk of fetal malformation is increased.\u003Ca id=\u0022xref-ref-248-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-248\u0022\u003E248\n            249\u003C\/a\u003E Despite the two isolated case reports of successful conception and viable\n          pregnancies during ICI therapy mentioned above,\u003Ca id=\u0022xref-ref-243-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-243\u0022\u003E243\n            244\u003C\/a\u003E due to limited safety data, initiation of checkpoint therapy during pregnancy\n          is discouraged.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-47\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EQOL and symptom monitoring\u003C\/h3\u003E\u003Cp id=\u0022p-144\u0022\u003ECurrently, the majority of experience with immunotherapy for breast cancer has been in\n          the advanced\/metastatic setting. Patients with metastatic breast cancer can experience an\n          accumulation of physical symptoms and psychosocial stressors that adversely affect their\n          QOL throughout their continued treatment. Over time, these effects usually become worse as\n          treatment is ongoing.\u003Ca id=\u0022xref-ref-238-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-238\u0022\u003E238 239\u003C\/a\u003E A robust corpus\n          of literature has described key QOL outcomes for patients receiving chemotherapy,\n          radiotherapy, endocrine therapy, or HER2-directed therapies. In addition, throughout a\n          patient\u0026acirc;\u0026#128;\u0026#153;s journey, multiple intrinsic and extrinsic factors may influence QOL,\n          including AEs associated with therapy as well as other characteristics of the individual\n          being treated (eg, menopausal status and socioeconomic status).\u003Ca id=\u0022xref-ref-250-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-250\u0022\u003E250\u0026acirc;\u0026#128;\u0026#147;253\u003C\/a\u003E However, data are currently lacking on\n          the QOL implications for the addition of ICIs to chemotherapy or other conventional\n          treatments.\u003C\/p\u003E\u003Cp id=\u0022p-145\u0022\u003EOngoing trials are also evaluating ICIs in early-stage disease. Patients with early-stage\n          breast cancer also experience both physical symptoms and psychosocial stressors that can\n          adversely affect their QOL.\u003Ca id=\u0022xref-ref-254-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-254\u0022\u003E254\u0026acirc;\u0026#128;\u0026#147;256\u003C\/a\u003E Although survivors of early-stage breast cancer generally report\n          high functioning after the conclusion of treatment, important rehabilitation problems may\n          persist beyond 1 year after primary treatment, including difficulties with physical and\n          recreational activities, body image, sexual interest, sexual function, and dating for\n          those who were single.\u003Ca id=\u0022xref-ref-238-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-238\u0022\u003E238\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-146\u0022\u003EAlthough QOL data are limited in patients with breast cancer who received immunotherapy,\n          the use of adjuvant immunotherapy in other cancers can help inform what to expect. Data\n          from other malignancies suggests that, due to the primed immune system, toxicities may be\n          greater in the adjuvant setting than in the advanced disease setting.\u003Ca id=\u0022xref-ref-257-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-257\u0022\u003E257\u003C\/a\u003E However, PRO data from IMpassion031 showed no meaningful\n          differences in HRQOL outcomes between the control and immunotherapy arms.\u003Ca id=\u0022xref-ref-258-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-258\u0022\u003E258\u003C\/a\u003E Regardless, if the adjuvant treatment landscape\n          for breast cancer expands to include ICIs (for more details on ongoing studies, see the\n            \u003Cstrong\u003EEmerging data on immunotherapy with PD-(L)1 inhibitors for early-stage\/locally\n            advanced breast cancer\u003C\/strong\u003E section), the decision to recommend must be carefully\n          considered, and patients must be active participants in the decision-making process.\n          Knowing that patients with early-stage disease are typically healthy prior to their\n          diagnosis, early identification of irAEs is imperative to minimize the detrimental effects\n          of QOL on treatment. Additionally, the potential for long-term toxicity affecting physical\n          activity and daily living means that their overall QOL may be impacted by immunotherapy\n          treatment. Therefore, assessing for the early or subtle signs and symptoms of irAEs is\n          critical for prompt diagnosis and management.\u003C\/p\u003E\u003Cp id=\u0022p-147\u0022\u003ENo significant effects on HRQOL were observed with the addition of atezolizumab to\n          nab-paclitaxel for the treatment of metastatic TNBC in IMpassion130.\u003Ca id=\u0022xref-ref-259-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-259\u0022\u003E259\u003C\/a\u003E A separate analysis of HRQOL in patients with metastatic TNBC\n          randomly assigned to receive either pembrolizumab or chemotherapy in the KEYNOTE-119 trial\n          found benefits for immunotherapy over standard of care in all PRO endpoints. Among the\n          patients with PD-L1 expression in tumors and immune-infiltrating cells, the median time to\n          QOL deterioration as measured by PRO was 4.3 months for pembrolizumab versus 1.7 months\n          with chemotherapy (HR 0.70; 95% CI 0.46 to 1.05). Additionally, deterioration in\n          fatigue, nausea and vomiting, pain, dyspnea, and loss of appetite were all observed with\n          chemotherapy but remained stable or improved slightly with immunotherapy.\u003Ca id=\u0022xref-ref-260-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-260\u0022\u003E260\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-148\u0022\u003EIt will be important to gather data on HRQOL in future trials, and to include assessments\n          with validated tools to enable meaningful comparisons across studies. Currently, the\n          European Organization for Research and Treatment of Cancer (EORTC) Quality of Life\n          Questionnaire (EORTC QLQ-C30) and the European Quality of Life 5 Dimension (EQ-5D) are the\n          most commonly used HRQOL assessment instruments in immunotherapy trials.\u003Ca id=\u0022xref-ref-261-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-261\u0022\u003E261\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-48\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPanel recommendations\u003C\/h3\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-6\u0022\u003E\u003Cli id=\u0022list-item-31\u0022\u003E\u003Cp id=\u0022p-149\u0022\u003EFor patients receiving immunotherapy, education should be provided, including the\n              differences between chemotherapy and immunotherapy. Whenever possible, caregivers and\n              family members should be included in these conversations.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-32\u0022\u003E\u003Cp id=\u0022p-150\u0022\u003EPatients should be encouraged to use contraception while receiving immunotherapy, and\n              a discussion about fertility should be initiated prior to treatment.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-33\u0022\u003E\u003Cp id=\u0022p-151\u0022\u003EPatients and providers should be educated about potential irAEs, including the\n              expected timing of symptom onset and management of toxicity with immunotherapies,\n              rationale for holding doses as opposed to dose reductions, and detailed parameters for\n              when to contact their care team.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-34\u0022\u003E\u003Cp id=\u0022p-152\u0022\u003EFor patients being treated with immunotherapy, education should include the\n              importance of early recognition and management of irAEs, emphasizing that some of the\n              more common toxicities have vague symptoms and therefore any change from baseline\n              health should be reported. Additionally, patients should be encouraged to inform all\n              their current and future healthcare providers that they have been treated with\n              immunotherapy.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-49\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ENovel combination strategies and intriguing future directions\u003C\/h2\u003E\u003Cp id=\u0022p-153\u0022\u003EA number of ongoing trials are evaluating novel immunotherapeutic strategies, including new\n        targets, emerging agents like bispecific antibodies, and combinations of checkpoint\n        inhibitors with other treatment modalities such as radiotherapy, cryotherapy, or targeted\n        drugs. Although none of these emerging strategies have gained FDA approval at this time, if\n        results from early studies are encouraging, they may develop into feasible options for\n        patients with breast cancer in the near future.\u003C\/p\u003E\u003Cdiv id=\u0022sec-50\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ERadiotherapy\u003C\/h3\u003E\u003Cp id=\u0022p-154\u0022\u003ECombining ICIs with local, ablative therapies is a strategy that has garnered substantial\n          enthusiasm. This is in part due to the potential for radiation to elicit systemic immune\n          responses, as well as advances in sophisticated radiation oncology technologies such as\n          stereotactic radiation, which permits high, ablative doses of radiation to be tailored to\n          the tumor volume while minimizing damage to surrounding normal tissue.\u003Ca id=\u0022xref-ref-190-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-190\u0022\u003E190\u003C\/a\u003E Although the bulk of evidence so far is\n            preclinical,\u003Ca id=\u0022xref-ref-262-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-262\u0022\u003E262\u003C\/a\u003E a few trials have evaluated the\n          integration of radiotherapy with checkpoint inhibition in patients with breast cancer. In\n          a phase II study evaluating the combination of hypofractionated radiotherapy and\n          pembrolizumab in 17 patients with metastatic TNBC unselected for PD-L1 status and heavily\n          pre-treated with prior lines of chemotherapy, the ORR for the entire cohort was\n          17.6% with 100% reduction in tumor volume outside of the irradiated portal\n          among responders.\u003Ca id=\u0022xref-ref-263-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-263\u0022\u003E263\u003C\/a\u003E Treating earlier in the\n          disease course and PD-L1 status appeared to be predictors of response. Another phase II\n          trial that enrolled eight patients with heavily pre-treated (median two prior lines of\n          chemotherapy) metastatic HR+ breast cancer for treatment with radiotherapy plus\n          pembrolizumab demonstrated no objective responses and halted accrual after the first\n            cohort.\u003Ca id=\u0022xref-ref-191-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-191\u0022\u003E191\u003C\/a\u003E\u003C\/p\u003E\u003Cp id=\u0022p-155\u0022\u003EThe strategy of combining radiation with ICIs and\/or other novel immune targets in the\n          preoperative setting for TNBC and HR+\/HER2\u0026acirc;\u0026#128;\u0026#147; breast cancer is currently being\n          evaluated in four clinical trials.\u003Ca id=\u0022xref-ref-264-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-264\u0022\u003E264\u003C\/a\u003E The largest\n          study, P-RAD: A Randomized Study of \u003Cspan class=\u0022underline\u0022\u003EP\u003C\/span\u003Ereoperative Chemotherapy,\n          Pembrolizumab and No, Low or High Dose \u003Cspan class=\u0022underline\u0022\u003ERAD\u003C\/span\u003Eiation in Node-Positive,\n          HER2-Negative Breast Cancer (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04443348\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022\u003ENCT04443348\u003C\/a\u003E), is evaluating two co-primary endpoints of\n          change in TILs and pathologic nodal response as a surrogate for the abscopal effect in\n          patients with node-positive, HER2\u0026acirc;\u0026#128;\u0026#147; breast cancer who receive neoadjuvant\n          pembrolizumab, chemotherapy and radiation to the intact breast tumor. Another endpoint of\n          this trial is to compare different radiation modalities, protons and photons, in\n          combination with pembrolizumab. Relative to standard photon therapy, proton therapy is a\n          highly precise form of radiation that is known for sharp dose fall-off beyond the tumor\n          target, which allows sparing of T-lymphocytes, hypothetically leaving them available to\n          generate a robust immune response. Other questions regarding the optimal sequencing,\n          timing, and modality of radiation to integrate with immunotherapy remain active topics of\n          investigation.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-51\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ECryotherapy\u003C\/h3\u003E\u003Cp id=\u0022p-156\u0022\u003EFeasibility and safety of cryotherapy in combination with ICIs was shown in a pilot study\n          of 19 women with breast cancer for whom mastectomy was planned where patients were treated\n          with preoperative tumor cryoablation (n=7), single-dose ipilimumab at 10 mg\/kg (n=6), or\n          both (n=6). The regimens were all safe and tolerable, and combination therapy was\n          associated with sustained peripheral elevations in Th1-type cytokines, activated and\n          proliferating CD4\u003Csup\u003E+\u003C\/sup\u003E and CD8\u003Csup\u003E+\u003C\/sup\u003E T cells, and a favorable ratio of\n          proliferative effector T cells relative to regulatory T cells within the tumors.\u003Ca id=\u0022xref-ref-265-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-265\u0022\u003E265\u003C\/a\u003E A phase II study of ipilimumab, nivolumab, and\n          cryoablation for patients with \u0026acirc;\u0026#137;\u0026yen;1 cm of residual TNBC after standard of care\n          chemotherapy is underway (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT03546686\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022\u003ENCT03546686\u003C\/a\u003E).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-52\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EDNA repair-based therapies\u003C\/h3\u003E\u003Cp id=\u0022p-157\u0022\u003ECombining immunotherapy with PARP inhibitors is also an appealing strategy that is\n          currently being explored in multiple trials. In breast cancers, loss of function mutations\n          in \u003Cem\u003EBRCA1\u003C\/em\u003E or \u003Cem\u003EBRCA2\u003C\/em\u003E lead to dependence on PARP for the\n          repair of double-stranded DNA breaks, which has led to the successful clinical use of\n          agents such as olaparib and talazoparib, selective, orally available PARP-inhibitors that\n          are FDA-approved for germline \u003Cem\u003EBRCA1\/2\u003C\/em\u003E-mutated metastatic breast\n            cancer.\u003Ca id=\u0022xref-ref-90-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-90\u0022\u003E90 110 111\u003C\/a\u003E The sustained DNA\n          damage that accumulates as a result of PARP inhibition can also drive the emergence of\n          neoantigens as well as the upregulation of interferons in the tumor microenvironment due\n          to cGAS\/STING sensing in repair-competent tumors, possibly potentiating the effects of\n            immunotherapy.\u003Ca id=\u0022xref-ref-266-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-266\u0022\u003E266\u003C\/a\u003E Based on that rationale, the\n          phase II TOPACIO\/KEYNOTE-162 trial evaluated the combination of the PARP inhibitor\n          niraparib and pembrolizumab in 54 patients with metastatic TNBC, only 12 of whom\n          (22%) had a deleterious \u003Cem\u003EBRCA1\/2\u003C\/em\u003E mutation. At the time of data\n          analysis, 45 patients were evaluable and the ORR was 29% with a disease control\n          rate (DCR) of 49%, including 3 CR (7%), 10 PR (22%), 9 SD\n          (20%), and 23 cases of progressive disease (51%).\u003Ca id=\u0022xref-ref-267-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-267\u0022\u003E267\u003C\/a\u003E Best responses were observed in patients with a tumor\n            \u003Cem\u003EBRCA1\/2\u003C\/em\u003E mutation. In the phase II single arm MEDIOLA trial, patients\n          with germline \u003Cem\u003EBRCA1\/2\u003C\/em\u003E mutations achieved a DCR of 80% at 12 weeks\n          using the combination of olaparib and durvalumab.\u003Ca id=\u0022xref-ref-268-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-268\u0022\u003E268\u003C\/a\u003E In a recently reported arm in the I-SPY2 trial, the addition of durvalumab\n          and olaparib to weekly paclitaxel treatments increased pCR rates across all biomarker\n          subsets of breast cancer (HER2\u0026acirc;\u0026#128;\u0026#147;, 22% vs 37%; ER+\/HER2\u0026acirc;\u0026#128;\u0026#147;\n          Mammaprint High Risk, 14% vs 28%; TNBC, 27% vs 47%).\u003Ca id=\u0022xref-ref-73-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-73\u0022\u003E73\u003C\/a\u003E Future trials will be important to define not only\n          the depth of response, but the durability of these responses as well.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-53\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAnti-VEGF and tyrosine kinase inhibitors\u003C\/h3\u003E\u003Cp id=\u0022p-158\u0022\u003ECombination trials evaluating checkpoint inhibitors with anti-VEGF agents and tyrosine\n          kinase inhibitors are also ongoing. The non-randomized, phase II NEWBEAT study reported\n          results for the addition of nivolumab to the combination of paclitaxel and the\n          anti-angiogenic monoclonal antibody, bevacizumab, for the first-line treatment in patients\n          with metastatic HER2\u0026acirc;\u0026#128;\u0026#147; breast cancer. The OS rate at 12 months was 87.1% and\n          the ORR was 75.4% in patients with ER+ tumors and 83.3% in patients with\n          TNBC. Median PFS was not yet reached at the time of reporting, but PFS rate at 12 months\n          was 75.8%.\u003Ca id=\u0022xref-ref-269-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-269\u0022\u003E269\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-54\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ECDK 4\/6 inhibitors\u003C\/h3\u003E\u003Cp id=\u0022p-159\u0022\u003EPreclinical studies demonstrate that CDK 4\/6 inhibition promotes antitumor immunity by\n          increasing antigen processing and presentation.\u003Ca id=\u0022xref-ref-270-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-270\u0022\u003E270\u003C\/a\u003E\n          Initial results of an ongoing phase Ib study of pembrolizumab plus the CDK 4\/6 inhibitor,\n          abemaciclib, showed a tolerable safety profile and potential clinical benefit, with a\n          14.3% ORR and a 60% rate of SD at 16 weeks.\u003Ca id=\u0022xref-ref-271-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-271\u0022\u003E271\u003C\/a\u003E In a follow-up analysis that included 26 patients, the DCR was 77%\n          and clinical benefit rate (CR+PR+SD persisting for \u0026acirc;\u0026#137;\u0026yen;6 months) was 27%.\n          Although grade 3 and grade 4 AEs were generally reversible following drug holds and\n          corticosteroids, preliminary results in a phase Ib study reported two fatal events as a\n          result of pneumonitis and 15 patients (58%) who discontinued treatment.\u003Ca id=\u0022xref-ref-272-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-272\u0022\u003E272\u003C\/a\u003E Another study, the phase II NEWFLAME trial, which\n          evaluated nivolumab in combination with abemaciclib plus endocrine therapy in patients\n          with HR+\/HER2\u0026acirc;\u0026#128;\u0026#147; metastatic breast cancer\u003Ca id=\u0022xref-ref-273-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-273\u0022\u003E273\u003C\/a\u003E\n          was discontinued early due to safety concerns.\u003Ca id=\u0022xref-ref-274-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-274\u0022\u003E274\u003C\/a\u003E\n          The phase II CheckMate 7A8 study that is investigating nivolumab plus the CDK 4\/6\n          inhibitor palbociclib plus anastrozole in postmenopausal women and men with\n          ER+\/HER2\u0026acirc;\u0026#128;\u0026#147; primary breast cancer\u003Ca id=\u0022xref-ref-275-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-275\u0022\u003E275\u003C\/a\u003E is\n          ongoing. As these studies are ongoing, caution should be made when considering the\n          tolerability of these combinations, which may differ based on the specific CDK 4\/6\n          inhibitors and\/or ICIs being considered.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-55\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EBispecific T cell engagers\u003C\/h3\u003E\u003Cp id=\u0022p-160\u0022\u003EOne factor potentially underlying breast cancer immune evasion is the downregulation or\n          total loss of human leukocyte antigen (HLA) class I on TCs.\u003Ca id=\u0022xref-ref-276-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-276\u0022\u003E276\u0026acirc;\u0026#128;\u0026#147;278\u003C\/a\u003E One strategy to overcome loss of antigenicity\n          by TCs involves bispecific antibodies that bridge T cell CD3 and cancer cell surface\n          markers. Several bispecifics directed against breast cancer-specific antigens are\n          currently in development, with some reporting tolerable safety and preliminary efficacy in\n          human trials. For instance, in a phase I study of PRS-343, the first HER2\/4-1BB bispecific\n          molecule to enter human trials, a DCR of 58% (with 11% confirmed PR per\n          RECIST v1.1) was reported among the 19 of 51 patients with a variety of solid tumors\n          (including 12 with breast cancer) who were evaluable at the time of analysis. No serious\n          AEs were reported.\u003Ca id=\u0022xref-ref-279-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-279\u0022\u003E279\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-56\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAdenosine receptor inhibitors\u003C\/h3\u003E\u003Cp id=\u0022p-161\u0022\u003EAdenosine is an immunosuppressive metabolite produced at high levels within the tumor\n          microenvironment. Hypoxia, high cell turnover, and expression of CD39 and CD73 are\n          important factors in adenosine production.\u003Ca id=\u0022xref-ref-280-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-280\u0022\u003E280\u003C\/a\u003E\n          Metabolic reprogramming has been linked to the emergence of treatment resistance in breast\n            cancer.\u003Ca id=\u0022xref-ref-281-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-281\u0022\u003E281 282\u003C\/a\u003E As one example, activation\n          of A2aR or another adenosine receptor, A2bR, suppresses T cell proliferation, cytokine\n          production, and cytotoxicity, and new agents such as the adenosine receptor inhibitor,\n          CPI-444, are being evaluated in combination with checkpoint inhibition.\u003Ca id=\u0022xref-ref-283-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-283\u0022\u003E283\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-57\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EVaccines\u003C\/h3\u003E\u003Cp id=\u0022p-162\u0022\u003ETherapeutic vaccines or intratumoral therapies for breast cancer have been evaluated in\n          early-phase and randomized trials. One feasibility study of cyclophosphamide, trastuzumab,\n          and an allogeneic granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting\n          breast tumor vaccine for HER2+ metastatic breast cancer enrolled 20 patients and reported\n          median PFS and OS of 7 months (95% CI 4 to 16) and 42 months (95% CI 22 to\n          70), respectively.\u003Ca id=\u0022xref-ref-284-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-284\u0022\u003E284\u003C\/a\u003E Another phase I\/II study of\n          concurrent HER2-specific vaccination in 22 patients with stage IV HER2+ tumors\n          demonstrated epitope spreading to additional tumor-related proteins after\n            immunization.\u003Ca id=\u0022xref-ref-285-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-285\u0022\u003E285\u003C\/a\u003E Enthusiasm for the vaccine\n          approach diminished somewhat after the phase III multicenter clinical trial of the\n          sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer\n          demonstrated no significant benefit in time to progression in 1,028 women.\u003Ca id=\u0022xref-ref-286-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-286\u0022\u003E286\u003C\/a\u003E Currently, several ongoing studies are evaluating\n          intratumoral oncolytic viral therapy, including, but not limited to, pelareorep talimogene\n          laherparepvec (T-VEC), and PVX-410 with pembrolizumab in HLA-A2+ metastatic TNBC\n          (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT03362060\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022\u003ENCT03362060\u003C\/a\u003E).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-58\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EOther immune targets\u003C\/h3\u003E\u003Cp id=\u0022p-163\u0022\u003ETargeting additional mechanisms of tumor immune evasion is critical to extending the\n          benefits of immunotherapy to breast cancer. Although the majority of published studies on\n          immunotherapy for breast cancer have evaluated agents targeting the PD-(L)1 axis, some\n          trials have reported initial efficacy with other immunotherapy targets. A phase I study\n          that evaluated anti-CTLA-4 tremelimumab plus exemestane in 26 patients with advanced,\n          hormone-responsive breast cancer found favorable safety, with most treatment-related AEs\n          being mild-to-moderate, and a best overall response of SD\n          \u003Cspan class=\u0022underline\u0022\u003E\u0026gt;\u003C\/span\u003E12 weeks in 11 patients (42%).\u003Ca id=\u0022xref-ref-287-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-287\u0022\u003E287\u003C\/a\u003E Other strategies that remain under investigation in early-phase\n          trials include combining checkpoint blockade with other agents modulating various targets,\n          including the lymphocyte-activation gene 3 (LAG-3), TIGIT, and the T cell agonist\n          OX40.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-59\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPanel recommendations\u003C\/h3\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-7\u0022\u003E\u003Cli id=\u0022list-item-35\u0022\u003E\u003Cp id=\u0022p-164\u0022\u003EGiven the limited activity with currently available single-agent immunotherapy, the\n              efficacy of immunotherapeutic strategies will likely be enhanced with combination\n              therapy adding chemotherapy, targeted therapies, radiotherapy, or other immunotherapy\n              agents.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-36\u0022\u003E\u003Cp id=\u0022p-165\u0022\u003EBased on current evidence, the combinations mentioned above are investigational and\n              should only be considered in the context of a clinical trial.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-37\u0022\u003E\u003Cp id=\u0022p-166\u0022\u003EThe optimal dose of radiation (low or high) to combine with ICIs in the preoperative\n              setting is the subject of an ongoing clinical trial (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04443348\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022\u003ENCT04443348\u003C\/a\u003E). Data from this\n              trial will permit design of large, phase II trials examining radiation and\n              immunotherapy combinations in the pre-operative setting.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-38\u0022\u003E\u003Cp id=\u0022p-167\u0022\u003EIn ongoing and planned studies involving combination approaches with immunotherapy,\n              both short-term and long-term toxicities should be a careful consideration.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-39\u0022\u003E\u003Cp id=\u0022p-168\u0022\u003ECompanion biomarkers that predict clinical benefit and\/or toxicity are essential in\n              the development of these strategies.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section conclusions\u0022 id=\u0022sec-60\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EConclusion\u003C\/h2\u003E\u003Cp id=\u0022p-169\u0022\u003EImmunotherapy is now offering extended survival to patients with TNBC, a subset of breast\n        cancer patients who formerly had very few treatment options. Despite these advances, many\n        patients with breast cancer are ineligible for immunotherapy in the standard of care\n        setting. As additional trials continue to report results, the outlook may further improve\n        for patients with earlier stages of TNBC or other disease subtypes. Future trials are needed\n        to address the impact of immunotherapy in HR+ and HER2+ subtypes as well as the optimal\n        chemotherapy partner(s) for ICIs, especially as oncologists and patients balance the\n        potential for harm and benefit in early-stage cancer. Furthermore, more studies will be\n        needed to determine the best options for patients who relapse after initial treatment with\n        immunotherapy. Careful consideration should also be given to tissue choice and assay choice\n        for biomarker assessment, and additional study is needed to determine the optimal\n        biomarker(s) for ICIs in breast cancer. In the future, the indications for existing\n        immunotherapies are likely to continue to expand, and novel combinations may be approved. It\n        is an exciting and dynamic time for immunotherapy in breast cancer, and these guidelines\n        will be updated as the field continues to evolve.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ethics-statement\u0022 id=\u0022sec-61\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EEthics statements\u003C\/h2\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-62\u0022\u003E\u003Ch3\u003EPatient consent for publication\u003C\/h3\u003E\u003Cp id=\u0022p-177\u0022 class=\u0022ethics-consent-to-publish\u0022\u003ENot required.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ack\u0022 id=\u0022ack-1\u0022\u003E\u003Ch2\u003EAcknowledgments\u003C\/h2\u003E\u003Cp id=\u0022p-170\u0022\u003EThe authors acknowledge SITC staff for their contributions to the development and\n        publication of this guideline including Sam Million-Weaver, PhD, for medical writing\n        support; Lionel Lim for project management assistance; and Angela Kilbert and Emily\n        Gronseth, PhD, for editorial support. Additionally, the authors wish to thank the society\n        for supporting the manuscript development.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list\u0022\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 1 in text\u0022 id=\u0022ref-1\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBerry\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECronin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPlevritis\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEffect of screening and adjuvant therapy on mortality from breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med Overseas Ed\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2005\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E353\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1784\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E92\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa050518\u0022\u003Edoi:10.1056\/NEJMoa050518\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%2BOverseas%2BEd%26rft.volume%253D353%26rft.spage%253D1784%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 2 in text\u0022 id=\u0022ref-2\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBleyer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWelch\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHG\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEffect of\n            three decades of screening mammography on breast-cancer incidence\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med Overseas Ed\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E367\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1998\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E2005\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa1206809\u0022\u003Edoi:10.1056\/NEJMoa1206809\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%2BOverseas%2BEd%26rft.volume%253D367%26rft.spage%253D1998%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 3 in text\u0022 id=\u0022ref-3\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.3\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHelvie\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBevers\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETB\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EScreening\n            mammography for average-risk women: the controversy and NCCN\u0027s\n            position\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Natl Compr Canc Netw\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1398\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E404\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.6004\/jnccn.2018.7081\u0022\u003Edoi:10.6004\/jnccn.2018.7081\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30442738\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BNatl%2BCompr%2BCanc%2BNetw%26rft.volume%253D16%26rft.spage%253D1398%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 4 in text\u0022 id=\u0022ref-4\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.4\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMunoz\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENear\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003Evan\n                Ravesteyn\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENT\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEffects of screening and systemic adjuvant therapy on ER-specific us\n            breast cancer mortality\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Natl Cancer Inst\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E106\u003C\/span\u003E. doi:\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/jnci\/dju289\u0022\u003Edoi:10.1093\/jnci\/dju289\u003C\/a\u003E.\n          [Epub ahead of print: \u003Cspan class=\u0022cit-comment\u0022\u003E24 09 2014\u003C\/span\u003E].\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25255803\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BNatl%2BCancer%2BInst%26rft.volume%253D106%26rft.atitle%253DEFFECTS%2BOF%2BSCREENING%2BAND%2BSYSTEMIC%2BADJUVANT%2BTHERAPY%2BON%2BER-SPECIFIC%2BUS%2BBREAST%2BCANCER%2BMORTALITY%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 5 in text\u0022 id=\u0022ref-5\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.5\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZielonke\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGini\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJansen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEEL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEvidence for reducing cancer-specific mortality due to screening for\n            breast cancer in Europe: a systematic review\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEur J\n            Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E127\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E191\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E206\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.ejca.2019.12.010\u0022\u003Edoi:10.1016\/j.ejca.2019.12.010\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31932175\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DEur%2BJ%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BCancer%26rft.volume%253D127%26rft.spage%253D191%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6 in text\u0022 id=\u0022ref-6\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVagia\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMahalingam\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECristofanilli\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EThe\n            landscape of targeted therapies in TNBC\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancers\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E. doi:\u003Ca href=\u0022http:\/\/dx.doi.org\/10.3390\/cancers12040916\u0022\u003Edoi:10.3390\/cancers12040916\u003C\/a\u003E. [Epub ahead of print: \u003Cspan class=\u0022cit-comment\u0022\u003E08 04\n            2020\u003C\/span\u003E].\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32276534\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancers%26rft.volume%253D12%26rft.atitle%253DTHE%2BLANDSCAPE%2BOF%2BTARGETED%2BTHERAPIES%2BIN%2BTNBC%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7 in text\u0022 id=\u0022ref-7\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEmens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EBreast\n            cancer immunotherapy: facts and hopes\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E24\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E511\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E20\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-16-3001\u0022\u003Edoi:10.1158\/1078-0432.CCR-16-3001\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28801472\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D24%26rft.spage%253D511%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 8 in text\u0022 id=\u0022ref-8\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EOner\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAltintas\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECanturk\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETriple-Negative breast cancer-Role of immunology: a systemic\n            review\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast J\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E995\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1111\/tbj.13696\u0022\u003Edoi:10.1111\/tbj.13696\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31797488\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BJ%26rft.volume%253D26%26rft.spage%253D995%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference 9 in text\u0022 id=\u0022ref-9\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGatti-Mays\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EME\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBalko\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGameiro\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EIf we build it they will come: targeting the immune response to breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENPJ Breast Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E37\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41523-019-0133-7\u0022\u003Edoi:10.1038\/s41523-019-0133-7\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31700993\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNPJ%2BBreast%2BCancer%26rft.volume%253D5%26rft.spage%253D37%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-2\u0022 title=\u0022View reference 10 in text\u0022 id=\u0022ref-10\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.10\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBurugu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAsleh-Aburaya\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENielsen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETO\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EImmune\n            infiltrates in the breast cancer microenvironment: detection, characterization and\n            clinical implication\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E24\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E3\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E15\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s12282-016-0698-z\u0022\u003Edoi:10.1007\/s12282-016-0698-z\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27138387\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BCancer%26rft.volume%253D24%26rft.spage%253D3%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-2\u0022 title=\u0022View reference 11 in text\u0022 id=\u0022ref-11\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.11\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECimino-Mathews\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFoote\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEmens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EImmune\n            targeting in breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E29\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E375\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E85\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25979549\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DOncology%26rft.volume%253D29%26rft.spage%253D375%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-2\u0022 title=\u0022View reference 12 in text\u0022 id=\u0022ref-12\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.12\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003Eda Silva\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECardoso\n                Nunes\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIzetti\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETriple negative breast cancer: a thorough review of\n            biomarkers\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECrit Rev Oncol Hematol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E145\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E102855\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.critrevonc.2019.102855\u0022\u003Edoi:10.1016\/j.critrevonc.2019.102855\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31927455\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCrit%2BRev%2BOncol%2BHematol%26rft.volume%253D145%26rft.spage%253D102855%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference 13 in text\u0022 id=\u0022ref-13\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.13\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECimino-Mathews\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EThompson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETaube\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPd-L1 (B7-H1) expression and the immune tumor microenvironment in primary\n            and metastatic breast carcinomas\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHum Pathol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E47\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E52\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E63\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.humpath.2015.09.003\u0022\u003Edoi:10.1016\/j.humpath.2015.09.003\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26527522\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DHum%2BPathol%26rft.volume%253D47%26rft.spage%253D52%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference 14 in text\u0022 id=\u0022ref-14\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.14\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHuang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShao\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPrognostic and clinicopathological value of PD-L1 expression in primary\n            breast cancer: a meta-analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast Cancer Res Treat\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E178\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E17\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E33\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s10549-019-05371-0\u0022\u003Edoi:10.1007\/s10549-019-05371-0\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31359214\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BCancer%2BRes%2BTreat%26rft.volume%253D178%26rft.spage%253D17%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-15-1\u0022 title=\u0022View reference 15 in text\u0022 id=\u0022ref-15\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.15\u0022 data-doi=\u002210.1016\/j.coi.2014.01.004\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMittal\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGubin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchreiber\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ENew insights into cancer immunoediting and its three component\n            phases--elimination, equilibrium and escape\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECurr Opin\n            Immunol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E27\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E16\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E25\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.coi.2014.01.004\u0022\u003Edoi:10.1016\/j.coi.2014.01.004\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24531241\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCurr%2BOpin%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BImmunol%26rft.volume%253D27%26rft.spage%253D16%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.coi.2014.01.004%26rft_id%253Dinfo%253Apmid%252F24531241%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.coi.2014.01.004\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=24531241\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-15-1\u0022 title=\u0022View reference 16 in text\u0022 id=\u0022ref-16\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.16\u0022 data-doi=\u002210.1016\/j.immuni.2013.07.012\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMellman\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EOncology\n            meets immunology: the cancer-immunity cycle\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EImmunity\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E39\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E10\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.immuni.2013.07.012\u0022\u003Edoi:10.1016\/j.immuni.2013.07.012\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23890059\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DImmunity%26rft.volume%253D39%26rft.spage%253D1%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.immuni.2013.07.012%26rft_id%253Dinfo%253Apmid%252F23890059%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.immuni.2013.07.012\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23890059\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-17-1\u0022 title=\u0022View reference 17 in text\u0022 id=\u0022ref-17\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.17\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENarayan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWahby\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGao\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EFDA approval summary: Atezolizumab plus paclitaxel protein-bound for the\n            treatment of patients with advanced or metastatic TNBC whose tumors express\n            PD-L1\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2284\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-19-3545\u0022\u003Edoi:10.1158\/1078-0432.CCR-19-3545\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32001481\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D26%26rft.spage%253D2284%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-1\u0022 title=\u0022View reference 18 in text\u0022 id=\u0022ref-18\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.18\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAtezolizumab and nab-paclitaxel in advanced triple-negative breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E379\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2108\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa1809615\u0022\u003Edoi:10.1056\/NEJMoa1809615\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30345906\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D379%26rft.spage%253D2108%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-19-1\u0022 title=\u0022View reference 19 in text\u0022 id=\u0022ref-19\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.19\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EMerck\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EPembrolizumab highlights of prescribng\n            information\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-loc\u0022\u003EUS FDA\u003C\/span\u003E:\n            \u003Cspan class=\u0022cit-publ-name\u0022\u003EDrugs@FDA\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-20-1\u0022 title=\u0022View reference 20 in text\u0022 id=\u0022ref-20\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.20\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EInstitute of Medicine Committee on Standards for Developing Trustworthy\n              Clinical Practice Guidelines\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EClinical practice\n            guidelines we can trust\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-loc\u0022\u003EWashington, DC\u003C\/span\u003E:\n            \u003Cspan class=\u0022cit-publ-name\u0022\u003ENational Academies Press (US)\u003C\/span\u003E,\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-21-1\u0022 title=\u0022View reference 21 in text\u0022 id=\u0022ref-21\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.21\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ERoche\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EAtezolizumab package insert\u003C\/span\u003E.\n            \u003Cspan class=\u0022cit-publ-loc\u0022\u003ESilver Spring, Maryland\u003C\/span\u003E:\n            \u003Cspan class=\u0022cit-publ-name\u0022\u003EDRUGS@FDA\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference 22 in text\u0022 id=\u0022ref-22\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.22\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDiamond\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHamilton\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPhase Ib trial of atezolizumab in combination with nab-paclitaxel in\n            patients with metastatic triple-negative breast cancer (mTNBC)\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E34\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E1009\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2016.34.15_suppl.1009\u0022\u003Edoi:10.1200\/JCO.2016.34.15_suppl.1009\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-23-1\u0022 title=\u0022View reference 23 in text\u0022 id=\u0022ref-23\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.23\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEmens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups\n            from the global, randomized, double-blind, placebo-controlled, phase III study of\n            atezolizumab + nab-paclitaxel in patients with treatment-na\u0026Atilde;\u0026macr;ve, locally advanced\n            or metastatic triple-negative breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer\n            Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E79\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EGS1-04-GS1-04\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-24-1\u0022 title=\u0022View reference 24 in text\u0022 id=\u0022ref-24\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.24\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAtezolizumab plus nab-paclitaxel as first-line treatment for\n            unresectable, locally advanced or metastatic triple-negative breast cancer\n            (IMpassion130): updated efficacy results from a randomised, double-blind,\n            placebo-controlled, phase 3 trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E21\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E44\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E59\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S1470-2045(19)30689-8\u0022\u003Edoi:10.1016\/S1470-2045(19)30689-8\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31786121\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%2BOncol%26rft.volume%253D21%26rft.spage%253D44%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-25-1\u0022 title=\u0022View reference 25 in text\u0022 id=\u0022ref-25\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.25\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEmens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarrios\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ELBA16 IMpassion130: final OS analysis from the pivotal phase III study of\n            atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated\n            locally advanced or metastatic triple-negative breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003ES1148\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.annonc.2020.08.2244\u0022\u003Edoi:10.1016\/j.annonc.2020.08.2244\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnnals%2Bof%2BOncology%26rft.volume%253D31%26rft.spage%253D1148S%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-1\u0022 title=\u0022View reference 26 in text\u0022 id=\u0022ref-26\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.26\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECortes\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECescon\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDW\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EKEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab +\n            chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent\n            inoperable or metastatic triple-negative breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal\n            of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E38\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E1000\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2020.38.15_suppl.1000\u0022\u003Edoi:10.1200\/JCO.2020.38.15_suppl.1000\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-27-1\u0022 title=\u0022View reference 27 in text\u0022 id=\u0022ref-27\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.27\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECescon\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDW\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENowecki\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAdditional\n            efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy\n            vs placebo plus chemotherapy as first-linetherapy for locally recurrent inoperable or\n            metastatic triple-negative breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003Ein 2020 San Antonio\n            Breast Cancer Symposium\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-28-1\u0022 title=\u0022View reference 28 in text\u0022 id=\u0022ref-28\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.28\u0022 data-doi=\u002210.1126\/science.aaf1490\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMcGranahan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFurness\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAJS\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERosenthal\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EClonal neoantigens elicit T cell immunoreactivity and sensitivity to\n            immune checkpoint blockade\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EScience\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E351\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1463\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1126\/science.aaf1490\u0022\u003Edoi:10.1126\/science.aaf1490\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26940869\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DScience%26rft.volume%253D351%26rft.spage%253D1463%26rft_id%253Dinfo%253Adoi%252F10.1126%252Fscience.aaf1490%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1126\/science.aaf1490\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-28-1\u0022 title=\u0022View reference 29 in text\u0022 id=\u0022ref-29\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.29\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EQin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhao\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EThe role of neoantigen in immune checkpoint blockade\n            therapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EExp Hematol Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E28\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s40164-018-0120-y\u0022\u003Edoi:10.1186\/s40164-018-0120-y\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30473928\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DExp%2BHematol%2BOncol%26rft.volume%253D7%26rft.spage%253D28%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-28-1\u0022 title=\u0022View reference 30 in text\u0022 id=\u0022ref-30\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.30\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHeemskerk\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKvistborg\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchumacher\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETNM\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EThe cancer\n            antigenome\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEmbo J\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E32\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E194\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E203\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/emboj.2012.333\u0022\u003Edoi:10.1038\/emboj.2012.333\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23258224\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DEmbo%2BJ%26rft.volume%253D32%26rft.spage%253D194%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-31-1\u0022 title=\u0022View reference 31 in text\u0022 id=\u0022ref-31\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.31\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERooney\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShukla\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EMolecular and genetic properties of tumors associated with local immune\n            cytolytic activity\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECell\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E160\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E48\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E61\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.cell.2014.12.033\u0022\u003Edoi:10.1016\/j.cell.2014.12.033\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25594174\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCell%26rft.volume%253D160%26rft.spage%253D48%26rft_id%253Dinfo%253Apmid%252F25594174%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25594174\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-31-1\u0022 title=\u0022View reference 32 in text\u0022 id=\u0022ref-32\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.32\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETurajlic\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELitchfield\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EXu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EInsertion-and-deletion-derived tumour-specific neoantigens and the\n            immunogenic phenotype: a pan-cancer analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet\n            Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E18\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1009\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S1470-2045(17)30516-8\u0022\u003Edoi:10.1016\/S1470-2045(17)30516-8\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28694034\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BOncol%26rft.volume%253D18%26rft.spage%253D1009%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-33-1\u0022 title=\u0022View reference 33 in text\u0022 id=\u0022ref-33\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.33\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHause\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPritchard\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShendure\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EClassification and characterization of microsatellite instability across\n            18 cancer types\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E22\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1342\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E50\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/nm.4191\u0022\u003Edoi:10.1038\/nm.4191\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27694933\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNat%2BMed%26rft.volume%253D22%26rft.spage%253D1342%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-34-1\u0022 title=\u0022View reference 34 in text\u0022 id=\u0022ref-34\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.34\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMarcus\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELemery\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKeegan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EFda approval summary: pembrolizumab for the treatment of microsatellite\n            instability-high solid tumors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E3753\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-18-4070\u0022\u003Edoi:10.1158\/1078-0432.CCR-18-4070\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30787022\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D25%26rft.spage%253D3753%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-35-1\u0022 title=\u0022View reference 35 in text\u0022 id=\u0022ref-35\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.35\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELe\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDT\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EUram\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJN\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPd-1 blockade in tumors with mismatch-repair deficiency\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E372\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2509\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E20\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa1500596\u0022\u003Edoi:10.1056\/NEJMoa1500596\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26028255\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D372%26rft.spage%253D2509%26rft_id%253Dinfo%253Apmid%252F26028255%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26028255\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-36-1\u0022 title=\u0022View reference 36 in text\u0022 id=\u0022ref-36\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.36\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELe\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDT\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKim\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETW\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVan\n                Cutsem\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPhase II open-label study of pembrolizumab in treatment-refractory,\n            microsatellite Instability-High\/Mismatch repair-deficient metastatic colorectal cancer:\n            KEYNOTE-164\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E38\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E11\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E19\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.19.02107\u0022\u003Edoi:10.1200\/JCO.19.02107\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31725351\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D38%26rft.spage%253D11%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-37-1\u0022 title=\u0022View reference 37 in text\u0022 id=\u0022ref-37\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.37\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENanda\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChow\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELQM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDees\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPembrolizumab in patients with advanced triple-negative breast cancer:\n            phase Ib KEYNOTE-012 study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E34\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2460\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E7\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2015.64.8931\u0022\u003Edoi:10.1200\/JCO.2015.64.8931\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27138582\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D34%26rft.spage%253D2460%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-38-1\u0022 title=\u0022View reference 38 in text\u0022 id=\u0022ref-38\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.38\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDelord\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ-P\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIm\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES-A\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESafety and antitumor activity of pembrolizumab in patients with estrogen\n            Receptor-Positive\/Human epidermal growth factor receptor 2-Negative advanced breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E24\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2804\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E11\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-17-3452\u0022\u003Edoi:10.1158\/1078-0432.CCR-17-3452\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29559561\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D24%26rft.spage%253D2804%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-39-1\u0022 title=\u0022View reference 39 in text\u0022 id=\u0022ref-39\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.39\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMarabelle\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELe\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDT\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAscierto\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEfficacy of pembrolizumab in patients with Noncolorectal high\n            microsatellite Instability\/Mismatch repair-deficient cancer: results from the phase II\n            KEYNOTE-158 study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E38\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E10\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.19.02105\u0022\u003Edoi:10.1200\/JCO.19.02105\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31682550\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D38%26rft.spage%253D1%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-40-1\u0022 title=\u0022View reference 40 in text\u0022 id=\u0022ref-40\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.40\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EFDA\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EFDA approves pembrolizumab for adults\n            and children with TMB-H solid tumors\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-loc\u0022\u003EUS FDA\u003C\/span\u003E:\n            \u003Cspan class=\u0022cit-publ-name\u0022\u003EDrug Approvals and Databases\u003C\/span\u003E,\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-41-1\u0022 title=\u0022View reference 41 in text\u0022 id=\u0022ref-41\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.41\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKurata\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKubo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMori\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract P1-06-11: microsatellite instability in triple negative breast\n            cancers\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E79\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EP1-06-11-P1-06-11\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-42-1\u0022 title=\u0022View reference 42 in text\u0022 id=\u0022ref-42\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.42\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECortes-Ciriano\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELee\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPark\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW-Y\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EA molecular portrait of microsatellite instability across multiple\n            cancers\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Commun\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E15180\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/ncomms15180\u0022\u003Edoi:10.1038\/ncomms15180\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28585546\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNat%2BCommun%26rft.volume%253D8%26rft.spage%253D15180%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-43-1\u0022 title=\u0022View reference 43 in text\u0022 id=\u0022ref-43\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.43\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EOzer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYuksel\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKizildag\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EMicrosatellite instability in early-onset breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPathol Res Pract\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2002\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E198\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E525\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E30\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1078\/0344-0338-00296\u0022\u003Edoi:10.1078\/0344-0338-00296\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12389995\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DPathol%2BRes%2BPract%26rft.volume%253D198%26rft.spage%253D525%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-43-1\u0022 title=\u0022View reference 44 in text\u0022 id=\u0022ref-44\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.44\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESiah\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EQuinn\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBennett\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EMicrosatellite instability markers in breast cancer: a review and study\n            showing MSI was not detected at \u0027BAT 25\u0027 and \u0027BAT 26\u0027\n            microsatellite markers in early-onset breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast\n            Cancer Res Treat\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2000\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E60\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E135\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E42\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1023\/A:1006315315060\u0022\u003Edoi:10.1023\/A:1006315315060\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10845276\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BCancer%2BRes%2BTreat%26rft.volume%253D60%26rft.spage%253D135%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-43-1\u0022 title=\u0022View reference 45 in text\u0022 id=\u0022ref-45\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.45\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAnbazhagan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFujii\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGabrielson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EMicrosatellite instability is uncommon in breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E1999\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E839\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E44\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10213220\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D5%26rft.spage%253D839%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-46-1\u0022 title=\u0022View reference 46 in text\u0022 id=\u0022ref-46\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.46\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarroso-Sousa\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJain\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECohen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EO\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPrevalence and mutational determinants of high tumor mutation burden in\n            breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E387\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E94\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.annonc.2019.11.010\u0022\u003Edoi:10.1016\/j.annonc.2019.11.010\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32067680\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D31%26rft.spage%253D387%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-47-1\u0022 title=\u0022View reference 47 in text\u0022 id=\u0022ref-47\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.47\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEmens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMolinero\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003E296P tumour mutational burden and clinical outcomes with first-line\n            atezolizumab and nab-paclitaxel in triple-negative breast cancer: exploratory analysis\n            of the phase III IMpassion130 trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003ES360\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E1\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.annonc.2020.08.398\u0022\u003Edoi:10.1016\/j.annonc.2020.08.398\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnnals%2Bof%2BOncology%26rft.volume%253D31%26rft.spage%253DS360%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-48-1\u0022 title=\u0022View reference 48 in text\u0022 id=\u0022ref-48\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.48\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAlva\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMangat\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPK\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGarrett-Mayer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPembrolizumab (P) in patients (PTS) with metastatic breast cancer (MBC)\n            with high tumor mutational burden (HTMB): results from the targeted agent and profiling\n            utilization registry (TAPUR) study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical\n            Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E1014\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2019.37.15_suppl.1014\u0022\u003Edoi:10.1200\/JCO.2019.37.15_suppl.1014\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-49-1\u0022 title=\u0022View reference 49 in text\u0022 id=\u0022ref-49\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.49\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWiner\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELipatov\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EO\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIm\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES-A\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAssociation of tumor mutational burden (TMB) and clinical outcomes with\n            pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic\n            triple-negative breast cancer (mTNBC) from KEYNOTE-119\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal\n            of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E38\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E1013\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2020.38.15_suppl.1013\u0022\u003Edoi:10.1200\/JCO.2020.38.15_suppl.1013\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-50-1\u0022 title=\u0022View reference 50 in text\u0022 id=\u0022ref-50\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.50\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMiles\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAndr\u0026Atilde;\u0026copy;\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGligorov\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract OT1-01-01: IMpassion131: a phase III study comparing 1L\n            atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with\n            inoperable locally advanced or metastatic triple negative breast cancer\n            (TNBC)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E74\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EOT1-01-01-OT1-01-01\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-51-1\u0022 title=\u0022View reference 51 in text\u0022 id=\u0022ref-51\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.51\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMiles\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDW\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGligorov\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAndr\u0026Atilde;\u0026copy;\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ELBA15 primary results from IMpassion131, a double-blind\n            placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) \u0026Acirc;\u0026plusmn;\n            atezolizumab (atezo) for unresectable locally advanced\/metastatic triple-negative breast\n            cancer (mTNBC)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003ES1147\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.annonc.2020.08.2243\u0022\u003Edoi:10.1016\/j.annonc.2020.08.2243\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnnals%2Bof%2BOncology%26rft.volume%253D31%26rft.spage%253DS1147%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-52-1\u0022 title=\u0022View reference 52 in text\u0022 id=\u0022ref-52\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.52\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EFDA\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EFDA issues alert about efficacy and\n            potential safety concerns with atezolizumab in combination with paclitaxel for treatment\n            of breast cancer, D. FDA, editor\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-loc\u0022\u003ESilver Spring,\n            Maryland\u003C\/span\u003E: \u003Cspan class=\u0022cit-publ-name\u0022\u003EUS FDA\u003C\/span\u003E,\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-53-1\u0022 title=\u0022View reference 53 in text\u0022 id=\u0022ref-53\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.53\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECort\u0026Atilde;\u0026copy;s\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAndr\u0026Atilde;\u0026copy;\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGon\u0026Atilde;\u0026sect;alves\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EIMpassion132 phase III trial: atezolizumab and chemotherapy in early\n            relapsing metastatic triple-negative breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFuture\n            Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1951\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E61\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.2217\/fon-2019-0059\u0022\u003Edoi:10.2217\/fon-2019-0059\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30977385\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DFuture%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BOncol%26rft.volume%253D15%26rft.spage%253D1951%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-54-1\u0022 title=\u0022View reference 54 in text\u0022 id=\u0022ref-54\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.54\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EToppmeyer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPembrolizumab monotherapy for previously untreated, PD-L1-positive,\n            metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086\n            study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E30\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E405\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E11\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdy518\u0022\u003Edoi:10.1093\/annonc\/mdy518\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30475947\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D30%26rft.spage%253D405%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-54-1\u0022 title=\u0022View reference 55 in text\u0022 id=\u0022ref-55\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.55\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPembrolizumab monotherapy for previously treated metastatic\n            triple-negative breast cancer: cohort a of the phase II KEYNOTE-086\n            study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E30\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E397\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E404\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdy517\u0022\u003Edoi:10.1093\/annonc\/mdy517\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30475950\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D30%26rft.spage%253D397%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-56-1\u0022 title=\u0022View reference 56 in text\u0022 id=\u0022ref-56\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.56\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EToppmeyer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPhase 2 study of pembrolizumab as first-line therapy for\n            PD-L1\u0026acirc;\u0026#128;\u0026#147;positive metastatic triple-negative breast cancer (mTNBC): preliminary data\n            from KEYNOTE-086 cohort B\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E35\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E1088\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2017.35.15_suppl.1088\u0022\u003Edoi:10.1200\/JCO.2017.35.15_suppl.1088\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-57-1\u0022 title=\u0022View reference 57 in text\u0022 id=\u0022ref-57\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.57\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPhase 2 study of pembrolizumab (pembro) monotherapy for previously\n            treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort\n            A\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E35\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E1008\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2017.35.15_suppl.1008\u0022\u003Edoi:10.1200\/JCO.2017.35.15_suppl.1008\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-58-1\u0022 title=\u0022View reference 58 in text\u0022 id=\u0022ref-58\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.58\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECort\u0026Atilde;\u0026copy;s\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELipatov\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EO\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIm\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES-A\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EKEYNOTE-119: phase III study of pembrolizumab (pembro) versus\n            single-agent chemotherapy (chemo) for metastatic triple negative breast cancer\n            (mTNBC)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E30\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Ev859\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E60\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdz394.010\u0022\u003Edoi:10.1093\/annonc\/mdz394.010\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnnals%2Bof%2BOncology%26rft.volume%253D30%26rft.spage%253Dv859%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-59-1\u0022 title=\u0022View reference 59 in text\u0022 id=\u0022ref-59\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.59\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EModi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESaura\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYamashita\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETrastuzumab Deruxtecan in previously treated HER2-positive breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med Overseas Ed\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E382\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E610\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa1914510\u0022\u003Edoi:10.1056\/NEJMoa1914510\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%2BOverseas%2BEd%26rft.volume%253D382%26rft.spage%253D610%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-59-1\u0022 title=\u0022View reference 60 in text\u0022 id=\u0022ref-60\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.60\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMurthy\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERK\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EOkines\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETucatinib, trastuzumab, and capecitabine for HER2-positive metastatic\n            breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med Overseas Ed\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E382\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E597\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E609\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa1914609\u0022\u003Edoi:10.1056\/NEJMoa1914609\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%2BOverseas%2BEd%26rft.volume%253D382%26rft.spage%253D597%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-61-1\u0022 title=\u0022View reference 61 in text\u0022 id=\u0022ref-61\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.61\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEmens LA\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEF\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBeresford\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESaura\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EResults from\n            KATE2, a randomized phase 2 study of atezolizumab (atezo)+ trastuzumab emtansine (T-DM1)\n            vs placebo (pbo)+ T-DM1 in previously treated HER2+ advanced breast cancer (BC):\n            SABCS\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E79\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-62-1\u0022 title=\u0022View reference 62 in text\u0022 id=\u0022ref-62\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.62\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGiobbie-Hurder\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGombos\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPembrolizumab plus trastuzumab in trastuzumab-resistant, advanced,\n            HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2\n            trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E371\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E82\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S1470-2045(18)30812-X\u0022\u003Edoi:10.1016\/S1470-2045(18)30812-X\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30765258\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%2BOncol%26rft.volume%253D20%26rft.spage%253D371%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-63-1\u0022 title=\u0022View reference 63 in text\u0022 id=\u0022ref-63\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.63\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDirix\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETakacs\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJerusalem\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAvelumab, an anti-PD-L1 antibody, in patients with locally advanced or\n            metastatic breast cancer: a phase 1B javelin solid tumor study\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast Cancer Res Treat\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E167\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E671\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E86\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s10549-017-4537-5\u0022\u003Edoi:10.1007\/s10549-017-4537-5\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29063313\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BCancer%2BRes%2BTreat%26rft.volume%253D167%26rft.spage%253D671%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-64-1\u0022 title=\u0022View reference 64 in text\u0022 id=\u0022ref-64\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.64\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETolaney\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESM\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarroso-Sousa\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKeenan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEffect of eribulin with or without pembrolizumab on progression-free\n            survival for patients with hormone receptor-positive, ERBB2-Negative metastatic breast\n            cancer: a randomized clinical trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1598\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E605\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamaoncol.2020.3524\u0022\u003Edoi:10.1001\/jamaoncol.2020.3524\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32880602\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%2BOncol%26rft.volume%253D6%26rft.spage%253D1598%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-65-1\u0022 title=\u0022View reference 65 in text\u0022 id=\u0022ref-65\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.65\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENanda\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELiu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYau\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEffect of pembrolizumab plus neoadjuvant chemotherapy on pathologic\n            complete response in women with early-stage breast cancer: an analysis of the ongoing\n            phase 2 adaptively randomized I-SPY2 trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E676\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E84\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamaoncol.2019.6650\u0022\u003Edoi:10.1001\/jamaoncol.2019.6650\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32053137\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%2BOncol%26rft.volume%253D6%26rft.spage%253D676%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-66-1\u0022 title=\u0022View reference 66 in text\u0022 id=\u0022ref-66\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.66\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELiu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERobinson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYau\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract P3-09-02: evaluation of a novel agent plus standard neoadjuvant\n            therapy in early stage, high-risk HER2 negative breast cancer: results from the I-SPY 2\n            trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E80\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EP3-09-02-P3-09-02\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-67-1\u0022 title=\u0022View reference 67 in text\u0022 id=\u0022ref-67\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.67\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPark\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYH\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMu\u0026Atilde;\u0026plusmn;oz-Couselo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract PD5-01: KEYNOTE-173: phase 1B multicohort study of pembrolizumab\n            (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative\n            breast cancer (TNBC)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E79\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EPD5-01-PD5-01\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-68-1\u0022 title=\u0022View reference 68 in text\u0022 id=\u0022ref-68\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.68\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESalgado\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPark\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk,\n            early-stage triple-negative breast cancer: results from the phase 1B open-label,\n            multicohort KEYNOTE-173 study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E569\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E81\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.annonc.2020.01.072\u0022\u003Edoi:10.1016\/j.annonc.2020.01.072\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32278621\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D31%26rft.spage%253D569%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-69-1\u0022 title=\u0022View reference 69 in text\u0022 id=\u0022ref-69\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.69\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECortes\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPusztai\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPembrolizumab for early triple-negative breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med Overseas Ed\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E382\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E810\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa1910549\u0022\u003Edoi:10.1056\/NEJMoa1910549\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%2BOverseas%2BEd%26rft.volume%253D382%26rft.spage%253D810%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-69-1\u0022 title=\u0022View reference 70 in text\u0022 id=\u0022ref-70\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.70\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECortes\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDent\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EKEYNOTE-522:\n            phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo\n            as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early\n            triple-negative breast cancer (TNBC), in ESMO 2019 Congress\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Ev851\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E934\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-71-1\u0022 title=\u0022View reference 71 in text\u0022 id=\u0022ref-71\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-9.8.e002597.71\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EMerck\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003E\u003Ca href=\u0022https:\/\/www.merck.com\/news\/fdas-oncologic-drugs-advisory-committee-to-discuss-mercks-application-for-keytruda-pembrolizumab-for-the-treatment-of-patients-with-high-risk-early-stage-triple-negative-brea-2\/\u0022\u003EKEYTRUDA\u0026Acirc;\u0026reg; (pembrolizumab) KEYNOTE-522 - Presentation to ODAC February 9,\n              2021\u003C\/a\u003E\u003C\/span\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E\n          \u003Ca href=\u0022https:\/\/www.merck.com\/news\/fdas-oncologic-drugs-advisory-committee-to-discuss-mercks-application-for-keytruda-pembrolizumab-for-the-treatment-of-patients-with-high-risk-early-stage-triple-negative-brea-2\/\u0022\u003Ehttps:\/\/www.merck.com\/news\/fdas-oncologic-drugs-advisory-committee-to-discuss-mercks-application-for-keytruda-pembrolizumab-for-the-treatment-of-patients-with-high-risk-early-stage-triple-negative-brea-2\/\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-72-1\u0022 title=\u0022View reference 72 in text\u0022 id=\u0022ref-72\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-confproc\u0022 id=\u0022cit-9.8.e002597.72\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003E\u003Ca href=\u0022https:\/\/www.esmo.org\/meetings\/past-meetings\/keynote-522-phase-iii-study-of-neoadjuvant-chemotherapy-vs-placebo-chemotherapy-followed-by-adjuvant-vs-placebo-for-early-stage-tnbc\u0022\u003EKEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo\n              + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage\n              TNBC\u003C\/a\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-conf-name\u0022\u003EESMO Virtual Plenary\u003C\/span\u003E;\n            \u003Cspan class=\u0022cit-conf-date\u0022\u003E2021\u003C\/span\u003E, \u003Cspan class=\u0022cit-conf-loc\u0022\u003EVirtual\u003C\/span\u003E,\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-73-1\u0022 title=\u0022View reference 73 in text\u0022 id=\u0022ref-73\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.73\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELajos Pusztai\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHSH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYau\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWolf\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEsserman,\n            Trial Consortium I-SPY 2. CT011 - Evaluation of durvalumab in combination with olaparib\n            and paclitaxel in high-risk HER2 negative stage II\/III breast cancer: results from the\n            I-SPY 2 TRIAL\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EIn 111th Annual Meeting of the American\n            Association for Cancer Research. 2020. Philadelphia, PA: AACR\u003C\/abbr\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-74-1\u0022 title=\u0022View reference 74 in text\u0022 id=\u0022ref-74\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.74\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoibl\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EUntch\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBurchardi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EA randomised phase II study investigating durvalumab in addition to an\n            anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer:\n            clinical results and biomarker analysis of GeparNuevo study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn\n            Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E30\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1279\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E88\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdz158\u0022\u003Edoi:10.1093\/annonc\/mdz158\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31095287\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BOncol%26rft.volume%253D30%26rft.spage%253D1279%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-75-1\u0022 title=\u0022View reference 75 in text\u0022 id=\u0022ref-75\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.75\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGianni\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYau\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract GS3-04: pathologic complete response (pCR) to neoadjuvant\n            treatment with or without atezolizumab in triple negative, early high-risk and locally\n            advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E80\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EGS3-04-GS3-04\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-75-1\u0022 title=\u0022View reference 76 in text\u0022 id=\u0022ref-76\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.76\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMcArthur\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHL\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIgnatiadis\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGuillaume\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EALEXANDRA\/IMpassion030: a phase III study of standard adjuvant\n            chemotherapy with or without atezolizumab in early-stage triple-negative breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003ETPS598\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS598\u0022\u003Edoi:10.1200\/JCO.2019.37.15_suppl.TPS598\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-77-1\u0022 title=\u0022View reference 77 in text\u0022 id=\u0022ref-77\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.77\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMittendorf\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarrios\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ENeoadjuvant atezolizumab in combination with sequential nab-paclitaxel\n            and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with\n            early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind,\n            phase 3 trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E396\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1090\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E100\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S0140-6736(20)31953-X\u0022\u003Edoi:10.1016\/S0140-6736(20)31953-X\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32966830\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%26rft.volume%253D396%26rft.spage%253D1090%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-78-1\u0022 title=\u0022View reference 78 in text\u0022 id=\u0022ref-78\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.78\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGeyer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoibl\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERastogi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract OT2-04-08: a randomized double-blind phase III clinical trial of\n            neoadjuvant chemotherapy (NAc) with atezolizumab or placebo in patients (PTS) with\n            triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP\n            B-59\/GBG 96-GeparDouze\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E80\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EOT2-04-08\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-79-1\u0022 title=\u0022View reference 79 in text\u0022 id=\u0022ref-79\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.79\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECardoso\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBardia\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAndre\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EKEYNOTE-756: randomized, double-blind, phase 3 study of pembrolizumab vs\n            placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for\n            high-risk, early-stage estrogen receptor\u0026acirc;\u0026#128;\u0026#147;positive, human epidermal growth factor\n            receptor 2\u0026acirc;\u0026#128;\u0026#147;negative (ER+\/HER2\u0026acirc;\u0026#136;\u0026#146;) breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003ETPS601\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS601\u0022\u003Edoi:10.1200\/JCO.2019.37.15_suppl.TPS601\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-80-1\u0022 title=\u0022View reference 80 in text\u0022 id=\u0022ref-80\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.80\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMcArthur\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHarbeck\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract OT2-04-03: nivolumab with neoadjuvant chemotherapy and adjuvant\n            endocrine therapy in ER+\/HER2- primary breast cancer: CheckMate 7FL\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E80\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EOT2-04-03-OT2-04-03\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-81-1\u0022 title=\u0022View reference 81 in text\u0022 id=\u0022ref-81\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.81\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPusztai\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarlow\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EWE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGanz\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract OT1-02-04: SWOG S1418\/NRG -BR006: A randomized, phase III trial\n            to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple\n            receptor-negative breast cancer with \u0026gt; 1 cm residual invasive cancer or positive\n            lymph nodes (\u0026gt;pN1mic) after neoadjuvant chemotherapy\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E78\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EOT1-02\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-82-1\u0022 title=\u0022View reference 82 in text\u0022 id=\u0022ref-82\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.82\u0022 data-doi=\u002210.1073\/pnas.191367098\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ES\u0026Atilde;\u0026cedil;rlie\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPerou\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECM\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETibshirani\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EGene expression patterns of breast carcinomas distinguish tumor\n            subclasses with clinical implications\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EProc Natl Acad Sci U S\n            A\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2001\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E98\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E10869\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E74\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1073\/pnas.191367098\u0022\u003Edoi:10.1073\/pnas.191367098\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11553815\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DProc%2BNatl%2BAcad%2BSci%2BU%2BS%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BA%26rft.volume%253D98%26rft.spage%253D10869%26rft_id%253Dinfo%253Adoi%252F10.1073%252Fpnas.191367098%26rft_id%253Dinfo%253Apmid%252F11553815%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1073\/pnas.191367098\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=11553815\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000170966800067\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-82-1\u0022 title=\u0022View reference 83 in text\u0022 id=\u0022ref-83\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.83\u0022 data-doi=\u002210.1073\/pnas.0932692100\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESorlie\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETibshirani\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EParker\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ERepeated observation of breast tumor subtypes in independent gene\n            expression data sets\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EProc Natl Acad Sci U S A\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2003\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E100\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E8418\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E23\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1073\/pnas.0932692100\u0022\u003Edoi:10.1073\/pnas.0932692100\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12829800\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DProc%2BNatl%2BAcad%2BSci%2BU%2BS%2BA%26rft.volume%253D100%26rft.spage%253D8418%26rft_id%253Dinfo%253Adoi%252F10.1073%252Fpnas.0932692100%26rft_id%253Dinfo%253Apmid%252F12829800%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1073\/pnas.0932692100\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=12829800\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-82-1\u0022 title=\u0022View reference 84 in text\u0022 id=\u0022ref-84\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.84\u0022 data-doi=\u002210.1073\/pnas.1732912100\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESotiriou\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENeo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES-Y\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMcShane\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EBreast cancer classification and prognosis based on gene expression\n            profiles from a population-based study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EProc Natl Acad Sci U S\n            A\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2003\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E100\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E10393\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1073\/pnas.1732912100\u0022\u003Edoi:10.1073\/pnas.1732912100\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12917485\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DProc%2BNatl%2BAcad%2BSci%2BU%2BS%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BA%26rft.volume%253D100%26rft.spage%253D10393%26rft_id%253Dinfo%253Adoi%252F10.1073%252Fpnas.1732912100%26rft_id%253Dinfo%253Apmid%252F12917485%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1073\/pnas.1732912100\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=12917485\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-85-1\u0022 title=\u0022View reference 85 in text\u0022 id=\u0022ref-85\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.85\u0022 data-doi=\u002210.1172\/JCI45014\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELehmann\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBD\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBauer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EIdentification of human triple-negative breast cancer subtypes and\n            preclinical models for selection of targeted therapies\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin\n            Invest\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E121\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2750\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E67\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1172\/JCI45014\u0022\u003Edoi:10.1172\/JCI45014\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BInvest%26rft.volume%253D121%26rft.spage%253D2750%26rft_id%253Dinfo%253Adoi%252F10.1172%252FJCI45014%26rft_id%253Dinfo%253Apmid%252F21633166%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1172\/JCI45014\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=21633166\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 86 in text\u0022 id=\u0022ref-86\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.86\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGiordano\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETemin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChandarlapaty\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESystemic therapy for patients with advanced human epidermal growth factor\n            receptor 2-positive breast cancer: ASCO clinical practice guideline\n            update\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2736\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E40\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2018.79.2697\u0022\u003Edoi:10.1200\/JCO.2018.79.2697\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29939838\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D36%26rft.spage%253D2736%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 87 in text\u0022 id=\u0022ref-87\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.87\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBurstein\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELacchetti\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAnderson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAdjuvant endocrine therapy for women with hormone receptor-positive\n            breast cancer: ASCO clinical practice guideline focused update\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E423\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E38\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.18.01160\u0022\u003Edoi:10.1200\/JCO.18.01160\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30452337\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D37%26rft.spage%253D423%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-88-1\u0022 title=\u0022View reference 88 in text\u0022 id=\u0022ref-88\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.88\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAllison\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHammond\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMEH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDowsett\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEstrogen and progesterone receptor testing in breast cancer: ASCO\/CAP\n            guideline update\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E38\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003EJCO.19.02309\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.19.02309\u0022\u003Edoi:10.1200\/JCO.19.02309\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31928404\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D38%26rft.spage%253DJCO1902309%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-88-1\u0022 title=\u0022View reference 89 in text\u0022 id=\u0022ref-89\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.89\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWolff\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHammond\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMEH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAllison\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EHuman epidermal growth factor receptor 2 testing in breast cancer:\n            American Society of clinical Oncology\/College of American pathologists clinical practice\n            guideline focused update\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2105\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E22\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2018.77.8738\u0022\u003Edoi:10.1200\/JCO.2018.77.8738\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29846122\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D36%26rft.spage%253D2105%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-90-1\u0022 title=\u0022View reference 90 in text\u0022 id=\u0022ref-90\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.90\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERobson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIm\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES-A\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESenkus\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EOlaparib for metastatic breast cancer in patients with a germline BRCA\n            mutation\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med Overseas Ed\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E377\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E523\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E33\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa1706450\u0022\u003Edoi:10.1056\/NEJMoa1706450\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%2BOverseas%2BEd%26rft.volume%253D377%26rft.spage%253D523%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-91-1\u0022 title=\u0022View reference 91 in text\u0022 id=\u0022ref-91\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.91\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBardia\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMayer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVahdat\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELT\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESacituzumab Govitecan-hziy in refractory metastatic triple-negative\n            breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E380\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E741\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E51\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa1814213\u0022\u003Edoi:10.1056\/NEJMoa1814213\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30786188\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D380%26rft.spage%253D741%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-92-1\u0022 title=\u0022View reference 92 in text\u0022 id=\u0022ref-92\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.92\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYates\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKnappskog\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWedge\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EGenomic evolution of breast cancer metastasis and\n          relapse\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Cell\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E32\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E169\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E84\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.ccell.2017.07.005\u0022\u003Edoi:10.1016\/j.ccell.2017.07.005\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28810143\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BCell%26rft.volume%253D32%26rft.spage%253D169%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-92-1\u0022 title=\u0022View reference 93 in text\u0022 id=\u0022ref-93\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.93\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAngus\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWilting\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EThe genomic landscape of metastatic breast cancer highlights changes in\n            mutation and signature frequencies\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Genet\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E51\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1450\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41588-019-0507-7\u0022\u003Edoi:10.1038\/s41588-019-0507-7\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31570896\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNat%2BGenet%26rft.volume%253D51%26rft.spage%253D1450%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-94-1\u0022 title=\u0022View reference 94 in text\u0022 id=\u0022ref-94\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.94\u0022 data-doi=\u002210.1200\/JCO.2011.37.2482\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELindstr\u0026Atilde;\u0026para;m\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKarlsson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWilking\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EUM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EClinically used breast cancer markers such as estrogen receptor,\n            progesterone receptor, and human epidermal growth factor receptor 2 are unstable\n            throughout tumor progression\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E30\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2601\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2011.37.2482\u0022\u003Edoi:10.1200\/JCO.2011.37.2482\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22711854\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D30%26rft.spage%253D2601%26rft_id%253Dinfo%253Adoi%252F10.1200%252FJCO.2011.37.2482%26rft_id%253Dinfo%253Apmid%252F22711854%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1200\/JCO.2011.37.2482\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=22711854\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-94-1\u0022 title=\u0022View reference 95 in text\u0022 id=\u0022ref-95\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.95\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMacfarlane\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESeal\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESpeers\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EMolecular alterations between the primary breast cancer and the\n            subsequent locoregional\/metastatic tumor\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOncologist\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E17\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E172\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1634\/theoncologist.2011-0127\u0022\u003Edoi:10.1634\/theoncologist.2011-0127\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22267852\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DOncologist%26rft.volume%253D17%26rft.spage%253D172%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-96-1\u0022 title=\u0022View reference 96 in text\u0022 id=\u0022ref-96\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.96\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003Evan de Ven\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESmit\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EVTHBM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDekker\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETJA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EDiscordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy\n            in breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Treat Rev\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E422\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E30\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.ctrv.2010.11.006\u0022\u003Edoi:10.1016\/j.ctrv.2010.11.006\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21177040\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BTreat%2BRev%26rft.volume%253D37%26rft.spage%253D422%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-92-2\u0022 title=\u0022View reference 97 in text\u0022 id=\u0022ref-97\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.97\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAndr\u0026Atilde;\u0026copy;\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBachelot\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECommo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EComparative genomic hybridisation array and DNA sequencing to direct\n            treatment of metastatic breast cancer: a multicentre, prospective trial\n            (SAFIR01\/UNICANCER)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E267\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E74\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S1470-2045(13)70611-9\u0022\u003Edoi:10.1016\/S1470-2045(13)70611-9\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24508104\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%2BOncol%26rft.volume%253D15%26rft.spage%253D267%26rft_id%253Dinfo%253Apmid%252F24508104%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=24508104\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-92-2\u0022 title=\u0022View reference 98 in text\u0022 id=\u0022ref-98\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.98\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELefebvre\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBachelot\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFilleron\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EMutational profile of metastatic breast cancers: a retrospective\n            analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E13\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003Ee1002201\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1371\/journal.pmed.1002201\u0022\u003Edoi:10.1371\/journal.pmed.1002201\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28027327\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DPLoS%2BMed%26rft.volume%253D13%26rft.spage%253D1002201e%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-99-1\u0022 title=\u0022View reference 99 in text\u0022 id=\u0022ref-99\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.99\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESzekely\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBossuyt\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmunological differences between primary and metastatic breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E29\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2232\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdy399\u0022\u003Edoi:10.1093\/annonc\/mdy399\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30203045\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D29%26rft.spage%253D2232%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-2\u0022 title=\u0022View reference 100 in text\u0022 id=\u0022ref-100\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.100\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECimino-Mathews\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYe\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMeeker\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EMetastatic triple-negative breast cancers at first relapse have fewer\n            tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot\n            study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHum Pathol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E44\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2055\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E63\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.humpath.2013.03.010\u0022\u003Edoi:10.1016\/j.humpath.2013.03.010\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23701942\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DHum%2BPathol%26rft.volume%253D44%26rft.spage%253D2055%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-101-1\u0022 title=\u0022View reference 101 in text\u0022 id=\u0022ref-101\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.101\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECW\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETran\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract PD6-01: prevalence of PDL1 and tumor infiltrating lymphocytes\n            (TILs) in primary and metastatic TNBC\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E78\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EPD6-01\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-102-1\u0022 title=\u0022View reference 102 in text\u0022 id=\u0022ref-102\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.102\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZheng\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETian\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ELiver-Mediated adaptive immune tolerance\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFront\n            Immunol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E10\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E2525\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.3389\/fimmu.2019.02525\u0022\u003Edoi:10.3389\/fimmu.2019.02525\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31787967\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DFront%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BImmunol%26rft.volume%253D10%26rft.spage%253D2525%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-102-1\u0022 title=\u0022View reference 103 in text\u0022 id=\u0022ref-103\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.103\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELee\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJC\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMehdizadeh\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ERegulatory T cell control of systemic immunity and immunotherapy response\n            in liver metastasis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESci Immunol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Eeaba0759\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1126\/sciimmunol.aba0759\u0022\u003Edoi:10.1126\/sciimmunol.aba0759\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33008914\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DSci%2BImmunol%26rft.volume%253D5%26rft.spage%253Deaba0759%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-3\u0022 title=\u0022View reference 104 in text\u0022 id=\u0022ref-104\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.104\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENarayan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWahby\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGao\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EFda approval summary: Atezolizumab plus paclitaxel protein-bound for the\n            treatment of patients with advanced or metastatic TNBC whose tumors express\n            PD-L1\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2284\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-19-3545\u0022\u003Edoi:10.1158\/1078-0432.CCR-19-3545\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32001481\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D26%26rft.spage%253D2284%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-105-1\u0022 title=\u0022View reference 105 in text\u0022 id=\u0022ref-105\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.105\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHoda\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBrogi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDos Anjos\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EClinical and pathologic features associated with PD-L1 (SP142) expression\n            in stromal tumor-infiltrating immune cells of triple-negative breast\n            carcinoma\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMod Pathol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E33\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2221\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E32\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41379-020-0606-0\u0022\u003Edoi:10.1038\/s41379-020-0606-0\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32612248\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DMod%2BPathol%26rft.volume%253D33%26rft.spage%253D2221%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-106-1\u0022 title=\u0022View reference 106 in text\u0022 id=\u0022ref-106\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.106\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EThomas\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERouth\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EED\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPullikuth\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETumor mutational burden is a determinant of immune-mediated survival in\n            breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOncoimmunology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003Ee1490854\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1080\/2162402X.2018.1490854\u0022\u003Edoi:10.1080\/2162402X.2018.1490854\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30386679\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DOncoimmunology%26rft.volume%253D7%26rft.spage%253D1490854e%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-106-1\u0022 title=\u0022View reference 107 in text\u0022 id=\u0022ref-107\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.107\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EXu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBao\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EElevated tumor mutation burden and immunogenic activity in patients with\n            hormone receptor-negative or human epidermal growth factor receptor 2-positive breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOncol Lett\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E18\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E449\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E55\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.3892\/ol.2019.10287\u0022\u003Edoi:10.3892\/ol.2019.10287\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31289516\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DOncol%2BLett%26rft.volume%253D18%26rft.spage%253D449%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-108-1\u0022 title=\u0022View reference 108 in text\u0022 id=\u0022ref-108\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.108\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EStein\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERimm\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EComparison of biomarker modalities for predicting response to PD-1\/PD-L1\n            checkpoint blockade: a systematic review and meta-analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA\n            Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1195\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E204\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamaoncol.2019.1549\u0022\u003Edoi:10.1001\/jamaoncol.2019.1549\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31318407\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BOncol%26rft.volume%253D5%26rft.spage%253D1195%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-109-1\u0022 title=\u0022View reference 109 in text\u0022 id=\u0022ref-109\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.109\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ENovartis\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EPIQRAY highlights of prescribing\n            information, U. FDA, editor\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-loc\u0022\u003ESilver Spring,\n            Maryland\u003C\/span\u003E: \u003Cspan class=\u0022cit-publ-name\u0022\u003EDrugs@FDA\u003C\/span\u003E,\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-110-1\u0022 title=\u0022View reference 110 in text\u0022 id=\u0022ref-110\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.110\u0022 data-doi=\u002210.1056\/NEJMoa0900212\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFong\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBoss\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYap\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation\n            carriers\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E361\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E123\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E34\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa0900212\u0022\u003Edoi:10.1056\/NEJMoa0900212\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19553641\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D361%26rft.spage%253D123%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa0900212%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMoa0900212\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-110-1\u0022 title=\u0022View reference 111 in text\u0022 id=\u0022ref-111\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.111\u0022 data-doi=\u002210.1016\/S0140-6736(10)60892-6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETutt\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERobson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGarber\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with\n            BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept\n            trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E376\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E235\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E44\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S0140-6736(10)60892-6\u0022\u003Edoi:10.1016\/S0140-6736(10)60892-6\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20609467\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%26rft.volume%253D376%26rft.spage%253D235%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0140-6736%252810%252960892-6%26rft_id%253Dinfo%253Apmid%252F20609467%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S0140-6736(10)60892-6\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=20609467\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000280457200032\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-112-1\u0022 title=\u0022View reference 112 in text\u0022 id=\u0022ref-112\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.112\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPrzybytkowski\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDavis\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHosny\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAn immune-centric exploration of BRCA1 and BRCA2 germline mutation\n            related breast and ovarian cancers\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBMC Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E197\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s12885-020-6605-1\u0022\u003Edoi:10.1186\/s12885-020-6605-1\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32164626\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBMC%2BCancer%26rft.volume%253D20%26rft.spage%253D197%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-112-1\u0022 title=\u0022View reference 113 in text\u0022 id=\u0022ref-113\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.113\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EWX\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELeong\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC-O\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAssociation of BRCA1- and BRCA2-deficiency with mutation burden,\n            expression of PD-L1\/PD-1, immune infiltrates, and T cell-inflamed signature in breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS One\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E14\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003Ee0215381\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1371\/journal.pone.0215381\u0022\u003Edoi:10.1371\/journal.pone.0215381\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31022191\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DPLoS%2BOne%26rft.volume%253D14%26rft.spage%253D0215381e%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-114-1\u0022 title=\u0022View reference 114 in text\u0022 id=\u0022ref-114\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.114\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERoy\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChun\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPowell\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESN\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EBrca1 and\n            BRCA2: different roles in a common pathway of genome protection\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Rev Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E68\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E78\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/nrc3181\u0022\u003Edoi:10.1038\/nrc3181\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22193408\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNat%2BRev%2BCancer%26rft.volume%253D12%26rft.spage%253D68%26rft_id%253Dinfo%253Apmid%252F22193408%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=22193408\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-115-1\u0022 title=\u0022View reference 115 in text\u0022 id=\u0022ref-115\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.115\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBelli\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDuso\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFerraro\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EHomologous recombination deficiency in triple negative breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E45\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E15\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.breast.2019.02.007\u0022\u003Edoi:10.1016\/j.breast.2019.02.007\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30818144\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%26rft.volume%253D45%26rft.spage%253D15%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-115-1\u0022 title=\u0022View reference 116 in text\u0022 id=\u0022ref-116\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.116\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP-H\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETsai\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL-W\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EUsing next-generation sequencing to redefine BRCAness in triple-negative\n            breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Sci\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E111\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1375\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E84\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1111\/cas.14313\u0022\u003Edoi:10.1111\/cas.14313\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31958182\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BSci%26rft.volume%253D111%26rft.spage%253D1375%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-117-1\u0022 title=\u0022View reference 117 in text\u0022 id=\u0022ref-117\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.117\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETaube\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGalon\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESholl\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImplications of the tumor immune microenvironment for staging and\n            therapeutics\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMod Pathol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E214\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E34\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/modpathol.2017.156\u0022\u003Edoi:10.1038\/modpathol.2017.156\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29192647\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DMod%2BPathol%26rft.volume%253D31%26rft.spage%253D214%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-118-1\u0022 title=\u0022View reference 118 in text\u0022 id=\u0022ref-118\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.118\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWalk\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYohe\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBeckman\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EThe cancer immunotherapy biomarker testing landscape\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EArch Pathol Lab Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E144\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E706\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E24\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.5858\/arpa.2018-0584-CP\u0022\u003Edoi:10.5858\/arpa.2018-0584-CP\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31714809\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DArch%2BPathol%2BLab%2BMed%26rft.volume%253D144%26rft.spage%253D706%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-119-1\u0022 title=\u0022View reference 119 in text\u0022 id=\u0022ref-119\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.119\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELian\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPrognostic role of programmed death ligand-1 expression in breast cancer:\n            a systematic review and meta-analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETarget Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E753\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E61\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s11523-016-0451-8\u0022\u003Edoi:10.1007\/s11523-016-0451-8\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27422273\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DTarget%2BOncol%26rft.volume%253D11%26rft.spage%253D753%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference 120 in text\u0022 id=\u0022ref-120\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.120\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhao\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPrognostic value of PD-L1 expression in tumor infiltrating immune cells\n            in cancers: a meta-analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS One\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003Ee0176822\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1371\/journal.pone.0176822\u0022\u003Edoi:10.1371\/journal.pone.0176822\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28453554\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DPLoS%2BOne%26rft.volume%253D12%26rft.spage%253De0176822%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 121 in text\u0022 id=\u0022ref-121\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.121\u0022 data-doi=\u002210.1158\/2326-6066.CIR-13-0127\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMittendorf\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPhilips\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAV\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMeric-Bernstam\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPd-L1 expression in triple-negative breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Immunol Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E2\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E361\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E70\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/2326-6066.CIR-13-0127\u0022\u003Edoi:10.1158\/2326-6066.CIR-13-0127\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BImmunology%2BResearch%26rft.stitle%253DCancer%2BImmunol%2BRes%26rft.aulast%253DMittendorf%26rft.auinit1%253DE.%2BA.%26rft.volume%253D2%26rft.issue%253D4%26rft.spage%253D361%26rft.epage%253D370%26rft.atitle%253DPD-L1%2BExpression%2Bin%2BTriple-Negative%2BBreast%2BCancer%26rft_id%253Dinfo%253Adoi%252F10.1158%252F2326-6066.CIR-13-0127%26rft_id%253Dinfo%253Apmid%252F24764583%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1158\/2326-6066.CIR-13-0127\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=24764583\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-122-1\u0022 title=\u0022View reference 122 in text\u0022 id=\u0022ref-122\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.122\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGaule\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESmithy\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJW\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EToki\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EA quantitative comparison of antibodies to programmed cell death 1 ligand\n            1\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E3\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E256\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamaoncol.2016.3015\u0022\u003Edoi:10.1001\/jamaoncol.2016.3015\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27541827\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%2BOncol%26rft.volume%253D3%26rft.spage%253D256%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-123-1\u0022 title=\u0022View reference 123 in text\u0022 id=\u0022ref-123\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.123\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESun\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EWY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELee\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYK\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKoo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJS\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EExpression\n            of PD-L1 in triple-negative breast cancer based on different immunohistochemical\n            antibodies\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Transl Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E14\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E173\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s12967-016-0925-6\u0022\u003Edoi:10.1186\/s12967-016-0925-6\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27286842\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BTransl%2BMed%26rft.volume%253D14%26rft.spage%253D173%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-123-1\u0022 title=\u0022View reference 124 in text\u0022 id=\u0022ref-124\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.124\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EO\u0027Malley\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBoisot\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmunohistochemical detection of PD-L1 among diverse human neoplasms in a\n            reference laboratory: observations based upon 62,896 cases\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMod\n            Pathol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E32\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E929\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E42\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41379-019-0210-3\u0022\u003Edoi:10.1038\/s41379-019-0210-3\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30760860\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DMod%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BPathol%26rft.volume%253D32%26rft.spage%253D929%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-123-1\u0022 title=\u0022View reference 125 in text\u0022 id=\u0022ref-125\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.125\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETorlakovic\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELim\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdam\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003E\u0022Interchangeability\u0022 of PD-L1 immunohistochemistry assays: a\n            meta-analysis of diagnostic accuracy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMod Pathol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E33\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E4\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E17\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41379-019-0327-4\u0022\u003Edoi:10.1038\/s41379-019-0327-4\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31383961\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DMod%2BPathol%26rft.volume%253D33%26rft.spage%253D4%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-123-1\u0022 title=\u0022View reference 126 in text\u0022 id=\u0022ref-126\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.126\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELee\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPark\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELim\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EConcordance of programmed Death-Ligand 1 expression between SP142 and\n            22C3\/SP263 assays in triple-negative breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Breast\n            Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E23\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E303\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E13\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.4048\/jbc.2020.23.e37\u0022\u003Edoi:10.4048\/jbc.2020.23.e37\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32595992\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BBreast%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BCancer%26rft.volume%253D23%26rft.spage%253D303%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-127-1\u0022 title=\u0022View reference 127 in text\u0022 id=\u0022ref-127\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.127\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EU.S. Food \u0026amp; Drug Administration (FDA)\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-source\u0022\u003EList of cleared or Approved companion diagnostic devices (in vitro and imaging\n            tools\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-loc\u0022\u003ESilver Spring, Maryland\u003C\/span\u003E:\n            \u003Cspan class=\u0022cit-publ-name\u0022\u003EU.S. Food \u0026amp; Drug Administration (FDA)\u003C\/span\u003E,\n            \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-117-2\u0022 title=\u0022View reference 128 in text\u0022 id=\u0022ref-128\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.128\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EScheerens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMalong\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBassett\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ECurrent status of companion and complementary diagnostics: strategic\n            considerations for development and Launch\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Transl\n            Sci\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E10\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E84\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E92\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1111\/cts.12455\u0022\u003Edoi:10.1111\/cts.12455\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28121072\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BTransl%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BSci%26rft.volume%253D10%26rft.spage%253D84%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-117-2\u0022 title=\u0022View reference 129 in text\u0022 id=\u0022ref-129\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.129\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECottrell\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETaube\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPd-L1 and\n            emerging biomarkers in immune checkpoint blockade therapy\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer J\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E24\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E41\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E6\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1097\/PPO.0000000000000301\u0022\u003Edoi:10.1097\/PPO.0000000000000301\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29360727\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BJ%26rft.volume%253D24%26rft.spage%253D41%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-130-1\u0022 title=\u0022View reference 130 in text\u0022 id=\u0022ref-130\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.130\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EVentana medical systems, Inc. and Roche diagnostics international,\n              Inc\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EVentana PD-L1 (SP142 assay) interpretation guide\n            for triple-negative breast carcinoma (TNBC\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-loc\u0022\u003EOro\n            Valley\u003C\/span\u003E: \u003Cspan class=\u0022cit-publ-name\u0022\u003EVentana medical systems, Inc. and Roche\n            diagnostics international, Inc\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-131-1\u0022 title=\u0022View reference 131 in text\u0022 id=\u0022ref-131\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.131\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPerformance of PD-L1 immunohistochemistry (IHC) assays in unresectable\n            locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis\n            of IMpassion130\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E30\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Ev858\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdz394.009\u0022\u003Edoi:10.1093\/annonc\/mdz394.009\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnnals%2Bof%2BOncology%26rft.volume%253D30%26rft.spage%253Dv858%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-131-1\u0022 title=\u0022View reference 132 in text\u0022 id=\u0022ref-132\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.132\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract PD1-07: exploratory analytical harmonization of PD-L1\n            immunohistochemistry assays in advanced triple-negative breast cancer: a retrospective\n            substudy of IMpassion130\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E80\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EPD1-07-PD1-07\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-133-1\u0022 title=\u0022View reference 133 in text\u0022 id=\u0022ref-133\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.133\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERimm\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETaube\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EReanalysis of the NCCN PD-L1 companion diagnostic assay study for lung\n            cancer in the context of PD-L1 expression findings in triple-negative breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E21\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E72\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s13058-019-1156-6\u0022\u003Edoi:10.1186\/s13058-019-1156-6\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31196152\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BCancer%2BRes%26rft.volume%253D21%26rft.spage%253D72%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-133-1\u0022 title=\u0022View reference 134 in text\u0022 id=\u0022ref-134\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.134\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EReisenbichler\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBellizzi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EProspective multi-institutional evaluation of pathologist assessment of\n            PD-L1 assays for patient selection in triple negative breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMod Pathol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E33\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1746\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E52\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41379-020-0544-x\u0022\u003Edoi:10.1038\/s41379-020-0544-x\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32300181\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DMod%2BPathol%26rft.volume%253D33%26rft.spage%253D1746%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-135-1\u0022 title=\u0022View reference 135 in text\u0022 id=\u0022ref-135\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.135\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJasani\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EB\u0026Atilde;\u0026curren;nfer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFish\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEvaluation of an online training tool for scoring programmed cell death\n            ligand-1 (PD-L1) diagnostic tests for lung cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EDiagn\n            Pathol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E37\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s13000-020-00953-9\u0022\u003Edoi:10.1186\/s13000-020-00953-9\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32303234\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DDiagn%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BPathol%26rft.volume%253D15%26rft.spage%253D37%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-136-1\u0022 title=\u0022View reference 136 in text\u0022 id=\u0022ref-136\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.136\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMartinez-Morilla\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMcGuire\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGaule\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EQuantitative assessment of PD-L1 as an analyte in immunohistochemistry\n            diagnostic assays using a standardized cell line tissue microarray\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELab Invest\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E100\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E4\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E15\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41374-019-0295-9\u0022\u003Edoi:10.1038\/s41374-019-0295-9\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31409885\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLab%2BInvest%26rft.volume%253D100%26rft.spage%253D4%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-137-1\u0022 title=\u0022View reference 137 in text\u0022 id=\u0022ref-137\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.137\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVennapusa\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBaker\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKowanetz\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EDevelopment of a PD-L1 complementary diagnostic immunohistochemistry\n            assay (SP142) for Atezolizumab\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAppl Immunohistochem Mol\n            Morphol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E27\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E92\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E100\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1097\/PAI.0000000000000594\u0022\u003Edoi:10.1097\/PAI.0000000000000594\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29346180\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAppl%2BImmunohistochem%2BMol%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BMorphol%26rft.volume%253D27%26rft.spage%253D92%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-2\u0022 title=\u0022View reference 138 in text\u0022 id=\u0022ref-138\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.138\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMalhotra\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMK\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEmens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EThe\n            evolving management of metastatic triple negative breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESemin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E47\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E229\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E37\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1053\/j.seminoncol.2020.05.005\u0022\u003Edoi:10.1053\/j.seminoncol.2020.05.005\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32563561\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DSemin%2BOncol%26rft.volume%253D47%26rft.spage%253D229%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-2\u0022 title=\u0022View reference 139 in text\u0022 id=\u0022ref-139\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.139\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECortes\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPusztai\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPembrolizumab for early triple-negative breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E382\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E810\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1056\/NEJMoa1910549\u0022\u003Edoi:10.1056\/NEJMoa1910549\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32101663\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D382%26rft.spage%253D810%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-2\u0022 title=\u0022View reference 140 in text\u0022 id=\u0022ref-140\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.140\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGiobbie-Hurder\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGombos\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPembrolizumab plus trastuzumab in trastuzumab-resistant, advanced,\n            HER2-positive breast cancer (panacea): a single-arm, multicentre, phase 1b-2\n            trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E371\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E82\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S1470-2045(18)30812-X\u0022\u003Edoi:10.1016\/S1470-2045(18)30812-X\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30765258\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%2BOncol%26rft.volume%253D20%26rft.spage%253D371%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-2\u0022 title=\u0022View reference 141 in text\u0022 id=\u0022ref-141\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.141\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChia\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBedard\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHilton\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EA phase Ib trial of Durvalumab in combination with trastuzumab in\n            HER2-positive metastatic breast cancer (Cctg IND.229)\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOncologist\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E24\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1439\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E45\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1634\/theoncologist.2019-0321\u0022\u003Edoi:10.1634\/theoncologist.2019-0321\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31420468\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DOncologist%26rft.volume%253D24%26rft.spage%253D1439%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-2\u0022 title=\u0022View reference 142 in text\u0022 id=\u0022ref-142\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.142\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELee\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ-M\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECimino-Mathews\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPeer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESafety and clinical activity of the programmed Death-Ligand 1 inhibitor\n            Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or\n            vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women\u0027s\n            cancers: a dose-escalation, phase I study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E35\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2193\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E202\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2016.72.1340\u0022\u003Edoi:10.1200\/JCO.2016.72.1340\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28471727\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D35%26rft.spage%253D2193%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-3\u0022 title=\u0022View reference 143 in text\u0022 id=\u0022ref-143\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.143\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEmens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EIMpassion130: efficacy in immune biomarker subgroups from the global,\n            randomized, double-blind, placebo-controlled, phase III study of atezolizumab+\n            nab-paclitaxel in patients with treatment-na\u0026Atilde;\u0026macr;ve, locally advanced or metastatic\n            triple-negative breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EIn San Antonio Breast Cancer\n            Symposium\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-144-1\u0022 title=\u0022View reference 144 in text\u0022 id=\u0022ref-144\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.144\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEmens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECruz\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEder\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ELong-Term clinical outcomes and biomarker analyses of Atezolizumab\n            therapy for patients with metastatic triple-negative breast cancer: a phase 1\n            study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E74\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E82\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamaoncol.2018.4224\u0022\u003Edoi:10.1001\/jamaoncol.2018.4224\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30242306\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%2BOncol%26rft.volume%253D5%26rft.spage%253D74%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-145-1\u0022 title=\u0022View reference 145 in text\u0022 id=\u0022ref-145\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.145\u0022 data-doi=\u002210.1093\/annonc\/mdu450\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESalgado\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDenkert\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDemaria\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EThe evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer:\n            recommendations by an international TILs Working group 2014\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn\n            Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E259\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E71\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdu450\u0022\u003Edoi:10.1093\/annonc\/mdu450\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25214542\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BOncol%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fannonc%252Fmdu450%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.ncbi.nlm.nih.gov%252Fpubmed%252F25214542%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiYW5ub25jIjtzOjU6InJlc2lkIjtzOjg6IjI2LzIvMjU5IjtzOjQ6ImF0b20iO3M6MjI6Ii9qaXRjLzkvOC9lMDAyNTk3LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-146-1\u0022 title=\u0022View reference 146 in text\u0022 id=\u0022ref-146\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.146\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELokuhetty\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-source\u0022\u003EWho classification of breast tumours\u003C\/span\u003E.\n            \u003Cspan class=\u0022cit-publ-loc\u0022\u003EGeneva\u003C\/span\u003E: \u003Cspan class=\u0022cit-publ-name\u0022\u003EWHO\u003C\/span\u003E,\n            \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1111\/his.14091\u0022\u003Edoi:\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-146-1\u0022 title=\u0022View reference 147 in text\u0022 id=\u0022ref-147\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.147\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEllis\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAllison\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EThe 2019 World Health Organization classification of tumours of the\n            breast\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHistopathology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E77\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E181\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E5\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1111\/his.14091\u0022\u003Edoi:10.1111\/his.14091\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32056259\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DHistopathology%26rft.volume%253D77%26rft.spage%253D181%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-148-1\u0022 title=\u0022View reference 148 in text\u0022 id=\u0022ref-148\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.148\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EO\u0027Loughlin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAndreu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBianchi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EReproducibility and predictive value of scoring stromal tumour\n            infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional\n            study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast Cancer Res Treat\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E171\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s10549-018-4825-8\u0022\u003Edoi:10.1007\/s10549-018-4825-8\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29774470\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BCancer%2BRes%2BTreat%26rft.volume%253D171%26rft.spage%253D1%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-2\u0022 title=\u0022View reference 149 in text\u0022 id=\u0022ref-149\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.149\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGray\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDemaria\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPrognostic value of tumor-infiltrating lymphocytes in triple-negative\n            breast cancers from two phase III randomized adjuvant breast cancer trials: ECoG 2197\n            and ECoG 1199\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E32\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2959\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E66\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2013.55.0491\u0022\u003Edoi:10.1200\/JCO.2013.55.0491\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25071121\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D32%26rft.spage%253D2959%26rft_id%253Dinfo%253Apmid%252F25071121%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25071121\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-2\u0022 title=\u0022View reference 150 in text\u0022 id=\u0022ref-150\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.150\u0022 data-doi=\u002210.1093\/annonc\/mdu112\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMichiels\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESalgado\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETumor infiltrating lymphocytes are prognostic in triple negative breast\n            cancer and predictive for trastuzumab benefit in early breast cancer: results from the\n            FinHER trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1544\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E50\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdu112\u0022\u003Edoi:10.1093\/annonc\/mdu112\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24608200\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D25%26rft.spage%253D1544%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fannonc%252Fmdu112%26rft_id%253Dinfo%253Apmid%252F24608200%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/annonc\/mdu112\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=24608200\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-2\u0022 title=\u0022View reference 151 in text\u0022 id=\u0022ref-151\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.151\u0022 data-doi=\u002210.1200\/JCO.2011.41.0902\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESirtaine\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPiette\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPrognostic and predictive value of tumor-infiltrating lymphocytes in a\n            phase III randomized adjuvant breast cancer trial in node-positive breast cancer\n            comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy:\n            big 02-98\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E860\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E7\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2011.41.0902\u0022\u003Edoi:10.1200\/JCO.2011.41.0902\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23341518\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D31%26rft.spage%253D860%26rft_id%253Dinfo%253Adoi%252F10.1200%252FJCO.2011.41.0902%26rft_id%253Dinfo%253Apmid%252F23341518%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1200\/JCO.2011.41.0902\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23341518\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-152-1\u0022 title=\u0022View reference 152 in text\u0022 id=\u0022ref-152\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.152\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDenkert\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003Evon\n                Minckwitz\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDarb-Esfahani\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETumour-Infiltrating lymphocytes and prognosis in different subtypes of\n            breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant\n            therapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E19\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E40\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E50\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S1470-2045(17)30904-X\u0022\u003Edoi:10.1016\/S1470-2045(17)30904-X\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29233559\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%2BOncol%26rft.volume%253D19%26rft.spage%253D40%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-151-2\u0022 title=\u0022View reference 153 in text\u0022 id=\u0022ref-153\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.153\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECriscitiello\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVingiani\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMaisonneuve\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETumor-Infiltrating lymphocytes (TILs) in ER+\/HER2- breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast Cancer Res Treat\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E183\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E347\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E54\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s10549-020-05771-7\u0022\u003Edoi:10.1007\/s10549-020-05771-7\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32621251\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BCancer%2BRes%2BTreat%26rft.volume%253D183%26rft.spage%253D347%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-154-1\u0022 title=\u0022View reference 154 in text\u0022 id=\u0022ref-154\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.154\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGruosso\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGigoux\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EManem\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EVSK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESpatially distinct tumor immune microenvironments stratify\n            triple-negative breast cancers\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Invest\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E129\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1785\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E800\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1172\/JCI96313\u0022\u003Edoi:10.1172\/JCI96313\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30753167\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BInvest%26rft.volume%253D129%26rft.spage%253D1785%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-155-1\u0022 title=\u0022View reference 155 in text\u0022 id=\u0022ref-155\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.155\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMani\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchalper\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHatzis\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EQuantitative assessment of the spatial heterogeneity of\n            tumor-infiltrating lymphocytes in breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast Cancer\n            Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E18\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E78\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s13058-016-0737-x\u0022\u003Edoi:10.1186\/s13058-016-0737-x\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27473061\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BCancer%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BRes%26rft.volume%253D18%26rft.spage%253D78%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-156-1\u0022 title=\u0022View reference 156 in text\u0022 id=\u0022ref-156\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.156\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESavas\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVirassamy\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYe\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESingle-Cell profiling of breast cancer T cells reveals a tissue-resident\n            memory subset associated with improved prognosis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat\n            Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E24\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E986\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E93\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41591-018-0078-7\u0022\u003Edoi:10.1038\/s41591-018-0078-7\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29942092\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNat%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BMed%26rft.volume%253D24%26rft.spage%253D986%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-157-1\u0022 title=\u0022View reference 157 in text\u0022 id=\u0022ref-157\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.157\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHeindl\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESestak\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENaidoo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ERelevance of spatial heterogeneity of immune infiltration for predicting\n            risk of recurrence after endocrine therapy of ER+ breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Natl Cancer Inst\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E110\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E166\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E75\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/jnci\/djx137\u0022\u003Edoi:10.1093\/jnci\/djx137\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28859291\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BNatl%2BCancer%2BInst%26rft.volume%253D110%26rft.spage%253D166%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-158-1\u0022 title=\u0022View reference 158 in text\u0022 id=\u0022ref-158\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.158\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGuo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPd-L1 expression and CD274 gene alteration in triple-negative breast\n            cancer: implication for prognostic biomarker\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESpringerplus\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E805\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s40064-016-2513-x\u0022\u003Edoi:10.1186\/s40064-016-2513-x\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27390646\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DSpringerplus%26rft.volume%253D5%26rft.spage%253D805%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-158-1\u0022 title=\u0022View reference 159 in text\u0022 id=\u0022ref-159\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.159\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGoodman\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPiccioni\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKato\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPrevalence of PDL1 amplification and preliminary response to immune\n            checkpoint blockade in solid tumors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1237\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E44\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamaoncol.2018.1701\u0022\u003Edoi:10.1001\/jamaoncol.2018.1701\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29902298\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%2BOncol%26rft.volume%253D4%26rft.spage%253D1237%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-160-1\u0022 title=\u0022View reference 160 in text\u0022 id=\u0022ref-160\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.160\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarrett\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMT\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAnderson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKS\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELenkiewicz\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EGenomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is\n            enriched in high-risk triple negative breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOncotarget\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E26483\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E93\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.18632\/oncotarget.4494\u0022\u003Edoi:10.18632\/oncotarget.4494\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26317899\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DOncotarget%26rft.volume%253D6%26rft.spage%253D26483%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-161-1\u0022 title=\u0022View reference 161 in text\u0022 id=\u0022ref-161\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.161\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBalko\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchwarz\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELuo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETriple-Negative breast cancers with amplification of JAK2 at the 9p24\n            locus demonstrate JAK2-specific dependence\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESci Transl\n            Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E334ra53\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1126\/scitranslmed.aad3001\u0022\u003Edoi:10.1126\/scitranslmed.aad3001\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27075627\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DSci%2BTransl%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BMed%26rft.volume%253D8%26rft.spage%253D334ra53%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-162-1\u0022 title=\u0022View reference 162 in text\u0022 id=\u0022ref-162\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.162\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBachelot\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFilleron\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDalenc\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003E128O PDL1\/CD274 gain\/amplification as a predictive marker of checkpoint\n            blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the\n            SAFIR02-IMMUNO randomized phase II trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of\n            Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003ES58\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.annonc.2020.03.231\u0022\u003Edoi:10.1016\/j.annonc.2020.03.231\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnnals%2Bof%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BOncology%26rft.volume%253D31%26rft.spage%253DS58%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-163-1\u0022 title=\u0022View reference 163 in text\u0022 id=\u0022ref-163\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.163\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAyers\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELunceford\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENebozhyn\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EIFN-\u0026Icirc;\u0026sup3;-related mRNA profile predicts clinical response to PD-1\n            blockade\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Invest\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E127\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2930\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E40\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1172\/JCI91190\u0022\u003Edoi:10.1172\/JCI91190\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28650338\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BInvest%26rft.volume%253D127%26rft.spage%253D2930%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-164-1\u0022 title=\u0022View reference 164 in text\u0022 id=\u0022ref-164\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.164\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVafaizadeh\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarekati\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmuno-Oncology biomarkers for personalized immunotherapy in breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFront Cell Dev Biol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E162\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.3389\/fcell.2020.00162\u0022\u003Edoi:10.3389\/fcell.2020.00162\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32258038\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DFront%2BCell%2BDev%2BBiol%26rft.volume%253D8%26rft.spage%253D162%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-165-1\u0022 title=\u0022View reference 165 in text\u0022 id=\u0022ref-165\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.165\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EOrganization, W.H\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EWHO Handbook for reporting\n            results of cancer treatment\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-loc\u0022\u003EGeneva\u003C\/span\u003E:\n            \u003Cspan class=\u0022cit-publ-name\u0022\u003EWorld Health Organization\u003C\/span\u003E,\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E1979\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-166-1\u0022 title=\u0022View reference 166 in text\u0022 id=\u0022ref-166\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.166\u0022 data-doi=\u002210.1093\/jnci\/92.3.205\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETherasse\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EArbuck\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESG\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEisenhauer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ENew guidelines to evaluate the response to treatment in solid\n            tumors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Natl Cancer Inst\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2000\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E92\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E205\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E16\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/jnci\/92.3.205\u0022\u003Edoi:10.1093\/jnci\/92.3.205\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BNatl%2BCancer%2BInst%26rft.volume%253D92%26rft.spage%253D205%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fjnci%252F92.3.205%26rft_id%253Dinfo%253Apmid%252F10655437%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/jnci\/92.3.205\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10655437\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-167-1\u0022 title=\u0022View reference 167 in text\u0022 id=\u0022ref-167\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.167\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EQueirolo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESpagnolo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAtypical\n            responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and\n            other solid tumors treated with anti-PD-1 drugs: a systematic review\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Treat Rev\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E59\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E71\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.ctrv.2017.07.002\u0022\u003Edoi:10.1016\/j.ctrv.2017.07.002\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28756306\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BTreat%2BRev%26rft.volume%253D59%26rft.spage%253D71%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-168-1\u0022 title=\u0022View reference 168 in text\u0022 id=\u0022ref-168\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.168\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETumeh\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERadu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERibas\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPet imaging\n            of cancer immunotherapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Nucl Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2008\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E49\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E865\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.2967\/jnumed.108.051342\u0022\u003Edoi:10.2967\/jnumed.108.051342\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18511842\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BNucl%2BMed%26rft.volume%253D49%26rft.spage%253D865%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-169-1\u0022 title=\u0022View reference 169 in text\u0022 id=\u0022ref-169\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.169\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDromain\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBeigelman\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPozzessere\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImaging of tumour response to immunotherapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEur\n            Radiol Exp\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s41747-019-0134-1\u0022\u003Edoi:10.1186\/s41747-019-0134-1\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31900689\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DEur%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BRadiol%2BExp%26rft.volume%253D4%26rft.spage%253D2%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-170-1\u0022 title=\u0022View reference 170 in text\u0022 id=\u0022ref-170\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.170\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKurra\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESullivan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGainor\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPseudoprogression in cancer immunotherapy: rates, time course and patient\n            outcomes\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E34\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E6580\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2016.34.15_suppl.6580\u0022\u003Edoi:10.1200\/JCO.2016.34.15_suppl.6580\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-171-1\u0022 title=\u0022View reference 171 in text\u0022 id=\u0022ref-171\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.171\u0022 data-doi=\u002210.1158\/1078-0432.CCR-09-1624\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWolchok\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJD\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHoos\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EO\u0027Day\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EGuidelines for the evaluation of immune therapy activity in solid tumors:\n            immune-related response criteria\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E7412\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E20\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-09-1624\u0022\u003Edoi:10.1158\/1078-0432.CCR-09-1624\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19934295\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D15%26rft.spage%253D7412%26rft_id%253Dinfo%253Adoi%252F10.1158%252F1078-0432.CCR-09-1624%26rft_id%253Dinfo%253Apmid%252F19934295%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1158\/1078-0432.CCR-09-1624\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=19934295\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-172-1\u0022 title=\u0022View reference 172 in text\u0022 id=\u0022ref-172\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.172\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENishino\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGiobbie-Hurder\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGargano\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EDeveloping a common language for tumor response to immunotherapy:\n            immune-related response criteria using unidimensional measurements\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E19\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E3936\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E43\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-13-0895\u0022\u003Edoi:10.1158\/1078-0432.CCR-13-0895\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23743568\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D19%26rft.spage%253D3936%26rft_id%253Dinfo%253Apmid%252F23743568%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23743568\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-173-1\u0022 title=\u0022View reference 173 in text\u0022 id=\u0022ref-173\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.173\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHodi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBallinger\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELyons\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmune-modified response evaluation criteria in solid tumors (imRECIST):\n            refining guidelines to assess the clinical benefit of cancer\n            immunotherapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E850\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2017.75.1644\u0022\u003Edoi:10.1200\/JCO.2017.75.1644\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29341833\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D36%26rft.spage%253D850%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-174-1\u0022 title=\u0022View reference 174 in text\u0022 id=\u0022ref-174\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.174\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESeymour\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBogaerts\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPerrone\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EiRECIST: guidelines for response criteria for use in trials testing\n            immunotherapeutics\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E18\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Ee143\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E52\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S1470-2045(17)30074-8\u0022\u003Edoi:10.1016\/S1470-2045(17)30074-8\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28271869\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%2BOncol%26rft.volume%253D18%26rft.spage%253De143%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-175-1\u0022 title=\u0022View reference 175 in text\u0022 id=\u0022ref-175\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.175\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENishino\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGargano\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESuda\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EOptimizing immune-related tumor response assessment: does reducing the\n            number of lesions impact response assessment in melanoma patients treated with\n            ipilimumab?\u003C\/span\u003E\n          \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E2\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E17\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/2051-1426-2-17\u0022\u003Edoi:10.1186\/2051-1426-2-17\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24991412\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%2BCancer%26rft.volume%253D2%26rft.spage%253D17%26rft_id%253Dinfo%253Apmid%252F24991412%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=24991412\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-176-1\u0022 title=\u0022View reference 176 in text\u0022 id=\u0022ref-176\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.176\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMulkey\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETheoret\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKeegan\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EComparison of iRECIST versus RECIST V.1.1 in patients treated with an\n            anti-PD-1 or PD-L1 antibody: pooled FDA analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother\n            Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003Ee000146\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1136\/jitc-2019-000146\u0022\u003Edoi:10.1136\/jitc-2019-000146\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32107275\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BCancer%26rft.volume%253D8%26rft.spage%253De000146%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-177-1\u0022 title=\u0022View reference 177 in text\u0022 id=\u0022ref-177\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.177\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EStein\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELipson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECottrell\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPan-tumor pathologic scoring of response to PD-(L)1\n            blockade\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E545\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E51\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-19-2379\u0022\u003Edoi:10.1158\/1078-0432.CCR-19-2379\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31672770\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D26%26rft.spage%253D545%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-177-1\u0022 title=\u0022View reference 178 in text\u0022 id=\u0022ref-178\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.178\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECottrell\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EThompson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EED\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EForde\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPathologic features of response to neoadjuvant anti-PD-1 in resected\n            non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic\n            response criteria (irPRC)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E29\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1853\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E60\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdy218\u0022\u003Edoi:10.1093\/annonc\/mdy218\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29982279\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D29%26rft.spage%253D1853%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-179-1\u0022 title=\u0022View reference 179 in text\u0022 id=\u0022ref-179\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.179\u0022 data-doi=\u002210.1016\/S1470-2045(15)00088-1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EOkada\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWeller\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHuang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmunotherapy response assessment in neuro-oncology: a report of the RANO\n            Working group\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Ee534\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E42\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S1470-2045(15)00088-1\u0022\u003Edoi:10.1016\/S1470-2045(15)00088-1\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26545842\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%2BOncol%26rft.volume%253D16%26rft.spage%253De534%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS1470-2045%252815%252900088-1%26rft_id%253Dinfo%253Apmid%252F26545842%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S1470-2045(15)00088-1\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26545842\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-180-1\u0022 title=\u0022View reference 180 in text\u0022 id=\u0022ref-180\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.180\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKuczynski\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESargent\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGrothey\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EDrug rechallenge and treatment beyond progression--implications for drug\n            resistance\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Rev Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E10\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E571\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E87\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/nrclinonc.2013.158\u0022\u003Edoi:10.1038\/nrclinonc.2013.158\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23999218\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNat%2BRev%2BClin%2BOncol%26rft.volume%253D10%26rft.spage%253D571%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-181-1\u0022 title=\u0022View reference 181 in text\u0022 id=\u0022ref-181\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.181\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPalmieri\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKrell\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJames\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ERechallenging with anthracyclines and taxanes in metastatic breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Rev Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E561\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E74\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/nrclinonc.2010.122\u0022\u003Edoi:10.1038\/nrclinonc.2010.122\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20808300\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNat%2BRev%2BClin%2BOncol%26rft.volume%253D7%26rft.spage%253D561%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-181-1\u0022 title=\u0022View reference 182 in text\u0022 id=\u0022ref-182\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.182\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECara\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETannock\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIF\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ERetreatment\n            of patients with the same chemotherapy: implications for clinical mechanisms of drug\n            resistance\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2001\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E23\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E7\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1023\/A:1008389706725\u0022\u003Edoi:10.1023\/A:1008389706725\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11249045\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D12%26rft.spage%253D23%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-183-1\u0022 title=\u0022View reference 183 in text\u0022 id=\u0022ref-183\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.183\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EGBG GERMAN BREAST GROUP\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPirvulescu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EUhlig\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETrastuzumab improves the efficacy of chemotherapy in breast cancer\n            treatment beyond progression\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast Care\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2008\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E3\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E364\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E5\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1159\/000175098\u0022\u003Edoi:10.1159\/000175098\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20824032\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BCare%26rft.volume%253D3%26rft.spage%253D364%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-184-1\u0022 title=\u0022View reference 184 in text\u0022 id=\u0022ref-184\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.184\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPark\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELee\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETrastuzumab treatment beyond brain progression in HER2-positive\n            metastatic breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E56\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E62\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdn539\u0022\u003Edoi:10.1093\/annonc\/mdn539\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18664558\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D20%26rft.spage%253D56%26rft_id%253Dinfo%253Apmid%252F18664558%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=18664558\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-185-1\u0022 title=\u0022View reference 185 in text\u0022 id=\u0022ref-185\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.185\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETsimberidou\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELevit\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchilsky\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETrial reporting in Immuno-Oncology (trio): an American Society of\n            clinical Oncology-Society for immunotherapy of cancer statement\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E72\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E80\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.18.00145\u0022\u003Edoi:10.1200\/JCO.18.00145\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30339040\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D37%26rft.spage%253D72%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-186-1\u0022 title=\u0022View reference 186 in text\u0022 id=\u0022ref-186\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.186\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDeutsch\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFlaherty\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKirchoff\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAssociation of surgical treatment, systemic therapy, and survival in\n            patients with abdominal visceral melanoma metastases, 1965-2014: relevance of surgical\n            cure in the era of modern systemic therapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Surg\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E152\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E672\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamasurg.2017.0459\u0022\u003Edoi:10.1001\/jamasurg.2017.0459\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28384791\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%2BSurg%26rft.volume%253D152%26rft.spage%253D672%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-186-1\u0022 title=\u0022View reference 187 in text\u0022 id=\u0022ref-187\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.187\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFlaherty\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDeutsch\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKirchoff\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAdrenalectomy for metastatic melanoma: current role in the age of\n            nonsurgical treatments\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm Surg\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E81\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1005\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1177\/000313481508101019\u0022\u003Edoi:10.1177\/000313481508101019\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26463298\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAm%2BSurg%26rft.volume%253D81%26rft.spage%253D1005%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-186-1\u0022 title=\u0022View reference 188 in text\u0022 id=\u0022ref-188\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.188\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFife\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EColman\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EStevens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EDeterminants of outcome in melanoma patients with cerebral\n            metastases\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2004\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E22\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1293\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E300\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2004.08.140\u0022\u003Edoi:10.1200\/JCO.2004.08.140\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15051777\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D22%26rft.spage%253D1293%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-189-1\u0022 title=\u0022View reference 189 in text\u0022 id=\u0022ref-189\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.189\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBale\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPutzer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchullian\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ELocal\n            treatment of breast cancer liver metastasis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancers\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E1341\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.3390\/cancers11091341\u0022\u003Edoi:10.3390\/cancers11091341\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31514362\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancers%26rft.volume%253D11%26rft.spage%253D1341%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-190-1\u0022 title=\u0022View reference 190 in text\u0022 id=\u0022ref-190\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.190\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EReynders\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIllidge\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESiva\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EThe abscopal effect of local radiotherapy: using immunotherapy to make a\n            rare event clinically relevant\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Treat Rev\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E41\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E503\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E10\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.ctrv.2015.03.011\u0022\u003Edoi:10.1016\/j.ctrv.2015.03.011\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25872878\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BTreat%2BRev%26rft.volume%253D41%26rft.spage%253D503%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-191-1\u0022 title=\u0022View reference 191 in text\u0022 id=\u0022ref-191\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.191\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarroso-Sousa\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKrop\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETrippa\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EA phase II study of pembrolizumab in combination with palliative\n            radiotherapy for hormone receptor-positive metastatic breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Breast Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E238\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E45\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.clbc.2020.01.012\u0022\u003Edoi:10.1016\/j.clbc.2020.01.012\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32113750\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BBreast%2BCancer%26rft.volume%253D20%26rft.spage%253D238%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-186-2\u0022 title=\u0022View reference 192 in text\u0022 id=\u0022ref-192\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.192\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERobert\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMarabelle\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHerrscher\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmunotherapy discontinuation - how, and when? Data from melanoma\n            as a paradigm\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Rev Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E17\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E707\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E15\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41571-020-0399-6\u0022\u003Edoi:10.1038\/s41571-020-0399-6\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32636502\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNat%2BRev%2BClin%2BOncol%26rft.volume%253D17%26rft.spage%253D707%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-193-1\u0022 title=\u0022View reference 193 in text\u0022 id=\u0022ref-193\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.193\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDiamond\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHamilton\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESafety and clinical activity of atezolizumab (anti-PDL1) in combination\n            with nab-paclitaxel in patients with metastatic triple-negative breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EIn Proceedings of the Thirty-Eighth Annual CTRC-AACR San\n            Antonio Breast Cancer Symposium\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E8\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E12\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-194-1\u0022 title=\u0022View reference 194 in text\u0022 id=\u0022ref-194\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.194\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPage\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBear\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPrabhakaran\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETwo may be better than one: PD-1\/PD-L1 blockade combination approaches in\n            metastatic breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENPJ Breast Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E34\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41523-019-0130-x\u0022\u003Edoi:10.1038\/s41523-019-0130-x\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31602395\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNPJ%2BBreast%2BCancer%26rft.volume%253D5%26rft.spage%253D34%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-195-1\u0022 title=\u0022View reference 195 in text\u0022 id=\u0022ref-195\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.195\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGoedert\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchairer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMcNeel\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ERisk of breast, ovary, and uterine corpus cancers among 85,268 women with\n            AIDS\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBr J Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2006\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E95\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E642\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/sj.bjc.6603282\u0022\u003Edoi:10.1038\/sj.bjc.6603282\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16868538\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBr%2BJ%2BCancer%26rft.volume%253D95%26rft.spage%253D642%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-196-1\u0022 title=\u0022View reference 196 in text\u0022 id=\u0022ref-196\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.196\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFranceschi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELise\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EClifford\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EChanging patterns of cancer incidence in the early- and late-HAART\n            periods: the Swiss HIV cohort study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBr J Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E103\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E416\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E22\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/sj.bjc.6605756\u0022\u003Edoi:10.1038\/sj.bjc.6605756\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20588274\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBr%2BJ%2BCancer%26rft.volume%253D103%26rft.spage%253D416%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-196-1\u0022 title=\u0022View reference 197 in text\u0022 id=\u0022ref-197\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.197\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECoghill\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShiels\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESuneja\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EElevated cancer-specific mortality among HIV-infected patients in the\n            United States\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E33\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2376\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E83\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2014.59.5967\u0022\u003Edoi:10.1200\/JCO.2014.59.5967\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26077242\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D33%26rft.spage%253D2376%26rft_id%253Dinfo%253Apmid%252F26077242%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26077242\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-196-1\u0022 title=\u0022View reference 198 in text\u0022 id=\u0022ref-198\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.198\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHessol\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENA\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWhittemore\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVittinghoff\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EIncidence of first and second primary cancers diagnosed among people with\n            HIV, 1985-2013: a population-based, registry linkage study\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet HIV\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Ee647\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E55\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S2352-3018(18)30179-6\u0022\u003Edoi:10.1016\/S2352-3018(18)30179-6\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30245004\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%2BHIV%26rft.volume%253D5%26rft.spage%253D647e%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-199-1\u0022 title=\u0022View reference 199 in text\u0022 id=\u0022ref-199\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.199\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECook\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKim\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ESafety and\n            efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and\n            advanced-stage cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1049\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E54\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamaoncol.2018.6737\u0022\u003Edoi:10.1001\/jamaoncol.2018.6737\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30730549\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%2BOncol%26rft.volume%253D5%26rft.spage%253D1049%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-200-1\u0022 title=\u0022View reference 200 in text\u0022 id=\u0022ref-200\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.200\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGonz\u0026Atilde;\u0026iexcl;lez-Cao\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMoran\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDalmau\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPhase II study of durvalumab (MEDI4736) in cancer patients\n            HIV-1-infected\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2501\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2019.37.15_suppl.2501\u0022\u003Edoi:10.1200\/JCO.2019.37.15_suppl.2501\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJournal%2Bof%2BClinical%2BOncology%26rft.volume%253D37%26rft.spage%253D2501%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-200-1\u0022 title=\u0022View reference 201 in text\u0022 id=\u0022ref-201\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.201\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EUldrick\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETS\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGon\u0026Atilde;\u0026sect;alves\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAbdul-Hay\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAssessment of the safety of pembrolizumab in patients with HIV and\n            advanced cancer-a phase 1 study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1332\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamaoncol.2019.2244\u0022\u003Edoi:10.1001\/jamaoncol.2019.2244\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31154457\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%2BOncol%26rft.volume%253D5%26rft.spage%253D1332%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-202-1\u0022 title=\u0022View reference 202 in text\u0022 id=\u0022ref-202\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.202\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMenzies\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJohnson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERamanujam\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAnti-Pd-1 therapy in patients with advanced melanoma and preexisting\n            autoimmune disorders or major toxicity with ipilimumab\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn\n            Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E28\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E368\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E76\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdw443\u0022\u003Edoi:10.1093\/annonc\/mdw443\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27687304\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BOncol%26rft.volume%253D28%26rft.spage%253D368%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-203-1\u0022 title=\u0022View reference 203 in text\u0022 id=\u0022ref-203\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.203\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003Evan Holstein\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKapiteijn\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBastiaannet\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEfficacy and adverse events of immunotherapy with checkpoint inhibitors\n            in older patients with cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EDrugs Aging\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E927\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E38\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s40266-019-00697-2\u0022\u003Edoi:10.1007\/s40266-019-00697-2\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31317421\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DDrugs%2BAging%26rft.volume%253D36%26rft.spage%253D927%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-204-1\u0022 title=\u0022View reference 204 in text\u0022 id=\u0022ref-204\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.204\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESattar\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKartolo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHopman\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EWM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EThe efficacy and toxicity of immune checkpoint inhibitors in a real-world\n            older patient population\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Geriatr Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E10\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E411\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E4\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.jgo.2018.07.015\u0022\u003Edoi:10.1016\/j.jgo.2018.07.015\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30104155\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BGeriatr%2BOncol%26rft.volume%253D10%26rft.spage%253D411%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-205-1\u0022 title=\u0022View reference 205 in text\u0022 id=\u0022ref-205\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.205\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKanesvaran\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECordoba\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMaggiore\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmunotherapy in older adults with advanced cancers: implications for\n            clinical decision-making and future research\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm Soc Clin Oncol\n            Educ Book\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E38\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E400\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E14\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/EDBK_201435\u0022\u003Edoi:10.1200\/EDBK_201435\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30231397\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAm%2BSoc%2BClin%2BOncol%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BEduc%2BBook%26rft.volume%253D38%26rft.spage%253D400%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-206-1\u0022 title=\u0022View reference 206 in text\u0022 id=\u0022ref-206\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.206\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EArbour\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMezquita\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELong\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImpact of baseline steroids on efficacy of programmed cell death-1 and\n            programmed Death-Ligand 1 blockade in patients with non-small-cell lung\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2872\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2018.79.0006\u0022\u003Edoi:10.1200\/JCO.2018.79.0006\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30125216\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D36%26rft.spage%253D2872%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-206-1\u0022 title=\u0022View reference 207 in text\u0022 id=\u0022ref-207\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.207\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EScott\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPennell\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENA\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEarly use\n            of systemic corticosteroids in patients with advanced NSCLC treated with\n            nivolumab\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Thorac Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E13\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1771\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E5\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.jtho.2018.06.004\u0022\u003Edoi:10.1016\/j.jtho.2018.06.004\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29935305\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BThorac%2BOncol%26rft.volume%253D13%26rft.spage%253D1771%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-208-1\u0022 title=\u0022View reference 208 in text\u0022 id=\u0022ref-208\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.208\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERicciuti\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDahlberg\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdeni\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmune checkpoint inhibitor outcomes for patients with non-small-cell\n            lung cancer receiving baseline corticosteroids for palliative versus Nonpalliative\n            indications\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1927\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E34\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.19.00189\u0022\u003Edoi:10.1200\/JCO.19.00189\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31206316\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D37%26rft.spage%253D1927%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-209-1\u0022 title=\u0022View reference 209 in text\u0022 id=\u0022ref-209\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.209\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVaidya\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJS\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBaldassarre\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EThorat\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ERole of glucocorticoids in breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECurr\n            Pharm Des\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E3593\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E600\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.2174\/138161210793797906\u0022\u003Edoi:10.2174\/138161210793797906\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20977423\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCurr%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BPharm%2BDes%26rft.volume%253D16%26rft.spage%253D3593%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-210-1\u0022 title=\u0022View reference 210 in text\u0022 id=\u0022ref-210\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.210\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMoutsatsou\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPapavassiliou\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAG\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EThe\n            glucocorticoid receptor signalling in breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Cell Mol\n            Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2008\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E145\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E63\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1111\/j.1582-4934.2007.00177.x\u0022\u003Edoi:10.1111\/j.1582-4934.2007.00177.x\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18053085\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BCell%2BMol%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BMed%26rft.volume%253D12%26rft.spage%253D145%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-211-1\u0022 title=\u0022View reference 211 in text\u0022 id=\u0022ref-211\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.211\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPetrelli\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESignorelli\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGhidini\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAssociation of steroids use with survival in patients treated with immune\n            checkpoint inhibitors: a systematic review and meta-analysis\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancers\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E. doi:\u003Ca href=\u0022http:\/\/dx.doi.org\/10.3390\/cancers12030546\u0022\u003Edoi:10.3390\/cancers12030546\u003C\/a\u003E. [Epub ahead of print: \u003Cspan class=\u0022cit-comment\u0022\u003E27 02\n            2020\u003C\/span\u003E].\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32120803\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancers%26rft.volume%253D12%26rft.atitle%253DASSOCIATION%2BOF%2BSTEROIDS%2BUSE%2BWITH%2BSURVIVAL%2BIN%2BPATIENTS%2BTREATED%2BWITH%2BIMMUNE%2BCHECKPOINT%2BINHIBITORS%253A%2BA%2BSYSTEMATIC%2BREVIEW%2BAND%2BMETA-ANALYSIS%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-212-1\u0022 title=\u0022View reference 212 in text\u0022 id=\u0022ref-212\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.212\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWong\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBadve\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EBreast cancer and transplantation\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm J\n            Transplant\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E17\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2243\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E53\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1111\/ajt.14368\u0022\u003Edoi:10.1111\/ajt.14368\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28544474\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAm%2BJ%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BTransplant%26rft.volume%253D17%26rft.spage%253D2243%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-213-1\u0022 title=\u0022View reference 213 in text\u0022 id=\u0022ref-213\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.213\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAbdel-Wahab\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESafa\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAbudayyeh\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ECheckpoint inhibitor therapy for cancer in solid organ transplantation\n            recipients: an institutional experience and a systematic review of the\n            literature\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E106\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s40425-019-0585-1\u0022\u003Edoi:10.1186\/s40425-019-0585-1\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30992053\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%2BCancer%26rft.volume%253D7%26rft.spage%253D106%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-214-1\u0022 title=\u0022View reference 214 in text\u0022 id=\u0022ref-214\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.214\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ED\u0027Abreo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmune-checkpoint inhibition for metastatic triple-negative breast\n            cancer: safety first?\u003C\/span\u003E\n          \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Rev Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E399\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E400\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/s41571-019-0216-2\u0022\u003Edoi:10.1038\/s41571-019-0216-2\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31053774\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNat%2BRev%2BClin%2BOncol%26rft.volume%253D16%26rft.spage%253D399%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-215-1\u0022 title=\u0022View reference 215 in text\u0022 id=\u0022ref-215\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.215\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPuzanov\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDiab\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAbdallah\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EManaging toxicities associated with immune checkpoint inhibitors:\n            consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity\n            management Working group\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E95\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s40425-017-0300-z\u0022\u003Edoi:10.1186\/s40425-017-0300-z\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003E29162153\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%2BCancer%26rft.volume%253D5%26rft.spage%253D95%26rft_id%253Dinfo%253Apmid%252F29162153%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=29162153\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-215-2\u0022 title=\u0022View reference 216 in text\u0022 id=\u0022ref-216\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.216\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPallin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBaugh\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECW\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPostow\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmune-Related adverse events in cancer patients\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAcad Emerg Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E819\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E27\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1111\/acem.13443\u0022\u003Edoi:10.1111\/acem.13443\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29729100\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAcad%2BEmerg%2BMed%26rft.volume%253D25%26rft.spage%253D819%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-215-3\u0022 title=\u0022View reference 217 in text\u0022 id=\u0022ref-217\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.217\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBrahmer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELacchetti\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchneider\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EManagement of immune-related adverse events in patients treated with\n            immune checkpoint inhibitor therapy: American Society of clinical oncology clinical\n            practice guideline\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1714\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E68\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2017.77.6385\u0022\u003Edoi:10.1200\/JCO.2017.77.6385\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29442540\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D36%26rft.spage%253D1714%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-215-3\u0022 title=\u0022View reference 218 in text\u0022 id=\u0022ref-218\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.218\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMyers\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmune-Related adverse events of immune checkpoint inhibitors: a brief\n            review\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECurr Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E342\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E7\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.3747\/co.25.4235\u0022\u003Edoi:10.3747\/co.25.4235\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30464684\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCurr%2BOncol%26rft.volume%253D25%26rft.spage%253D342%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-219-1\u0022 title=\u0022View reference 219 in text\u0022 id=\u0022ref-219\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.219\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWeber\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHodi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWolchok\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESafety profile of nivolumab monotherapy: a pooled analysis of patients\n            with advanced melanoma\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E35\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E785\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E92\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2015.66.1389\u0022\u003Edoi:10.1200\/JCO.2015.66.1389\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28068177\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D35%26rft.spage%253D785%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-215-5\u0022 title=\u0022View reference 220 in text\u0022 id=\u0022ref-220\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.220\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBrahmer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAbu-Sbeih\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAscierto\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESociety for immunotherapy of cancer (SITC) clinical practice guideline on\n            immune checkpoint inhibitor-related adverse events\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother\n            Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E9\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Ee002435\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1136\/jitc-2021-002435\u0022\u003Edoi:10.1136\/jitc-2021-002435\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34172516\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BCancer%26rft.volume%253D9%26rft.spage%253De002435%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-221-1\u0022 title=\u0022View reference 221 in text\u0022 id=\u0022ref-221\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.221\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarroso-Sousa\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarry\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EWT\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGarrido-Castro\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EIncidence of endocrine dysfunction following the use of different immune\n            checkpoint inhibitor regimens: a systematic review and meta-analysis\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E173\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E82\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamaoncol.2017.3064\u0022\u003Edoi:10.1001\/jamaoncol.2017.3064\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28973656\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%2BOncol%26rft.volume%253D4%26rft.spage%253D173%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-222-1\u0022 title=\u0022View reference 222 in text\u0022 id=\u0022ref-222\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.222\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EQuandt\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETrupin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEvans\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESAT-418 finding the needles in the haystack: harnessing the electronic\n            health record to find thyroid immune related adverse events\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ\n            Endocr Soc\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003ESAT-418\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1210\/jendso\/bvaa046.127\u0022\u003Edoi:10.1210\/jendso\/bvaa046.127\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BEndocr%2BSoc%26rft.volume%253D4%26rft.spage%253DSAT-418%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-223-1\u0022 title=\u0022View reference 223 in text\u0022 id=\u0022ref-223\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.223\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhai\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYe\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHu\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEndocrine toxicity of immune checkpoint inhibitors: a real-world study\n            Leveraging US food and drug administration adverse events reporting\n            system\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E286\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s40425-019-0754-2\u0022\u003Edoi:10.1186\/s40425-019-0754-2\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31694698\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%2BCancer%26rft.volume%253D7%26rft.spage%253D286%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-224-1\u0022 title=\u0022View reference 224 in text\u0022 id=\u0022ref-224\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.224\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETW\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERazak\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBedard\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EA systematic review of immune-related adverse event reporting in clinical\n            trials of immune checkpoint inhibitors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1824\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdv182\u0022\u003Edoi:10.1093\/annonc\/mdv182\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25888611\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D26%26rft.spage%253D1824%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-225-1\u0022 title=\u0022View reference 225 in text\u0022 id=\u0022ref-225\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.225\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECouey\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBell\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPatel\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EDelayed immune-related events (dire) after discontinuation of\n            immunotherapy: diagnostic hazard of autoimmunity at a distance\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E165\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s40425-019-0645-6\u0022\u003Edoi:10.1186\/s40425-019-0645-6\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31269983\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%2BCancer%26rft.volume%253D7%26rft.spage%253D165%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-215-7\u0022 title=\u0022View reference 226 in text\u0022 id=\u0022ref-226\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.226\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESimonaggio\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMichot\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVoisin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEvaluation of readministration of immune checkpoint inhibitors after\n            immune-related adverse events in patients with cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA\n            Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1310\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E7\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1001\/jamaoncol.2019.1022\u0022\u003Edoi:10.1001\/jamaoncol.2019.1022\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31169866\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJAMA%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BOncol%26rft.volume%253D5%26rft.spage%253D1310%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-227-1\u0022 title=\u0022View reference 227 in text\u0022 id=\u0022ref-227\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.227\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAbu-Sbeih\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAli\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENaqash\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EResumption of immune checkpoint inhibitor therapy after immune-mediated\n            colitis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E2738\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E45\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.19.00320\u0022\u003Edoi:10.1200\/JCO.19.00320\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31163011\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D37%26rft.spage%253D2738%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-228-1\u0022 title=\u0022View reference 228 in text\u0022 id=\u0022ref-228\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.228\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDas\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJohnson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDB\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmune-Related adverse events and anti-tumor efficacy of immune\n            checkpoint inhibitors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E306\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s40425-019-0805-8\u0022\u003Edoi:10.1186\/s40425-019-0805-8\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31730012\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%2BCancer%26rft.volume%253D7%26rft.spage%253D306%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-65-4\u0022 title=\u0022View reference 229 in text\u0022 id=\u0022ref-229\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.229\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMittendorf\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarrios\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHarbeck\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract OT2-07-03: IMpassion031: a phase III study comparing neoadjuvant\n            atezolizumab vs placebo in combination with nab-paclitaxel\u0026acirc;\u0026#128;\u0026#147;based chemotherapy in\n            early triple-negative breast cancer (TNBC)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer\n            Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E78\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-230-1\u0022 title=\u0022View reference 230 in text\u0022 id=\u0022ref-230\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.230\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELouvel\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBahleda\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAmmari\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmunotherapy and pulmonary toxicities: can concomitant immune-checkpoint\n            inhibitors with radiotherapy increase the risk of radiation\n            pneumonitis?\u003C\/span\u003E\n          \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEur Respir J\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E51\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E1701737\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1183\/13993003.01737-2017\u0022\u003Edoi:10.1183\/13993003.01737-2017\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29301923\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DEur%2BRespir%2BJ%26rft.volume%253D51%26rft.spage%253D1701737%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-230-1\u0022 title=\u0022View reference 231 in text\u0022 id=\u0022ref-231\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.231\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchoenfeld\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJD\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENishino\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESevergnini\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPneumonitis resulting from radiation and immune checkpoint blockade\n            illustrates characteristic clinical, radiologic and circulating biomarker\n            features\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E112\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s40425-019-0583-3\u0022\u003Edoi:10.1186\/s40425-019-0583-3\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31014385\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%2BCancer%26rft.volume%253D7%26rft.spage%253D112%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-232-1\u0022 title=\u0022View reference 232 in text\u0022 id=\u0022ref-232\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.232\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECooksley\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECD\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAvritscher\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEBC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBekele\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEpidemiology and outcomes of serious influenza-related infections in the\n            cancer population\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2005\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E104\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E618\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E28\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1002\/cncr.21203\u0022\u003Edoi:10.1002\/cncr.21203\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15973737\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%26rft.volume%253D104%26rft.spage%253D618%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-232-1\u0022 title=\u0022View reference 233 in text\u0022 id=\u0022ref-233\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.233\u0022 data-doi=\u002210.1016\/S1473-3099(09)70175-6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKunisaki\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJanoff\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEN\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EInfluenza\n            in immunosuppressed populations: a review of infection frequency, morbidity, mortality,\n            and vaccine responses\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Infect Dis\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E9\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E493\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E504\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S1473-3099(09)70175-6\u0022\u003Edoi:10.1016\/S1473-3099(09)70175-6\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19628174\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%2BInfect%2BDis%26rft.volume%253D9%26rft.spage%253D493%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS1473-3099%252809%252970175-6%26rft_id%253Dinfo%253Apmid%252F19628174%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S1473-3099(09)70175-6\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=19628174\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000268625400017\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-234-1\u0022 title=\u0022View reference 234 in text\u0022 id=\u0022ref-234\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.234\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGwynn\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EME\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDeRemer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESaunders\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmune-Mediated adverse events following influenza vaccine in cancer\n            patients receiving immune checkpoint inhibitors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Oncol Pharm\n            Pract\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E647\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E54\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1177\/1078155219868758\u0022\u003Edoi:10.1177\/1078155219868758\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31474214\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BOncol%2BPharm%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BPract%26rft.volume%253D26%26rft.spage%253D647%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-234-1\u0022 title=\u0022View reference 235 in text\u0022 id=\u0022ref-235\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.235\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChong\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPark\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EVJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECohen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ESafety of inactivated influenza vaccine in cancer patients receiving\n            immune checkpoint inhibitors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Infect Dis\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E70\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E193\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/cid\/ciz202\u0022\u003Edoi:10.1093\/cid\/ciz202\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30874791\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BInfect%2BDis%26rft.volume%253D70%26rft.spage%253D193%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-236-1\u0022 title=\u0022View reference 236 in text\u0022 id=\u0022ref-236\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.236\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShah\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMK\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKamboj\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EImmunizing\n            cancer patients: which patients? which vaccines? when to\n            give?\u003C\/span\u003E\n          \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E32\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E254\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29847857\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DOncology%26rft.volume%253D32%26rft.spage%253D254%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-237-1\u0022 title=\u0022View reference 237 in text\u0022 id=\u0022ref-237\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-9.8.e002597.237\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERubin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKM\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-ed\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMelanoma\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-ed\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBastian\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-comment\u0022\u003Eeds\u003C\/span\u003E.\n            \u003Cspan class=\u0022cit-source\u0022\u003EEvolving role of the oncology nurse in the care of patients with\n            melanoma\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-loc\u0022\u003ESpringer New York\u003C\/span\u003E: \u003Cspan class=\u0022cit-publ-name\u0022\u003ENew\n            York, NY\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E:\n          \u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E27\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-238-1\u0022 title=\u0022View reference 238 in text\u0022 id=\u0022ref-238\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.238\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGanz\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECoscarelli\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFred\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EBreast cancer survivors: psychosocial concerns and quality of\n            life\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast Cancer Res Treat\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E1996\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E38\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E183\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E99\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/BF01806673\u0022\u003Edoi:10.1007\/BF01806673\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8861837\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BCancer%2BRes%2BTreat%26rft.volume%253D38%26rft.spage%253D183%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-238-1\u0022 title=\u0022View reference 239 in text\u0022 id=\u0022ref-239\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.239\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMehmood\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EQuality of\n            life and psychosocial needs of metastatic breast cancer patients\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E29\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Eix19\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdy428.016\u0022\u003Edoi:10.1093\/annonc\/mdy428.016\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnnals%2Bof%2BOncology%26rft.volume%253D29%26rft.spage%253Dix19%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-240-1\u0022 title=\u0022View reference 240 in text\u0022 id=\u0022ref-240\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.240\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDi\u0026Atilde;\u0026copy;ras\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarrios\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPatient-Reported outcomes from the phase III IMpassion130 trial of\n            atezolizumab plus nab-paclitaxel in metastatic triple-negative breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E582\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.annonc.2020.02.003\u0022\u003Edoi:10.1016\/j.annonc.2020.02.003\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32178964\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D31%26rft.spage%253D582%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-241-1\u0022 title=\u0022View reference 241 in text\u0022 id=\u0022ref-241\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.241\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDineen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EThompson\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESherlock\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAdrenal\n            crisis: prevention and management in adult patients\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETher Adv\n            Endocrinol Metab\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E10\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E2042018819848218\u003C\/span\u003E.\n            \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1177\/2042018819848218\u0022\u003Edoi:10.1177\/2042018819848218\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31223468\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DTher%2BAdv%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BEndocrinol%2BMetab%26rft.volume%253D10%26rft.spage%253D2042018819848218%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-242-1\u0022 title=\u0022View reference 242 in text\u0022 id=\u0022ref-242\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.242\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDuma\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELambertini\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EIt is time\n            to talk about fertility and immunotherapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOncologist\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E277\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1634\/theoncologist.2019-0837\u0022\u003Edoi:10.1634\/theoncologist.2019-0837\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32091651\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DOncologist%26rft.volume%253D25%26rft.spage%253D277%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-243-1\u0022 title=\u0022View reference 243 in text\u0022 id=\u0022ref-243\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.243\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMehta\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKim\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKB\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMinor\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDR\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ECase report\n            of a pregnancy during ipilimumab therapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Glob Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E3\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JGO.17.00019\u0022\u003Edoi:10.1200\/JGO.17.00019\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30241195\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BGlob%2BOncol%26rft.volume%253D4%26rft.spage%253D1%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-243-1\u0022 title=\u0022View reference 244 in text\u0022 id=\u0022ref-244\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.244\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBucheit\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAD\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHardy\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJT\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESzender\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EConception and viable twin pregnancy in a patient with metastatic\n            melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMelanoma Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E30\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E423\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E5\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1097\/CMR.0000000000000657\u0022\u003Edoi:10.1097\/CMR.0000000000000657\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32073510\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DMelanoma%2BRes%26rft.volume%253D30%26rft.spage%253D423%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-245-1\u0022 title=\u0022View reference 245 in text\u0022 id=\u0022ref-245\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.245\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWoodruff\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETK\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EOncofertility: a grand collaboration between reproductive medicine and\n            oncology\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EReproduction\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E150\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003ES1\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E10\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1530\/REP-15-0163\u0022\u003Edoi:10.1530\/REP-15-0163\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26130814\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DReproduction%26rft.volume%253D150%26rft.spage%253DS1%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-246-1\u0022 title=\u0022View reference 246 in text\u0022 id=\u0022ref-246\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.246\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFaje\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EImmunotherapy and hypophysitis: clinical presentation, treatment, and\n            biologic insights\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPituitary\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E19\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E82\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E92\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s11102-015-0671-4\u0022\u003Edoi:10.1007\/s11102-015-0671-4\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26186958\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DPituitary%26rft.volume%253D19%26rft.spage%253D82%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-247-1\u0022 title=\u0022View reference 247 in text\u0022 id=\u0022ref-247\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.247\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EFood and Drug Administration, HHS\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EContent and format of labeling for human prescription drug and biological\n            products; requirements for pregnancy and lactation labeling. final rule\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFed Regist\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E79\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E72063\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E103\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25509060\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DFed%2BRegist%26rft.volume%253D79%26rft.spage%253D72063%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-248-1\u0022 title=\u0022View reference 248 in text\u0022 id=\u0022ref-248\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.248\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECoscia\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EArmenti\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKing\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERW\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EUpdate on the teratogenicity of maternal mycophenolate\n            mofetil\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Pediatr Genet\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E42\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E55\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1055\/s-0035-1556743\u0022\u003Edoi:10.1055\/s-0035-1556743\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27617117\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BPediatr%2BGenet%26rft.volume%253D4%26rft.spage%253D42%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-248-1\u0022 title=\u0022View reference 249 in text\u0022 id=\u0022ref-249\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.249\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPonticelli\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMoroni\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EFetal\n            toxicity of immunosuppressive drugs in pregnancy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin\n            Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E552\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.3390\/jcm7120552\u0022\u003Edoi:10.3390\/jcm7120552\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30558290\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BMed%26rft.volume%253D7%26rft.spage%253D552%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-250-1\u0022 title=\u0022View reference 250 in text\u0022 id=\u0022ref-250\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.250\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFerreira\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDi Meglio\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPistilli\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EDifferential impact of endocrine therapy and chemotherapy on quality of\n            life of breast cancer survivors: a prospective patient-reported outcomes\n            analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E30\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1784\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E95\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdz298\u0022\u003Edoi:10.1093\/annonc\/mdz298\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31591636\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BOncol%26rft.volume%253D30%26rft.spage%253D1784%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-250-1\u0022 title=\u0022View reference 251 in text\u0022 id=\u0022ref-251\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.251\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EOsoba\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESlamon\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBurchmore\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEffects on quality of life of combined trastuzumab and chemotherapy in\n            women with metastatic breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2002\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E3106\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E13\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2002.03.090\u0022\u003Edoi:10.1200\/JCO.2002.03.090\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12118024\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D20%26rft.spage%253D3106%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-250-1\u0022 title=\u0022View reference 252 in text\u0022 id=\u0022ref-252\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.252\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHwang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPark\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB-W\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EDoes\n            chemotherapy really affect the quality of life of women with breast\n            cancer?\u003C\/span\u003E\n          \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Breast Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E229\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E35\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.4048\/jbc.2013.16.2.229\u0022\u003Edoi:10.4048\/jbc.2013.16.2.229\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23843858\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BBreast%2BCancer%26rft.volume%253D16%26rft.spage%253D229%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-250-1\u0022 title=\u0022View reference 253 in text\u0022 id=\u0022ref-253\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.253\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESharma\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPurkayastha\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EFactors\n            affecting quality of life in breast cancer patients: a descriptive and cross-sectional\n            study with review of literature\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Midlife Health\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E75\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E83\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.4103\/jmh.JMH_15_17\u0022\u003Edoi:10.4103\/jmh.JMH_15_17\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28706408\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BMidlife%2BHealth%26rft.volume%253D8%26rft.spage%253D75%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-254-1\u0022 title=\u0022View reference 254 in text\u0022 id=\u0022ref-254\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.254\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPerry\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKowalski\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC-H\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EQuality of\n            life assessment in women with breast cancer: benefits, acceptability and\n            utilization\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHealth Qual Life Outcomes\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2007\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E24\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/1477-7525-5-24\u0022\u003Edoi:10.1186\/1477-7525-5-24\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17474993\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DHealth%2BQual%2BLife%2BOutcomes%26rft.volume%253D5%26rft.spage%253D24%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-254-1\u0022 title=\u0022View reference 255 in text\u0022 id=\u0022ref-255\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.255\u0022 data-doi=\u002210.1200\/JCO.2005.05.130\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAvis\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENE\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECrawford\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EManuel\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EQuality of\n            life among younger women with breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin\n            Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2005\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E23\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E3322\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E30\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2005.05.130\u0022\u003Edoi:10.1200\/JCO.2005.05.130\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15908646\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BOncol%26rft.volume%253D23%26rft.spage%253D3322%26rft_id%253Dinfo%253Adoi%252F10.1200%252FJCO.2005.05.130%26rft_id%253Dinfo%253Apmid%252F15908646%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1200\/JCO.2005.05.130\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=15908646\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-254-1\u0022 title=\u0022View reference 256 in text\u0022 id=\u0022ref-256\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.256\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMarschner\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETrarbach\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERauh\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EQuality of life in pre- and postmenopausal patients with early breast\n            cancer: a comprehensive analysis from the prospective MaLife project\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBreast Cancer Res Treat\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E175\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E701\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E12\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s10549-019-05197-w\u0022\u003Edoi:10.1007\/s10549-019-05197-w\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30868393\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DBreast%2BCancer%2BRes%2BTreat%26rft.volume%253D175%26rft.spage%253D701%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-257-1\u0022 title=\u0022View reference 257 in text\u0022 id=\u0022ref-257\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.257\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENapolitano\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBrancaccio\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EArgenziano\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EIt is finally time for adjuvant therapy in melanoma\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Treat Rev\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E69\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E101\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E11\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.ctrv.2018.06.003\u0022\u003Edoi:10.1016\/j.ctrv.2018.06.003\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29957365\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BTreat%2BRev%26rft.volume%253D69%26rft.spage%253D101%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-258-1\u0022 title=\u0022View reference 258 in text\u0022 id=\u0022ref-258\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.258\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMittendorf\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHong\n                Zhang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESaji\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EBarrios, Patient-reported outcomes (PROs) from the Ph 3 IMpassion031\n            trial of neoadjuvant (NA) atezolizumab + chemo in early triple-negative breast\n            cancer(eTNBC)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EIn 2020 San Antonio Breast Cancer\n            Symposium\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-259-1\u0022 title=\u0022View reference 259 in text\u0022 id=\u0022ref-259\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.259\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESyed\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESyed,\n                Atezolizumab\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYY\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAtezolizumab (in combination with nab-paclitaxel): a review in advanced\n            triple-negative breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EDrugs\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E80\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E601\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E7\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s40265-020-01295-y\u0022\u003Edoi:10.1007\/s40265-020-01295-y\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32248356\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DDrugs%26rft.volume%253D80%26rft.spage%253D601%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-260-1\u0022 title=\u0022View reference 260 in text\u0022 id=\u0022ref-260\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.260\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmid\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHaiderali\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMejia\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003E141P impact of pembrolizumab versus chemotherapy on health-related\n            quality of life in patients with metastatic triple negative breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003ES65\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E6\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.annonc.2020.03.242\u0022\u003Edoi:10.1016\/j.annonc.2020.03.242\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnnals%2Bof%2BOncology%26rft.volume%253D31%26rft.spage%253DS65%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-261-1\u0022 title=\u0022View reference 261 in text\u0022 id=\u0022ref-261\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.261\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFaury\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFoucaud\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EHealth-Related quality of life in cancer patients treated with immune\n            checkpoint inhibitors: a systematic review on reporting of methods in randomized\n            controlled trials\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS One\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003Ee0227344\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1371\/journal.pone.0227344\u0022\u003Edoi:10.1371\/journal.pone.0227344\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31978145\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DPLoS%2BOne%26rft.volume%253D15%26rft.spage%253De0227344%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-262-1\u0022 title=\u0022View reference 262 in text\u0022 id=\u0022ref-262\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.262\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETsoutsou\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZaman\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMartin\n                Lluesma\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EEmerging opportunities of radiotherapy combined with immunotherapy in the\n            era of breast cancer heterogeneity\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFront Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E609\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.3389\/fonc.2018.00609\u0022\u003Edoi:10.3389\/fonc.2018.00609\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30619749\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DFront%2BOncol%26rft.volume%253D8%26rft.spage%253D609%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-263-1\u0022 title=\u0022View reference 263 in text\u0022 id=\u0022ref-263\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.263\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarker\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EArnold\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EA phase 2 clinical trial\u0026acirc;\u0026#128;\u0026macr;assessing the\u0026acirc;\u0026#128;\u0026macr;efficacy and safety of\n            pembrolizumab and radiotherapy in patients with metastatic triple-negative breast\n            cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E126\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E850\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E60\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1002\/cncr.32599\u0022\u003Edoi:10.1002\/cncr.32599\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31747077\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%26rft.volume%253D126%26rft.spage%253D850%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-264-1\u0022 title=\u0022View reference 264 in text\u0022 id=\u0022ref-264\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.264\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWright\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBlitzblau\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EOptimizing radiation therapy to boost systemic immune responses in breast\n            cancer: a critical review for breast radiation oncologists\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EInt\n            J Radiat Oncol Biol Phys\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E108\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E227\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E41\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.ijrobp.2020.05.011\u0022\u003Edoi:10.1016\/j.ijrobp.2020.05.011\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32417409\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DInt%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BJ%2BRadiat%2BOncol%2BBiol%2BPhys%26rft.volume%253D108%26rft.spage%253D227%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-265-1\u0022 title=\u0022View reference 265 in text\u0022 id=\u0022ref-265\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.265\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMcArthur\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHL\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDiab\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPage\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EA pilot study of preoperative single-dose ipilimumab and\/or cryoablation\n            in women with early-stage breast cancer with comprehensive immune\n            profiling\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E22\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E5729\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E37\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-16-0190\u0022\u003Edoi:10.1158\/1078-0432.CCR-16-0190\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27566765\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D22%26rft.spage%253D5729%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-266-1\u0022 title=\u0022View reference 266 in text\u0022 id=\u0022ref-266\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.266\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVikas\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBorcherding\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChennamadhavuni\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETherapeutic potential of combining PARP inhibitor and immunotherapy in\n            solid tumors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFront Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E10\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E570\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.3389\/fonc.2020.00570\u0022\u003Edoi:10.3389\/fonc.2020.00570\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32457830\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DFront%2BOncol%26rft.volume%253D10%26rft.spage%253D570%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-267-1\u0022 title=\u0022View reference 267 in text\u0022 id=\u0022ref-267\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.267\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVinayak\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETolaney\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESM\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchwartzberg\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETOPACIO\/Keynote-162: Niraparib + pembrolizumab in patients (PTS) with\n            metastatic triple-negative breast cancer (TNBC), a phase 2 trial\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E1011\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2018.36.15_suppl.1011\u0022\u003Edoi:10.1200\/JCO.2018.36.15_suppl.1011\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-268-1\u0022 title=\u0022View reference 268 in text\u0022 id=\u0022ref-268\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.268\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDomchek\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPostel-Vinay\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIm\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES-A\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPhase II study of olaparib (o) and durvalumab (D) (MEDIOLA): updated\n            results in patients (PTS) with germline BRCA-mutated (gBRCAm) metastatic breast cancer\n            (MBC)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E30\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Ev477\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/annonc\/mdz253.017\u0022\u003Edoi:10.1093\/annonc\/mdz253.017\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnnals%2Bof%2BOncology%26rft.volume%253D30%26rft.spage%253Dv477%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-269-1\u0022 title=\u0022View reference 269 in text\u0022 id=\u0022ref-269\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.269\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYukinori Ozaki\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETsurutani\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETakahashi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EA\n            multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus\n            bevacizumab triple-combination therapy as a first-line treatment in patients with\n            HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EIn San Antonio Breast Cancer Symposium 2019: San Antonio, TX\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-270-1\u0022 title=\u0022View reference 270 in text\u0022 id=\u0022ref-270\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.270\u0022 data-doi=\u002210.1038\/nature23465\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGoel\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDeCristo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWatt\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ECdk4\/6 inhibition triggers anti-tumour immunity\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENature\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E548\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E471\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E5\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1038\/nature23465\u0022\u003Edoi:10.1038\/nature23465\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28813415\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DNature%26rft.volume%253D548%26rft.spage%253D471%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnature23465%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/nature23465\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-271-1\u0022 title=\u0022View reference 271 in text\u0022 id=\u0022ref-271\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.271\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETolaney\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKabos\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDickler\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EUpdated efficacy, safety, \u0026amp; PD-L1 status of patients with HR+,\n            HER2- metastatic breast cancer administered abemaciclib plus\n            pembrolizumab\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E1059\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2018.36.15_suppl.1059\u0022\u003Edoi:10.1200\/JCO.2018.36.15_suppl.1059\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-272-1\u0022 title=\u0022View reference 272 in text\u0022 id=\u0022ref-272\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.272\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERugo\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBeck\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJT\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJerusalem\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract CT108: a phase 1B study of abemaciclib in combination with\n            pembrolizumab for patients (PTS) with hormone receptor positive (HR+), human epidermal\n            growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT02779751\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022\u003ENCT02779751\u003C\/a\u003E):\n            preliminary results\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E80\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003ECT108\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-273-1\u0022 title=\u0022View reference 273 in text\u0022 id=\u0022ref-273\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.273\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMasuda\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETsurutani\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMasuda\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EAbstract OT2-04-07: phase II study of nivolumab in combination with\n            abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human\n            epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B,\n            NEWFLAME trial)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Research\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E80\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003EOT2-04-07\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-274-1\u0022 title=\u0022View reference 274 in text\u0022 id=\u0022ref-274\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.274\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMasuda J\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMasuda\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETsurutani\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPhase II study of nivolumab in combination with abemaciclib plus\n            endocrine therapy in patients with HR+, HER2- metastatic breast cancer: WJOG11418B\n            NEWFLAME trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EIn 2020 Virtual San Antonio Breast Cancer\n            Symposium\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-275-1\u0022 title=\u0022View reference 275 in text\u0022 id=\u0022ref-275\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.275\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETolaney\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJerusalem\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESalgado\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EA phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole\n            (ANA) in postmenopausal women and men with estrogen receptor (ER)+\/human epidermal\n            growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Clinical Oncology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E38\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003ETPS1105\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS1105\u0022\u003Edoi:10.1200\/JCO.2020.38.15_suppl.TPS1105\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-276-1\u0022 title=\u0022View reference 276 in text\u0022 id=\u0022ref-276\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.276\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMadjd\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESpendlove\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPinder\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETotal loss of MHC class I is an independent indicator of good prognosis\n            in breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EInt J Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2005\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E117\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E248\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E55\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1002\/ijc.21163\u0022\u003Edoi:10.1002\/ijc.21163\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15900607\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DInt%2BJ%2BCancer%26rft.volume%253D117%26rft.spage%253D248%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-276-1\u0022 title=\u0022View reference 277 in text\u0022 id=\u0022ref-277\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.277\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPark\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHS\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECho\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EU\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIm\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ELoss of human leukocyte antigen class I expression is associated with\n            poor prognosis in patients with advanced breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Pathol\n            Transl Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E53\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E75\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E85\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.4132\/jptm.2018.10.11\u0022\u003Edoi:10.4132\/jptm.2018.10.11\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30424591\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BPathol%250A%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2B%2BTransl%2BMed%26rft.volume%253D53%26rft.spage%253D75%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-276-1\u0022 title=\u0022View reference 278 in text\u0022 id=\u0022ref-278\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.278\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EInoue\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMimura\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIzawa\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EExpression of MHC class I on breast cancer cells correlates inversely\n            with HER2 expression\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOncoimmunology\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E1\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1104\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E10\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.4161\/onci.21056\u0022\u003Edoi:10.4161\/onci.21056\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23170258\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DOncoimmunology%26rft.volume%253D1%26rft.spage%253D1104%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-279-1\u0022 title=\u0022View reference 279 in text\u0022 id=\u0022ref-279\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.279\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPiha-Paul\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBendell\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETolcher\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EO82\u0026acirc;\u0026#128;\u0026#133;A phase 1 dose escalation study of PRS-343, a HER2\/4\u0026acirc;\u0026#128;\u0026#147;1BB\n            bispecific molecule, in patients with HER2-positive malignancies\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003EA1.2\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E2\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1136\/LBA2019.2\u0022\u003Edoi:10.1136\/LBA2019.2\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%2BCancer%26rft.volume%253D8%26rft.spage%253DA1.2%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-280-1\u0022 title=\u0022View reference 280 in text\u0022 id=\u0022ref-280\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.280\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELeone\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERD\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEmens\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELA\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ETargeting\n            adenosine for cancer immunotherapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E57\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s40425-018-0360-8\u0022\u003Edoi:10.1186\/s40425-018-0360-8\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29914571\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BImmunother%2BCancer%26rft.volume%253D6%26rft.spage%253D57%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-281-1\u0022 title=\u0022View reference 281 in text\u0022 id=\u0022ref-281\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.281\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGandhi\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDas\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGM\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EMetabolic\n            reprogramming in breast cancer and its therapeutic implications\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECells\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E89\u003C\/span\u003E. \u003Ca href=\u0022http:\/\/dx.doi.org\/10.3390\/cells8020089\u0022\u003Edoi:10.3390\/cells8020089\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30691108\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCells%26rft.volume%253D8%26rft.spage%253D89%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-281-1\u0022 title=\u0022View reference 282 in text\u0022 id=\u0022ref-282\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.282\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGang\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDilda\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPJ\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHogg\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETargeting of two aspects of metabolism in breast cancer\n            treatment\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Biol Ther\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1533\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E41\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.4161\/15384047.2014.955992\u0022\u003Edoi:10.4161\/15384047.2014.955992\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25482950\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BBiol%2BTher%26rft.volume%253D15%26rft.spage%253D1533%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-283-1\u0022 title=\u0022View reference 283 in text\u0022 id=\u0022ref-283\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.283\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBeavis\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDivisekera\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EU\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPaget\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EBlockade of A2A receptors potently suppresses the metastasis of CD73+\n            tumors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EProc Natl Acad Sci U S A\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E110\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E14711\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E6\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1073\/pnas.1308209110\u0022\u003Edoi:10.1073\/pnas.1308209110\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23964122\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DProc%2BNatl%2BAcad%2BSci%2BU%2BS%2BA%26rft.volume%253D110%26rft.spage%253D14711%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-284-1\u0022 title=\u0022View reference 284 in text\u0022 id=\u0022ref-284\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.284\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGupta\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPetrik\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EA feasibility study of cyclophosphamide, trastuzumab, and an allogeneic\n            GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast\n          cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Immunol Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E2\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E949\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E61\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/2326-6066.CIR-14-0058\u0022\u003Edoi:10.1158\/2326-6066.CIR-14-0058\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25116755\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BImmunol%2BRes%26rft.volume%253D2%26rft.spage%253D949%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-285-1\u0022 title=\u0022View reference 285 in text\u0022 id=\u0022ref-285\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.285\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDisis\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EML\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWallace\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDR\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGooley\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EConcurrent trastuzumab and HER2\/neu-specific vaccination in patients with\n            metastatic breast cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E27\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E4685\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E92\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1200\/JCO.2008.20.6789\u0022\u003Edoi:10.1200\/JCO.2008.20.6789\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19720923\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D27%26rft.spage%253D4685%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-286-1\u0022 title=\u0022View reference 286 in text\u0022 id=\u0022ref-286\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.286\u0022 data-doi=\u002210.1634\/theoncologist.2010-0307\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMiles\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E,\n                \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERoch\u0026Atilde;\u0026copy;\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMartin\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003EPhase III multicenter clinical trial of the sialyl-TN (STn)-keyhole\n            limpet hemocyanin (KLH) vaccine for metastatic breast cancer\u003C\/span\u003E.\n            \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOncologist\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1092\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E100\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1634\/theoncologist.2010-0307\u0022\u003Edoi:10.1634\/theoncologist.2010-0307\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21572124\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DOncologist%26rft.volume%253D16%26rft.spage%253D1092%26rft_id%253Dinfo%253Adoi%252F10.1634%252Ftheoncologist.2010-0307%26rft_id%253Dinfo%253Apmid%252F21572124%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1634\/theoncologist.2010-0307\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=21572124\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000294291800006\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-287-1\u0022 title=\u0022View reference 287 in text\u0022 id=\u0022ref-287\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.287\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVonderheide\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERH\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoRusso\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPM\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKhalil\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ETremelimumab in combination with exemestane in patients with advanced\n            breast cancer and treatment-associated modulation of inducible costimulator expression\n            on patient T cells\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E3485\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E94\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-10-0505\u0022\u003Edoi:10.1158\/1078-0432.CCR-10-0505\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20479064\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft.volume%253D16%26rft.spage%253D3485%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-288-1\u0022 title=\u0022View reference 288 in text\u0022 id=\u0022ref-288\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-9.8.e002597.288\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKataoka\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHirano\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EWhich\n            criteria should we use to evaluate the efficacy of immune-checkpoint\n            inhibitors?\u003C\/span\u003E\n          \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Transl Med\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E222\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.21037\/atm.2018.04.17\u0022\u003Edoi:10.21037\/atm.2018.04.17\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30023385\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DAnn%2BTransl%2BMed%26rft.volume%253D6%26rft.spage%253D222%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-9.8.e002597.289\u0022 data-doi=\u002210.1016\/j.ejca.2008.10.026\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEisenhauer\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEA\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETherasse\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBogaerts\u003C\/span\u003E\n               \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E.\n            \u003Cspan class=\u0022cit-article-title\u0022\u003ENew response evaluation criteria in solid tumours: revised RECIST\n            guideline (version 1.1)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEur J Cancer\u003C\/abbr\u003E\n          \u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E45\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E228\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E47\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/j.ejca.2008.10.026\u0022\u003Edoi:10.1016\/j.ejca.2008.10.026\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19097774\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DEur%2BJ%2BCancer%26rft.volume%253D45%26rft.spage%253D228%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.ejca.2008.10.026%26rft_id%253Dinfo%253Apmid%252F19097774%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.ejca.2008.10.026\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=19097774\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F9%2F8%2Fe002597.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup footnotes\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 class=\u0022content-block-markup\u0022 xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 class=\u0022section fn-group\u0022 id=\u0022fn-group-1\u0022\u003E\u003Ch2\u003EFootnotes\u003C\/h2\u003E\u003Cul\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-9\u0022\u003E\u003Cp id=\u0022p-171\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003ETwitter\u003C\/span\u003E @EmensLeisha, @DrGattiMays, @hmcarthur, @RitaNandaMD, @jenniferlitton\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-10\u0022\u003E\u003Cp id=\u0022p-172\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003ECorrection notice\u003C\/span\u003E This article has been corrected since it was first published. On August 27, 2021, the\n          indication for atezolizumab in combination with nab-paclitaxel as treatment for patients\n          with triple-negative breast cancer whose tumors express PD-L1 was voluntarily withdrawn by\n          the manufacturer. Amendments have been made to this article in light of the\n          withdrawal.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-11\u0022\u003E\u003Cp id=\u0022p-173\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003EContributors\u003C\/span\u003E All authors served on the SITC Breast Cancer Immunotherapy Guideline Expert Panel,\n          drafted content, and provided critical review during the manuscript development. LAE and\n          JKL provided leadership as Chairs of the Expert Panel and provided guidance on the\n          manuscript structure and content and thus are first and last authors; all other authors\n          are listed alphabetically by last name. PAS was the patient advocate representative.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-12\u0022\u003E\u003Cp id=\u0022p-174\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003EFunding\u003C\/span\u003E The authors have not declared a specific grant for this research from any funding agency\n          in the public, commercial or not-for-profit sectors.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-conflict\u0022 id=\u0022fn-13\u0022\u003E\u003Cp id=\u0022p-175\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003ECompeting interests\u003C\/span\u003E SA\u0026acirc;\u0026#128;\u0026#147;Contracted research: Funding to institution from Amgen, Bristol Myers Squibb,\n          Merck, Celgene, Roche. AC-M\u0026acirc;\u0026#128;\u0026#147;Consulting fees: Bristol Myers Squibb, Roche\n          Diagnostics; Contracted research: Bristol Myers Squibb; Partner Salary: Vivante Health;\n          Royalty: Springer\/Demos Publishing-Textbooks. MLD\u0026acirc;\u0026#128;\u0026#147;Contracted research: Pfizer, EMD\n          Serono, Bavarian Nordisk, Precigen, Epithany, Silverback Therapeutics, Celgene; IP Rights:\n          University of Washington; Non-CME Services: SITC; Ownership interest: Epithany; Partner\n          ownership interest: Epithany; Partner salary: Cox Cable; Royalty: University of\n          Washington; Salary: University of Washington. LAE\u0026acirc;\u0026#128;\u0026#147;Contracted research: Aduro\n          Biotech, AstraZeneca, Bristol Myers Squibb, Corvus, EMD Serono, Genentech, F Hoffman La\n          Roche, Maxcyte, Merck, Tempest, Silverback, Bolt, Compugen, Takeda, CytomX; Consulting\n          fees: Genentech, F Hoffman La Roche, Syndax, Lilly, AbbVie, Amgen, AstraZeneca, Bayer,\n          Bristol Myers Squibb, Celgene, Chugai, F Hoffman La Roche, GCPR, Genentech, Gilead,\n          Gritstone, Medimmune, Macrogenics, Novartis, Peregrine, Replimune, Shionogi, Silverback,\n          Vaccinex; IP Rights: Aduro Biotech; Royalty: Elsevier; Salary: University of Pittsburgh,\n          UPMC UPP; Grants from non-industry entities: HeritX Incorporated, NSABP Foundation,\n          Translational Breast Cancer Research Consortium, Breast Cancer Research Foundation,\n          National Cancer Institute, Department of Defense, Johns Hopkins University, University of\n          California San Francisco, Cornell University; Ownership interest: Molecuvax-potential for\n          royalties in the future. MG-M\u0026acirc;\u0026#128;\u0026#147;Trial funding to institution: EMD Serono (OSU Site\n          PI). AYH\u0026acirc;\u0026#128;\u0026#147;Consulting fees: Seattle Genetics; La Roche-Posay; Contracted research:\n          Merck and GSK. KK\u0026acirc;\u0026#128;\u0026#147;Consulting fees: Eli Lilly, Pfizer, Novartis, Eisai, AstraZeneca,\n          Merck, Seattle Genetics; Contracted research: Incyte, Genentech, Eli Lilly, Pfizer,\n          Calithera Biosciences, Acetylon, Seattle Genetics, Amgen, ZenoPharmaceuticals, CytomX\n          Therapeutics; Partner Salary: Pfizer, Array Biopharma - no longer employee at either;\n          Speaker Bureau: Eli Lilly. JKL\u0026acirc;\u0026#128;\u0026#147;Contracted research: Novartis, Medivation\/Pfizer,\n          Genentech, GSK, EMD Serono, AstraZeneca, Medimmune, Zenith, Jounce (All were payments to\n          my Institution of for writing support for manuscripts of multicenter trials. No payments\n          directly to Dr Litton); Consulting fees: Pfizer\/Medivation, AstraZeneca, Ayala (All\n          honorariums were refused); Salary: The University of Texas MD Anderson Cancer Center.\n          HLM\u0026acirc;\u0026#128;\u0026#147;Consulting fees: Bristol Myers Squibb, Eli Lilly, Genentech\/Roche, Merck,\n          Pfizer, Puma, Daiichi Sankyo, Seattle Genetics, AstraZeneca; Contracted Research: Bristol\n          Myers Squibb, MedImmune, LLC\/AstraZeneca, BTG, Merck. EAM\u0026acirc;\u0026#128;\u0026#147;Consulting fees: Merck,\n          Genomic Health, Roche\/Genentech; Contracted research: GlaxoSmithKline; NPI: 1831388596.\n          RN\u0026acirc;\u0026#128;\u0026#147;Consulting fees: Clovis, Immunomedics, Macrogenics, Merck, Pfizer, Seattle\n          Genetics; Contracted research: AstraZeneca, Celgene, Corcept Therapeutics,\n          Genentech\/Roche, Immunomedics, Merck, OBI Pharma, Odonate Therapeutics, Pfizer, Seattle\n          Genetics; DSMB: G1 Therapeutics. DBP\u0026acirc;\u0026#128;\u0026#147;Consulting fees: Genentech, Merck, Brooklyn\n          Immunotherapeutics; Contracted research: Merck, Brooklyn Immunotherapeutics, Bristol Myers\n          Squibb; Speaker bureau: Genentech, Novartis. HSR\u0026acirc;\u0026#128;\u0026#147;Consulting fees: Puma, Samsung -\n          Limited consulting; Contracted research: Pfizer, Merck, Novartis, Lilly, Genentech, OBI,\n          Odonate, Daiichi, Seattle Genetics, Eisai, Macrogenics, Immunomedics; Travel support for\n          educational programs: Daiichi, Mylan, Pfizer, Merck, AstraZeneca, Novartis, Macrogenics.\n          KMR\u0026acirc;\u0026#128;\u0026#147;Consulting fees: Merck, Bristol Myers Squibb, Eisai. HS\u0026acirc;\u0026#128;\u0026#147;Consulting fees:\n          AstraZeneca, Eisai, Novartis, Celgene, PUMA, Seattle Genetics. PAS\u0026acirc;\u0026#128;\u0026#147;Consulting fees:\n          Pfizer. SMT\u0026acirc;\u0026#128;\u0026#147;Consulting fees: AstraZeneca, Eli Lilly, Merck, Nektar, Novartis,\n          Pfizer, Genentech, Immunomedics, Bristol Myers Squibb, Eisai, Nanostring, Puma, Sanofi,\n          Celldex, Paxman, Odonate, Seattle Genetics, Silverback Therapeutics, G1 Therapeutics,\n          AbbVie, Anthenex, Oncopep; Contracted research: AstraZeneca, Eli Lilly, Merck, Nektar,\n          Novartis, Pfizer, Genentech, Immunomedics, Bristol Myers Squibb, Eisai, Nanostring,\n          Sanofi, Exelisis, Seattle Genetics, Cyclacel, Odonate. SITC Staff: SMW\u0026acirc;\u0026#128;\u0026#148;Shares\n          owned: Pacific Biosciences of California, Editas Medicine. EG, AK, LL\u0026acirc;\u0026#128;\u0026#148;Nothing to\n          disclose.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-14\u0022\u003E\u003Cp id=\u0022p-176\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003EProvenance and peer review\u003C\/span\u003E Not commissioned; externally peer reviewed.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/www.highwirestage.com\/sites\/default\/files\/js\/js_EATguP3NLbmqtQfeg3KSqAcc769Ag5YhOLoY5gjCzqk.js\u0022\u003E\u003C\/script\u003E\u003C\/body\u003E\u003C\/html\u003E\n"}